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Part I: General introduction 9 
1. COPD 
1.1 COPD: a common disease in the elderly 
Chronic Obstructive Pulmonary Disease (COPD) is defined by the Global initiative for chronic 
Obstructive Lung Disease (GOLD) as a common preventable and treatable disease, which is 
characterized by a persistent airflow limitation that is usually progressive and associated 
with an enhanced chronic inflammatory response of the airways and lungs to noxious 
particles or gases.1 Since 2010, COPD is globally the third leading cause of death.2 Each year, 
approximately 200 000 to 300 000 people die in Europe because of COPD.3 The morbidity, 
economic and social impact of COPD is substantial and increasing.2 Among respiratory 
diseases, COPD is the leading cause of lost work days and it has an estimated cost of 3 to 4% 
(or 38.6 billion €) of the total health care budget in the European Union.3, 4  
Previously, we found that the prevalence of COPD was 11.6% in a Dutch population-based 
cohort study of subjects aged 55 years and over.5 A similar prevalence has been observed in 
the United States.6 Although COPD is generally known as a disease of older smoking men, a 
high incidence of COPD was noted in young women and might suggest some shift in the 
gender distribution of COPD in Western Europe.7, 8 Moreover, an estimated 25% to 45% of 
COPD patients worldwide have never smoked, suggesting that long-term exposure to 
biomass smoke or occupational dusts and air pollution are other major risk factors to 
develop COPD.9 Despite the enormous global impact of COPD, there are no current drug 
therapies that have conclusively demonstrated to prevent disease progression or reduce 
mortality.10  
1.2 Pathogenesis 
Noxious particles and gases cause abnormal inflammatory immune responses of the lung in 
patients with COPD. The mechanisms for this amplified inflammation are currently not fully 
understood but may be genetically determined. Genome-Wide Association Studies (GWAS) 
for lung function and COPD have identified several genetic loci with genome-wide 
significance.1, 11, 12 Both the innate and adaptive immune system are involved in the 
amplified persistent lung inflammation.13 Noxious particles cause direct injury of airway 
epithelial cells, eventually leading to the release of cytokines. These cytokines attract 
macrophages, neutrophils and dendritic cells to the site of inflammation to set up the innate 
immune response. Proteolytic enzymes and reactive oxygen species are produced and, if not 
sufficiently counterbalanced by antiproteases and antioxidant factors, damage will occur, 
resulting in parenchymal destruction and small-airways fibrosis.14 On the other hand, 
immature dendritic cells pick-up self-antigens, released from damaged tissue, and foreign 
particles, and present them to naïve T-cells in draining lymph nodes. This leads to the 
recruitment of antigen specific CD-4 and CD-8 T cells and antibody-producing B cells to the 
lung, driving the response of the adaptive immune system. This adaptive (and sometimes 
autoimmune) response is partially held responsible for the persistent lung inflammation, 
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even after smoking cessation.13 The chronic inflammatory response stimulates remodeling of 
the small-airway compartment (resulting in small airways fibrosis and increased airway 
resistance) and emphysematous destruction of parenchyma (resulting in loss of elastic 
recoil).15 According to Hogg’s hypothesis, terminal bronchiolar loss preceeds the onset of 
emphysematous destruction.16 Both widespread narrowing and reduction in numbers of 
terminal bronchioles contribute to the characteristic physiologic abnormalities and 
symptoms of COPD, including a progressive decline of forced expiratory volume in 1 second 
(FEV1), inadequate lung emptying on expiration, and subsequent static and dynamic 
hyperinflation.17, 18 
1.3 Diagnosis, classification and assessment within the Rotterdam Study 
According to the GOLD guidelines, a clinical diagnosis of COPD should be considered in any 
patient experiencing dyspnea, chronic cough and/or chronic sputum production, who has a 
history of exposure to risk factors for COPD.1 The presence of a post-bronchodilator ratio of 
FEV1 to forced vital capacity (FEV1/FVC) less than 0.70  is required to make the diagnosis.1 
FEV1 is the maximum volume of air exhaled in the first second of a forced expiration from a 
position of full inspiration. FVC is the maximum volume of air exhaled with maximally forced 
effort from a maximal inspiration, i.e. the vital capacity performed with a maximally forced 
expiratory effort.19 Both parameters are measured during the most common pulmonary 
function test, i.e. spirometry.  
All studies of this thesis are embedded within the Rotterdam Study, a prospective 
population-based cohort study among almost 15 000 participants in the city of Rotterdam, 
the Netherlands.20 In short, all inhabitants of the Ommoord district of Rotterdam, aged 55 
years of age and older were invited to participate (n=10 215).21 At baseline, from 1990 
through 1993, 7 983 participants (response rate 78%) were included (Figure 1). In 2000, an 
additional 3 011 participants, out of 4 472 invitees, were enrolled (response rate 67%). This 
extension consisted of all persons living in the study district who had become 55 years old or 
had moved into the study district. A second similar extension of the cohort was initiated in 
2006, in which 3 932 participants (out of 6 057 invitees; response rate 65%), aged 45 years 
and older were included.20 Follow-up examinations are conducted periodically, 
approximately every four to five years. Examinations consist of a home interview and an 
extensive set of tests at a specially built research facility in the study district. Besides this, 
participants are continuously monitored for major morbidity and mortality through linkage 
of records from general practitioners and municipality to the study base.  
 
 
 
 
  
Part I: General introduction 11 
 
Figure 1: “Diagram of examination cycles of the Rotterdam Study (RS). RS-I-1 refers to the 
baseline examination of the original cohort (pilot phase 07/1989–12/1989; cohort 
recruitment 01/1990–09/1993). RS-I-2, RS-I-3, RS-I-4, and RS-I-5 refer to re-examinations of 
the original cohort members. RS-II-1 refers to the extension of the cohort with persons in the 
study district that became 55 years since the start of the study or those of 55 years or over 
that migrated into the study district. RS-II-2 and RS-II-3 refer to re-examinations of the 
extension cohort. RS-III-1 refers to the baseline examination of all persons aged 45 years and 
over living in the study district that had not been examined already (i.e., mainly comprising 
those aged 45–60 years). RS-III-2 refers to the first re-examination of this third cohort which 
will be completed by June 2014. Examinations RS-I-4 and RS-II-2 were conducted as one 
project and feature an identical research program. Similarly, examinations RS-I-5, RS-II-3, 
and RSIII-2 share the same program items.” (Adapted from Hofman et al., EJEP, 2013) 
 
Within the Rotterdam Study, COPD was diagnosed by an obstructive spirometry (FEV1/FVC < 
0.70) performed at the research center visit since 2002. Since 2009, diffusing capacity tests 
are additionally performed using the Master Screen® PFT Pro (CareFusion, San Diego, CA) by 
trained paramedical personnel according to the American Thoracic Society(ATS)/European 
Respiratory Society (ERS) guidelines.22, 23 To check reproducibility, multiple efforts were 
required. The values of the best acceptable effort have been considered for spirometry and 
the mean of two acceptable and reproducible efforts for diffusing capacity. Spirometries and 
diffusing capacity tests that did not meet ATS/ERS acceptability and reproducibility criteria 
were classified as “not interpretable”. In absence of spirometry, all medical information, 
including files from specialists and general practitioners, of subjects who used respiratory 
medication for at least 6 months (Anatomical Therapeutic Chemical (ATC) classification code: 
12 
 
R03) or indicated multiple respiratory symptoms in a questionnaire, was reviewed. 
Reversibility tests were not performed in this population-based setting; however, asthma 
patients were consistently excluded from COPD analyses. For cross-sectional analyses at the 
time of the research center visit, subjects with a spirometry report suggestive of a restrictive 
syndrome (FEV1/FVC ≥ 0.7 and FVC < 80% predicted) were also excluded. For longitudinal 
analyses, an incident COPD date was defined as the date of COPD diagnosis in the medical 
records, the date of a first COPD medication prescription or the date of an obstructive lung 
function examination, whichever came first. Medication use was obtained through 
automated linkage with pharmacy filled prescription data.  
COPD is a very complex, heterogeneous disease and it is of current debate which 
characteristics or clusters of characteristics (i.e. phenotypes) define the disease severity best 
or would lead to the most optimal tailored treatment options. According to the modified 
GOLD criteria (2007), COPD is classified according to the severity of airflow limitation into 
mild (FEV1≥ 80%), moderate (50%≤FEV1<80%), severe (30%≤FEV1<50%) and very severe 
COPD (FEV1<30%).24 A recent GOLD update (2011) however, highlights that the classification 
of a patient with COPD should include the evaluation of symptoms and the history of 
exacerbations next to the severity of airflow limitation, leading to four categories (A, B, C, 
and D, see Figure 2).1 COPD exacerbations are episodes of worsening of symptoms, 
accompanied by increased airway and systemic inflammation and physiological changes, 
leading to substantial morbidity and mortality.25 
 
Figure 2: “Combined COPD assessment. When assessing risk, choose the highest risk 
according to GOLD spirometric grade or exacerbation history”  
Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic 
Society. Vestbo J, Hurd SS, Agusti AG, et al. 2013 Global strategy for the diagnosis, management, and 
prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care 
Med. 187(4):347-65. Official Journal of the American Thoracic Society. 
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Group A consists of patients with a low risk and less symptoms (i.e. mild or moderate airflow 
limitation), (n)one exacerbation a year and a modified Medical Research Council Dyspnea 
Scale (mMRC) grade 0 to 1 or a COPD Assessment Test (CAT) score less than 10. Group B 
includes patients with a low risk but with more symptoms (mMRC grade ≥ 2 or CAT score ≥ 
10). Group C gathers patients with high risk (severe or very severe airflow limitation and/or ≥ 
2 exacerbations a year and/or > 1 hospitalized exacerbation a year) but less symptoms. 
Finally, group D consists of patients with a high risk and more symptoms.  
Within the Rotterdam Study, we evaluated the ABCD distribution of a cross-sectional study 
sample.(Figure 3) Our distribution of ABCD (group A: 49.1%, group B: 35.2%, group C: 4.2% 
and group D: 11.5%) is similar to two recent studies which sampled from the general 
population in Copenhagen and Norway.26, 27 Group C consistently represents the smallest 
group. Because we sampled from the general population where the airflow limitation is 
frequently still mild, Group A is the most prevalent group, whereas in studies recruiting 
patients from secondary and tertiary care, group D is the most prevalent group.28  
 
 
Figure 3: Comparison of the GOLD ABCD distribution of participants with COPD across 
studies which sampled from the general population.26, 27 
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2. Systemic effects and comorbidities of COPD 
2.1 Frequently described comorbidities in COPD 
A comorbidity is a disease coexisting with the primary disease of interest, here COPD.29 It is 
increasingly recognized that COPD is not only affecting the lungs, as systemic consequences 
and several comorbid diseases often coexist and are common at any severity of COPD.30 
Known comorbidities are cardiovascular disease, metabolic syndrome, skeletal muscle 
dysfunction, osteoporosis, depression, and lung cancer.1 Although the causal mechanisms by 
which COPD might increase the risk for other concomitant diseases is still under 
investigation, there is no doubt on the major impact of these comorbidities on the quality of 
life and survival in patients with COPD. Comorbidities not only significantly contribute to the 
clinical presentation of patients with COPD, their presence might increase moreover the 
need for hospitalization during a COPD exacerbation.24 Furthermore, a substantial 
proportion of mortality is due to nonrespiratory diseases, especially in COPD patients with 
mild and moderate disease.31 Therefore, the identification and treatment of comorbid 
diseases are key elements in COPD management.1 In future, more holistic care might be 
achieved by shifting from comorbidity towards multimorbidity. Herein, the prioritized 
specific disease approach is left in favor of multidisciplinary collaboration to treat the co-
occurrence of multiple diseases within one person.  
2.2 Potential underlying mechanisms 
The precise pathobiology of the association between COPD and the described comorbidities 
is still unknown, although several hypotheses including biological and genetic mechanisms 
are proposed. Next to the fact that airflow limitation and hyperinflation affects cardiac 
function and gas exchange, other potential underlying mechanisms as systemic 
inflammation, oxidative stress, physical inactivity, abnormalities of the vascular wall, 
accelerated aging, and protease/antiprotease imbalances were enumerated.32 Regarding the 
systemic inflammation, a spill-over of the abnormal inflammatory lung response to the 
systemic circulation is supposed to initiate or aggravate the consequential (cardiovascular) 
diseases.(Figure 4) Patients with COPD, especially those with comorbidity or an acute 
exacerbation, have indeed increased levels of systemic biomarkers of inflammation and 
procoagulant activity, including circulating cytokines such as interleukin 6 (IL6) and acute 
phase response proteins as high sensitivity C reactive protein (hsCRP), and fibrinogen.33 
However, since a persistent systemic inflammation was only observed in a proportion of 
moderate to very severe COPD patients in a recent clinical cohort study, the exact and 
unique role of systemic inflammation remains subject of debate.34 The debate is further 
fueled by the role of common risk factors of COPD and the frequently described 
comorbidities, including aging, smoking and sedentarism. These factors could also induce a 
chronic low grade systemic inflammation in susceptible persons leading to a multimorbidity 
state where COPD represents only the pulmonary abnormalities. Although a recent 
systematic review concluded that COPD is associated with an increased risk of cardiovascular 
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disease independent from (known) shared risk factors, further research might reveal yet 
unknown common risk factors or shed new light on the underlying mechanisms.35 
 
Figure 4: “Proposed mechanism by which lung inflammation causes cardiovascular disease in 
chronic obstructive pulmonary disease (COPD). COPD is associated with chronic lung 
inflammation. Some inflammatory mediators such as IL6, GM-CSF, and others escape into 
the systemic circulation and induce bone marrow to release inflammatory cells such as 
neutrophils, monocytes, and megakaryocytes that can directly invade atherosclerotic 
plaques. IL6 and other inflammatory cells released by the lungs can also stimulate 
hepatocytes to release acute phase reactants such as CRP, SAA, fibrinogen, and procoagulant 
factors such as factor VIII into the systemic circulation, which together confer a 
“proinflammatory” phenotype to the plaques. The inflamed lungs can release inflammatory 
proteins such as IL6 and certain surfactants that can directly promote atherogenesis. Thus, 
directly or indirectly (through the liver or bone marrow), the inflamed COPD lungs can make 
plaques more vulnerable by promoting their growth, increasing their lipid content, causing 
hemorrhage, and accelerating thrombosis (after plaque rupture or erosion). CRP = C-reactive 
protein; GM-CSF= granulocyte macrophage colony–stimulating factor; SAA = serum amyloid 
A; WBC = white blood count.  
Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic 
Society.Sin DD, MacNee W. 2013 Chronic obstructive pulmonary disease and cardiovascular diseases: 
a "vulnerable" relationship. Am J Respir Crit Care Med. 187(1):2-4. Official Journal of the American 
Thoracic Society. 
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3. Frailty 
3.1 Frailty: the identification of vulnerable elderly 
One of the major rising determinants of COPD-prevalence and incidence is the aging 
population. In Europe, the population aged ≥ 65 years is expected to rise from 17% in 2010 
to 30% in 2060, and those aged ≥ 80 from 5% to 12% over the same period.36 The concept of 
frailty was introduced as being the most problematic expression of population aging.37 
Frailty is defined as a biological syndrome in which a progressive, cumulative decline in the 
reserve capacity of multiple physiological systems elicits an abnormal vulnerability to 
common stressors.38 In short, frailty could be defined as the disability to compensate 
function loss. 25%-50% of people aged ≥ 85 years are estimated to be frail and these people 
have a substantially increased risk of adverse health outcomes including disability, falls, 
hospitalizations, institutionalizations and death.37-42 The demographic change is a great 
challenge for social welfare systems, pensions and healthcare funding where healthy aging is 
becoming increasingly important. Therefore, the identification of vulnerable elderly and 
their risk factors is crucial to optimize prevention and treatment strategies. 
3.2 Pathogenesis 
Frailty is a disorder of several interrelated physiological systems and the number of 
abnormal systems seems more predictive for frailty than an abnormality in any of the 
individual systems, implying a potential threshold of age-related cumulative decline.37, 43  
First, the aging brain might be a potential regulator of organismal aging, through hormonal 
feedback circuits.37, 44 Especially microglial cells, the macrophages of the brain, and neurons 
with high metabolic demands, for example in the hippocampus, seem to be affected.37 Brain 
injury, local and systemic inflammation activate microglial cells which become 
hyperresponsive with aging.37 Moreover, the hippocampus might lose its ability of repressing 
glucocorticoid release by the hypothalamus due to chronically elevated glucocorticoid 
concentrations during aging, which exposes the entire organism to elevated stress hormone 
concentrations.44 This leads us inevitably to the frail endocrine system wherein circulating 
hormones like insulin-like growth factor-1 (IGF-1) and dehydroepiandrosterone sulfate 
(DHEA-S) are decreased, possibly contributing to the observed skeletal muscle weakness.37 A 
third organ system related to the development of frailty is the immune system, in which 
several inflammatory markers, such as white blood cell (WBC) count, CRP, IL6 and tumor 
necrosis factor-α (TNF-α) are elevated.37, 45-51 IL6 in particular has been associated with 
anemia, decreased lean body mass and sarcopenia and is inversely correlated with IGF-1 and 
DHEA-S in frail elderly.47, 52, 53 All these observations make clear that the different systems 
are intrinsically linked and that accumulating deficits during aging might generate a vicious 
circle leading towards frailty in susceptible persons. 
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4. Aims and outline of this thesis 
The main aim of this thesis is to identify and explore systemic effects and comorbidities of 
COPD. First, a general aim will be to identify all COPD subjects within the Rotterdam Study 
by validating the lung function tests and additionally, by carefully exploring all relevant 
information from the study questionnaires and from the linkage of the study database with 
the medical files and filled prescriptions of the participants. Furthermore, as mentioned in 
this introduction, exacerbations are associated with an increased airway and systemic 
inflammation and are recently introduced in the classification of COPD patients because of 
their important influence on the morbidity and mortality in patients with COPD. Therefore, 
another general aim will be the assessment of exacerbations to identify frequent 
exacerbators and evaluate the influence of COPD exacerbations on the systemic effects and 
investigated comorbidities. 
 
Regarding the specific aims, because there is a high need for research into the underlying 
inflammatory mechanisms of COPD, we want to know whether interleukin 6 (IL6) is causally 
involved in the pathogenesis of COPD or just a bystander. To examine this causal effect, we 
will use the Mendelian randomization approach in chapter 5. The underlying idea is that if 
common variation in the IL6 gene (which raises plasma levels of IL6) modifies the 
susceptibility of an individual to develop COPD, then increased plasma levels of IL6 are 
causally related to incident COPD. Previously, our Laboratory for Translational Research in 
Obstructive Pulmonary Diseases demonstrated in a murine model of COPD that - although 
IL6 levels were significantly increased after cigarette smoke exposure - the cigarette smoke-
induced pulmonary and systemic inflammation were IL6 independent.54 However, human 
studies are highly clinical relevant since tocilizumab, a humanized monoclonal IL6 receptor 
antagonist, is already successfully implemented in the treatment of refractory rheumatoid 
arthritis. 
By this last sentence, I immediately introduce another need in COPD science, namely the 
quest to drug therapies that actually reduce the mortality in COPD patients. In chapter 6, we 
will investigate whether statins have a beneficial effect on the mortality in subjects with 
COPD. Because statins possess pleiotropic anti-inflammatory and immunomodulating 
properties, we hypothesize that potential effects are modulated by the baseline levels of 
high-sensitivity C-reactive protein (hsCRP), a validated biomarker of systemic inflammation 
in COPD. In chapter 6, we will also identify the most frequent causes of death in COPD, 
including death to cardiovascular causes. After exploring the systemic inflammation in COPD, 
this leads us to the aim of studying comorbidities in COPD. A great advantage of the 
Rotterdam Study is that cardiovascular, dermatological, endocrine, hepatic, neurological, 
oncological, ophthalmic and psychiatric diseases are very well documented.20 For this thesis 
in particular, an extensive assessment of sudden cardiac death, carotid artery plaques, 
cerebral microbleeds and stroke is crucial. 
18 
 
Additionally in Part II, we will investigate the association of COPD and cardiovascular 
mortality. Regarding the cardiovascular comorbidities, there is a need for longitudinal 
studies which explore the link between COPD, systemic inflammation and cardiovascular 
morbidity and mortality in the general population. Therefore, we will determine in chapter 7 
whether COPD is an independent risk factor for sudden cardiac death in the general 
population. 
 
In Part III, we will further explore the cerebrovascular comorbidities in COPD by starting with 
a general overview of the current literature in chapter 8. In the subsequent chapters, the 
aim is to further explore the epidemiology of vascular dysfunction in subjects with COPD. In 
chapter 9, we want to investigate the relationship between COPD and macroangiopathy. 
Herein, the aim is to reveal noninvasively the composition of atherosclerotic plaques in the 
carotid arteries of subjects with COPD. In all participants of the Rotterdam study, 
ultrasonographic assessments of carotid intima-media thickness and carotid plaques are 
conducted.20 Since 2007, carotid plaque components are measured using high-resolution 
magnetic resonance imaging (MRI) in all participants with carotid wall thickening on 
conventional carotid ultrasound.55 Through the MRI scans, we have the ability to distinguish 
calcification, lipid and hemorrhagic components in carotid artery plaques.  
 
In chapter 10, we want to investigate the relation of COPD and microangiopathy. Herein, the 
aim is to explore whether COPD is associated with an increased risk of cerebral microbleeds 
which is a marker of cerebral small-vessel disease. Furthermore, we want to explore 
whether the microbleed location differs from subjects with COPD to subjects without COPD. 
For this study, we will combine the lung function tests with the extensive brain imaging 
which is performed from 2005 onwards in all study participants without contra-indications 
using the 1.5 Tesla MRI scanner. This will allow us to identify the presence and location of 
cerebral microbleeds.(Figure 5) Finally in chapter 11, we like to explore whether vascular 
dysfunction in subjects with COPD leads to an increased risk of stroke. Within the Rotterdam 
Study, the history of stroke was assessed through interview and verified in medical records 
at baseline.20 In addition, incident strokes are identified and further characterized and 
validated through the linkage of the study database with files from general practitioners, 
nursing home physicians, the municipality and hospital records.20  
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Figure 5: “The topography of cerebral microbleeds and their magnetic resonance imaging 
(MRI) features. Microbleeds are small collections of blood-breakdown products 
(hemosiderin laden macrophages) that can be seen in vivo through blood-sensitive MRI 
sequences. Depending on their location, microbleeds are defined as “lobar” or “deep” and 
reflect different pathological processes affecting the brain’s small vessels. Lobar microbleeds 
(left side) affect small arteries, arterioles, and capillaries in the cerebral cortex, overlying 
leptomeninges and the gray–white matter junction; are caused by cerebral amyloid 
angiopathy; reflect the accumulation of amyloid β in the vessel walls (short blue lines in the 
upper left box); and appear as black spots in cortical or subcortical areas in the MRI images 
(yellow arrows in the left lower box). Deep and infratentorial microbleeds (right side) affect 
deep small arterioles; are caused by hypertensive arteriopathy, including lipohyalinosis and 
atherosclerosis; reflect damage to small perforating end arteries (short black lines in the 
upper right box); and appear as black spots in the basal ganglia in the MRI images (yellow 
arrows in the right lower box). The prevalence of deep and infratentorial microbleeds is 
associated with age and with cardiovascular risk factors. Also, they seem to have effects on 
cognition and increase the risk of stroke. Image courtesy of Amicus Visual Solutions.” 
Reprinted with permission of the American Thoracic Society. Copyright © 2014 American Thoracic 
Society. Rodriguez-Roisin R, Llufriu S, Fabbri LM. 2013 Changes in your breathing can change your 
brain. Am J Respir Crit Care Med. Oct 1;188(7):763-4 
Official Journal of the American Thoracic Society. 
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Part IV of this thesis elaborates on the potential associations between COPD and frailty. Both 
frailty and COPD are prevalent syndromes in the general elderly population, associated with 
substantial morbidity, disability and mortality. Conceptually, it is important to distinguish 
frailty from disability and comorbidity.(Figure 6) Although these three different entities are 
related, they are not identical.56 Therefore, it is important not to use an instrument 
integrating disability or comorbidity items to measure frailty.57 An unambiguous definition of 
frailty is of great importance for clinicians to identify those at an increased risk of adverse 
health outcomes, but also for policy makers to make cost-effective decisions in health care.58 
We will define frailty according to the physical definition wherein the nutritional status, 
physical activity, gait velocity, grip strength and exhaustion are evaluated.38 In chapter 12, 
the aim is to assess frail persons according to this definition within the Rotterdam Study. 
Both frailty and COPD are moreover associated with a decline in function across multiple 
systems that in composite contribute to geriatric syndromes, including osteoporosis, 
cognitive decline, anemia, immune deficiency, weight loss and muscle wasting. Investigating 
the interrelationship between COPD and frailty may contribute to the general knowledge of 
both and even could help identify a new COPD phenotype. Therefore, the objective in 
chapter 13 is to investigate the interrelationship between COPD and frailty. Regarding the 
effects on the musculoskeletal system (although vascular dysfunction might also play a role) 
and in this context of disability and the gait velocity assessment within frailty, we want to 
investigate in chapter 14 whether COPD is associated with various gait domains and explore 
a potential link with falling. 
 
 
 
Figure 6: Although frailty, disability and comorbidity overlap, they are not identical. 
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PART II: COPD, SYSTEMIC INFLAMMATION 
AND CARDIOVASCULAR MORTALITY 
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ABSTRACT 
 
Background 
Cross-sectional studies have demonstrated that increased levels of interleukin 6 (IL6) are 
present in the airways and blood samples of patients with chronic obstructive pulmonary 
disease (COPD). 
 
Objectives 
To investigate the association between IL6 and the risk of COPD using a Mendelian 
randomization approach. 
 
Methods 
Eight common SNPs in the region of the IL6 gene were genotyped by using both  TaqMan 
and Illumina in the Rotterdam Study, a prospective population-based cohort study 
consisting of 7983 participants aged 55 years or older, including 928 COPD patients. At 
baseline, blood was drawn in a random sample of 714 subjects to measure the IL6 plasma 
level. Analysis of variance, logistic regression and cox proportional hazard models -adjusted 
for age, gender, pack years and body mass index- were used for analyses. 
 
Results  
High levels of IL6 (>2.4 pg/ml, the highest tertile) were associated with a threefold increased 
risk of developing COPD, in comparison to low levels (<1.4 pg/ml, the lowest tertile). The 
rs2056576 SNP was associated with a 10% increase in the risk of COPD per additional T-
allele. However, the association was no longer significant after adjustment. No association 
was found with other common SNPs in the IL6 gene and COPD. 
 
Conclusions 
Although increased IL6 plasma levels at baseline are associated with the risk of developing 
COPD during follow-up, there was no strong evidence for an association between common 
variation in the IL6 gene and the risk of COPD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reprinted with permission of S. Karger AG. Copyright © 2014 S. Karger A, Switzerland.  
van Durme YMTA*, Lahousse L*, Verhamme KMC, Stolk L, Eijgelsheim M, Loth DW, Uitterlinden AG, Breteler 
MMB, Joos GF, Hofman A, Stricker BH, Brusselle GG. 2011 Mendelian Randomization Study of Interleukin 6 in 
Chronic Obstructive Pulmonary Disease. Respiration. 82:530–53. 
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5. The role of Interleukin-6 in COPD development 
INTRODUCTION 
Worldwide, chronic obstructive pulmonary disease (COPD) is a major and still increasing 
health problem. The disease is characterized by progressive airflow limitation, driven by an 
abnormal inflammatory response of the airways to inhaled particles and fumes.59, 60 
Recently, COPD has been associated with elevated levels of several inflammatory markers in 
the systemic circulation including interleukin 6 (IL6) and C-reactive protein (CRP).61-65 This 
may be a key link to various extrapulmonary effects which have been described in relation to 
COPD, such as cachexia, osteoporosis, skeletal muscle wasting, diabetes mellitus, 
cardiovascular disease and depression.30, 66, 67 
Interleukin 6 (IL6) is a powerful stimulant of the immune system and has been shown to be 
present in sputum, broncheoalveolar lavage fluid and in blood samples of stable patients 
with mild COPD after a hypoxic challenge and during COPD exacerbations.68-70 Elevated 
plasma levels of IL6 also appear to correlate with disease severity.71 IL6 is a protein with a 
helical structure, mainly secreted by monocytes and macrophages, but can also be released 
in the airways by bronchial epithelial cells and fibroblasts.72 IL6 is a multifunctional cytokine, 
originally identified as a B-cell differentiation factor, with a central role in the induction of 
hepatically derived acute-phase proteins such as CRP.73-76 In addition, IL6 also mediates the 
activation, growth, differentiation and survival of T-cells and has emerged as a key 
regulatory signal in the development of the new T-helper17 subset.75, 77 
The rs1800795 single nucleotide polymorphism (SNP) in the promoter region of the IL6 gene 
influences plasma levels of IL6 and CRP.78, 79 Although variation in this SNP has been 
associated with the risk and outcome of several inflammatory diseases, three studies could 
not find any association between this SNP and the risk of COPD.80-82 In contrast, a recent 
report associated the rs1800795 SNP with rapid decline of FEV1 and susceptibility to COPD in 
smokers.83 In addition, other variants in the IL6 gene have been linked with the risk of 
COPD.81, 84 
In this Mendelian randomization study we hypothesized that common variation in the IL6 
gene that raises plasma levels of IL6, would modify the susceptibility of an individual to 
develop COPD, implicating that increased plasma levels of IL6 would be causally related to 
incident COPD. We tested these hypotheses in a large prospective population-based cohort 
with more than 15 years of follow-up. 
METHODS  
Study design and setting 
The present study is part of the Rotterdam Study, a population-based cohort study to assess 
the occurrence of, and risk factors for chronic diseases in the elderly. Objectives and 
methods of the Rotterdam Study have been described elsewhere.21, 85 In short, the 
Rotterdam Study cohort includes 7983 participants aged ≥ 55 years, living in Ommoord, a 
24 
 
well-defined suburb of the city of Rotterdam, the Netherlands. Almost all participants 
(99.8%) are of Caucasian descent. Baseline data were collected from 1989 until 1993. 
Participants were visited at home at the start of the study for a standardized interview on 
their health status. Since the start of the Rotterdam Study, each participant visited the 
research center every 2 to 3 years, during which several measurements were performed. In 
addition, participants were continuously monitored for the onset of major events which 
occurred during follow-up through automated linkage with files from general practitioners. 
Trained research assistants collected information from medical records of the general 
practitioners, medical specialists (e.g. respiratory physicians), hospitals and nursing homes. 
The medical ethics committee of the Erasmus Medical Center, Rotterdam, and the review 
board of The Netherlands Ministry of Health, Welfare and Sports, approved the study. 
Participants gave written informed consent and permission to retrieve information from 
treating physicians.  
Study participants  
Information about the COPD cohort definition and spirometry examination has been 
described previously.5 In short, the diagnosis of COPD was classified as definite or probable. 
Definite COPD was defined by a moderate-to-severe obstructive spirometry (FEV1/FVC < 0.7 
and FEV1 < 80% predicted), or as COPD diagnosed by a specialist in internal medicine (mainly 
respiratory physicians or internists with a subspeciality in respiratory medicine) based upon 
the combination of clinical history, physical examination and spirometry. Probable COPD was 
defined by a mild obstructive spirometry (FEV1/FVC < 0.7 and FEV1 ≥ 80% predicted) or as 
COPD diagnosed by a physician in another medical speciality (e.g. a general practitioner). For 
the risk analyses, participants with indication of asthma in the medical files or a spirometry 
report suggestive of restrictive respiratory disease (FEV1/FVC ≥ 0.7 and FEV1 < 80% 
predicted), were excluded. Spirometry was performed by using a SpiroPro® portable 
spirometer (Erich Jaeger GmbH, Hoechberg, Germany), according to the ATS/ERS guidelines 
by trained paramedical personnel.22 Forced expiratory volume in one second (FEV1), forced 
vital capacity (FVC) and FEV1/FVC ratio were measured; the spirogram (volume-time curve) 
and maximal expiratory flow-volume curve were also recorded. Spirometries that yielded 
results which did not meet ATS/ERS criteria for acceptability and reproducibility were 
classified as “not interpretable” (9.6% of spirometries). The interpretation of spirometries 
was performed independently by two researchers; in case of discordance (6.1% of 
spirometries), the final protocol was made by a senior respiratory physician.5  
The index date was defined as the date of diagnosis of COPD found in the medical reports or 
the date of a first prescription of COPD medication in someone with definite or probable 
COPD or the date of the obstructive lung function examination, whichever came first. 
Follow-up time was defined as the time period between cohort entry and the diagnosis of 
COPD, death, loss to follow-up or the end of the study period on 31 December 2004, 
whichever came first.  
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Measurement of IL6 plasma levels and common variation in the IL6 gene 
Plasma IL6 and high-sensitivity (hs)CRP levels, were measured as previously described.61, 86, 87 
IL6 plasma levels were measured in 714 subjects, a 10% random subset of 7081 participants 
who gave permission to give blood. As previously described, a venapuncture was performed 
at the start of the study (1990-1993) by application of minimal stasis with a 21-gauge 
butterfly needle tube (Surflo winged infusion set, Terumo).86, 88 Non-fasting blood was 
collected in tubes containing 0.129 mol/L sodium citrate at 4°C. Plasma was collected after 
centrifugation for 10 min at 3000 rpm. Subsequently, platelet-free plasma was obtained by 
centrifugation for 10 min at 10000 rpm, immediately frozen in liquid nitrogen, and stored at 
-80°C. IL 6 levels were measured by using a commercially available ELISA (Quantikine HS IL6 
kit from R&D Systems Europe). The inter assay coefficient of variation for IL 6 was 8.7%.  
The rs1800795 (-174G/C) SNP was genotyped in 6071 participants by using a TaqMan allelic 
discrimination assay (Applied Biosystems, Foster City, California, USA). In short, DNA was 
isolated using standard procedures and genotyping was performed using baseline samples 
stored at -80°C. Genotypes were determined in 2 ng genomic DNA with the TaqMan allelic 
discrimination assay. Primer and probe sequences were optimized by using the SNP-assay-by 
design service of Applied Biosystems. Reactions were performed with the TaqMan Prism 
7900HT 384 wells format in 2 µL of reaction volume.  
In addition, seven common tagging SNPs within the IL6 gene ± 10 kb and minor allele 
frequency (MAF) > 0.10 (rs7801617, rs7805828, rs1880242, rs10499563, rs2056576, 
rs1554606 and rs10242595; chromosome 7, NCBI build) were extracted based on data from 
the Illumina Infinium II HumanHap550K BeadChip in 5639 participants (version 3) that 
genotyped participants with available DNA from the Rotterdam Study, as previously 
described.87 Genotyping was performed at the Department of Internal Medicine, Erasmus 
Medical Center using BeadStudio software (version 0.3.10.14) for genotyping calling. 
Participants with call rate < 97.5%, excess autosomal heterozygosity, sex mismatch, or 
outlying identity-by-state clustering estimates were excluded.  
Statistical analyses 
Demographic and clinical characteristics of the study population are expressed as the 
median and the interquartile range (IQR) for description in the text. The eight SNPs in the IL6 
gene were tested for Hardy Weinberg Equilibrium with χ2 statistics.  
First, we studied the association between the eight SNPs in the IL6 gene and COPD. A logistic 
regression model -adjusted for age at baseline, gender, total amount of pack years smoked 
and BMI- was used to calculate odds ratios (OR) and the 95% confidence intervals (CI) for the 
association between the different genotypes and COPD. Overall, additive genetic models in 
which persons homozygous for the common allele were used as the reference category were 
applied. All prevalent and incident COPD cases were used for analyses.  
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Second, hazard ratios (HR) and the 95% CI for the association between plasma levels of IL6 
and incident COPD were evaluated by use of Cox proportional hazard analyses. Hereto, 
prevalent cases -subjects with a follow-up time of less than three years since the index date- 
were excluded. The Cox models were adjusted for covariates that changed the point 
estimate by more than 10% or that were biologically plausible according to previous 
literature. The following covariates were considered as potential confounders: age, gender, 
body mass index, the total amount of pack years smoked, diabetes and cardiovascular 
comorbidity. Cigarette pack years were computed as duration of smoking (years) multiplied 
by the number of smoked cigarettes, divided by 20. Missing pack years values were imputed 
for the analyses by predicted values, based on a logistic regression analysis adjusted for age 
and gender. Diabetes mellitus was defined as a non-fasting or 2-hour post load glucose level 
of ≥ 11.1 mol/l or antidiabetic medication use at baseline. Cardiovascular disease included 
myocardial infarction, coronary artery bypass graft, percutaneous transluminal coronary 
angioplasty, atrial fibrillation and heart failure. Interaction terms and subanalyses were 
introduced to explore for potential effect modification.  
Differences in the IL6 and hsCRP levels according to the IL6 genotypes were tested by means 
of analysis of variance (ANOVA). All participants with a blood sample were used for analyses. 
Because of the skewed absolute values of hsCRP and IL6 in our cohort, the natural 
logarithmic transformation of these markers was entered as a continuous variable in the 
models.  
The difference between hazard ratios was interpreted by reference to 95% confidence 
intervals for each of the parameters of interest. P-values below the conventional level of 
significance (p < 0.05) were considered as statistically significant. All statistical analyses were 
performed using PASW Statistics for Windows version 18 (SPSS Inc, Chicago, IL). 
RESULTS 
Baseline characteristics 
Of the 7983 participants in the Rotterdam Study, 7081 donated a blood sample. 288 subjects 
were excluded because of a diagnosis of asthma in the medical files or a spirometry report 
suggestive of a restrictive syndrome. The rs1800795 SNP was successfully genotyped by the 
Taqman method in 6071 participants of whom 779 had COPD. Regarding the other seven 
SNPs, Illumina genotyping data were available in 5639 participants of whom 732 had COPD. 
(Figure 1) With these data we cover 76%, 84% and 92% of the common variation in the IL6 
gene as present in the Caucasion HapMap reference population at r² tresholds of 1, ≥ 0.7 
and ≥ 0.5, respectively. 
Among the participants who were randomly selected from the cohort for IL6 plasma level 
measurement, subjects with prevalent COPD or a follow-up time of less than 3 years were 
excluded from the analyses. In the remaining subgroup of 572 participants, 55 subjects 
developed COPD during a median follow-up time of 12 years (IQR, 4) (Figure 1). Table 1 
  
Part II: COPD, systemic inflammation and cardiovascular mortality 27 
shows the baseline characteristics of the study populations. Overall, the COPD cases were 
more often male and (current) smokers.  
 
 
 
 Figure 1: Cohort definition. 
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572 participants  without 
prevalent COPD, with 
successful plasma IL6-
measurement and follow-up 
time of  ≥ 3 years
55 subjects with 
incident COPD
517 subjects without 
incident COPD
288 participants with diagnosis of asthma 
or a spirometry suggestive of a restrictive 
syndrome
902 participants declined to 
give blood
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Table 1: Baseline characteristics of the study population. 
Baseline 
characteristics 
rs1800795 genotyped by 
Taqman 
7 SNPs genotyped by 
Illumina 
Random sample of 
subjects with IL6 plasma 
COPD Controls Overall COPD Controls Overall COPD Controls Overall 
Number of participants 779 5292 6071 732 4907 5639 55 517 572 
Median age at entry 
(years) 
67  
(62-72) 
69  
(62-76) 
68  
(62-76) 
67 
(62-72) 
69  
(62-76) 
68  
(62-76) 
66  
(61-72) 
70  
(62-77) 
69  
(62-77) 
Male 
448  
(58) 
2031 
(38) 
2479 
(41) 
422  
(58) 
1879 
(38) 
2301 
(41) 
37  
(67) 
230  
(45) 
267  
(47) 
Smoking behaviour          
Never smoker  
121  
(16) 
 
1953 
(37) 
2074 
(34) 
109  
(15) 
 
1812 
(37) 
1921 
(34) 
 
8  
(15) 
 
186  
(36) 
 
194  
(34) 
 
Current smoker  
313  
(40) 
 
1042 
(20) 
1355 
(22) 
296  
(40) 
 
980  
(20) 
 
1276 
(23) 
22 
(40) 
 
93  
(18) 
 
115  
(20) 
 
Former smoker  
340  
(44) 
 
2136 
(40) 
2476 
(41) 
322  
(44) 
 
1970 
(40) 
2292 
(41) 
25  
(46) 
 
229  
(44) 
 
254  
(44) 
 
Missing  5 (1) 161 (3) 166 (3) 5 (1) 145 (3) 150 (3) 0 (0) 9 (2) 9 (2) 
Median pack years 
26 
(9-45) 
4  
(0-25) 
6  
(0-29) 
26  
(9-45) 
4  
(0-25) 
7  
(0-29) 
30  
(15-49) 
6  
(0-26) 
9  
(0-30) 
Body mass index (kg/m²)  
25  
(23-28) 
26  
(24-28) 
26  
(24-28) 
25  
(23-28) 
26  
(24-28) 
26 
(24-28) 
26  
(23-28) 
26  
(24-29) 
26 
 (24-28) 
Diabetes 64 (8) 566 (11) 630 (10) 60 (8) 526 (11) 586 (10) 4 (7) 38 (7) 42 (7) 
Cardiovascular 
comorbidity 
246 (32) 
 
1625 
(32) 
1871 
(32) 
226 (31) 
 
1501 
(32) 
1727 
(32) 
14 (26) 
 
142 (28) 
 
156 (28) 
 
Median IL6 plasma level 
(pg/ml) 
2.0  
(1.4-3.5) 
1.9  
(1.2-3.1) 
1.9  
(1.2-3.1) 
2.0  
(1.3-3.3) 
1.9  
(1.2-3.0) 
1.9  
(1.2-3.0) 
2.0  
(1.3-3.6) 
1.9  
(1.2-2.9) 
1.9  
(1.2-3.0) 
Categorical variables are expressed as count (percentage). Values of continuous variables are expressed as 
median (25-75 percentiles).  
Abbreviations: COPD=Chronic Obstructive Pulmonary Disease; IL6= Interleukin 6; SNPs = Single Nucleotide 
Polymorphisms. 
Association between common variants in the IL6 gene and COPD 
The rs1800795 TaqMan genotyped SNP was in Hardy Weinberg equilibrium (χ2 = 1.79, p = 
0.181). The C-allele of the rs1800795 SNP was positively associated with higher hsCRP levels. 
(Table 2). No association was found between the rs1800795 SNP and the total group of 
COPD patients.(Table 3) 
All seven common SNPs genotyped on Illumina arrays were in Hardy-Weinberg equilibrium. 
None of the seven SNPs were significantly associated with plasma IL6 levels. Three SNPs 
(rs10499563, rs1554606 and rs10242595) correlated significantly with plasma hsCRP levels 
.(Table 2) Only the rs2056576 SNP demonstrated an association with COPD (OR 1.1; 95% CI 
1.01-1.27; Table 3); however, this was no longer significant after adjustment for age, gender, 
the total amount of pack years smoked at the start of the study and BMI. Prevalent diabetes 
or cardiovascular diseases did not substantially change the risk estimates. Additional 
subanalyses demonstrated that the increase in risk for this SNP was most pronounced in 
females (OR 1.2; 95% CI 1.02-1.43) and in never-smokers (OR 1.4; 95% CI 1.02-1.80).  
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Table 2: Association between common SNPs in the IL6 gene and plasma IL6 and serum hsCRP 
levels.  
IL6 gene 
Genotype 
 IL6 level (pg/ml) hsCRP level (mg/L) 
Db SNP Number Ln IL6a P-valuec Number Ln CRPb P-valuec 
rs1800795 
GG 238 0.72 (0.05)   2151 0.56   
GC 311 0.72 (0.04) 0.990 2839 0.65 0.006 
CC 102 0.70 (0.07) 0.802 996 0.65 0.026 
rs7801617 
GG 466 0.71 (0.03)   4479 0.62   
GA 120 0.67 (0.07) 0.675 1017 0.63 0.785 
AA 13 0.77 (0.17) 0.766 66 0.74 0.359 
rs7805828 
GG 191 0.64 (0.05)    1754 0.64   
GA 306 0.73 (0.04) 0.171 2753 0.63 0.774 
AA 102 0.72 (0.08) 0.391 1054 0.57 0.087 
rs1880242 
TT 172 0.73 (0.06)   1648 0.59   
TG 311 0.72 (0.04) 0.912 2726 0.64 0.078 
GG 113 0.63 (0.07) 0.255 1176 0.63 0.323 
rs10499563 
TT 330 0.68 (0.04)   3263 0.65   
TC 237 0.70 (0.04) 0.719 1989 0.58 0.036 
CC 30 0.91 (0.16) 0.091 307 0.61 0.569 
rs2056576 
CC 281 0.69 (0.04)   2473  0.62   
CT 258 0.71 (0.04) 0.689 2446 0.61 0.690 
TT 60 0.73 (0.11) 0.688 645 0.67 0.347 
rs1554606 
GG 197  0.69 (0.05)   1828 0.56  
GT 297 0.72 (0.04) 0.658 2712 0.65 0.003 
TT 105 0.65(0.07) 0.589 1018 0.65 0.031 
rs10242595 
GG 295 0.68 (0.04)   2811 0.65   
GA 241 0.74 (0.04) 0.348 2280 0.60 0.061 
AA 63 0.62 (0.08) 0.556 472 0.53 0.017 
ANOVA was used for analyses.  * Seattle SNP database number. 
a Ln IL6 values are mean (standard error). b Ln CRP-values are mean (standard error).  
c P-values (2-tailed) are calculated by a contrast test of the first genotype versus the second genotype; the first 
genotype versus the third genotype. 
Abbreviations: hsCRP= High-sensitivity C-reactive protein; IL6= Interleukin 6; Ln= Logaritmus Naturalis; SNPs = 
Single Nucleotide Polymorphisms. 
 
Table 3: Association between common SNPs in the IL6 gene and COPD. 
IL6 gene No. Patients/ Model 1 Model 2 
Db SNP No.* cohort OR 95% CI P-value OR 95% CI P-value 
rs1800795 779/6071 1.0 0.87-1.08 0.602 1.0 0.88-1.10 0.779 
rs7801617 731/5637 1.0 0.87-1.24 0.678 1.1 0.89-1.29 0.460 
rs7805828 732/5637 1.1 0.95-1.18 0.339 1.0 0.91-1.15 0.694 
rs1880242 732/5625 0.9 0.84-1.05 0.267 1.0 0.85-1.07 0.425 
rs10499563 731/5634 0.9 0.82-1.07 0.334 0.9 0.81-1.06 0.246 
rs2056576 732/5639 1.1 1.01-1.27 0.037 1.1 0.99-1.25 0.076 
rs1554606 731/5633 1.0 0.89-1.11 0.925 1.0 0.91-1.14 0.752 
rs10242595 732/5638 1.1 0.93-1.19 0.404 1.0 0.92-1.17 0.560 
Additive genetic models were used for analyses. * Seattle SNP database number. 
Model 1: not adjusted for confounders. 
Model 2: adjusted for age, gender, total amount of pack years smoked at the start of the study and BMI. 
Abbreviations: CI=Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; IL6= Interleukin 6; OR= 
Odds Ratio; SNPs = Single Nucleotide Polymorphisms. 
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Association between IL6 plasma levels and incident COPD 
The median IL6 plasma level was 2.0 pg/ml (IQR 2.3) in COPD cases and 1.9 (IQR 1.7) in 
control subjects (Table 1). Female COPD cases had a significantly lower log mean IL6 plasma 
level (1.8 pg/ml) than men (2.7 pg/ml) (p=0.011). When stratified according to smoking, 
current smokers showed the highest log mean IL6 level (2.4 pg/ml) in comparison to 
participants who had never smoked (1.9 pg/ml, p=0.004) or who were former smokers (2.0 
pg/ml, p=0.011). 
An elevated plasma level of IL6 (>2.4 pg/ml, the highest tertile) was associated with a 
threefold increased risk to develop definite COPD (95% CI, 1.20 - 8.13, p = 0.020), in 
comparison to a low level of IL6 (<1.4 pg/ml, the lowest tertile) (Table 4). The risk remained 
significantly increased when the analyses were adjusted (95% CI 1.11 - 8.76, p = 0.031). The 
increase in risk was less pronounced and no more significant in the total group of definite 
and probable COPD patients (HR 1.9; 95% CI 0.97-3.53; p=0.062). Subanalyses suggested that 
the increase in risk was most pronounced in men and smokers; however, comparative 
numbers of women and never-smokers were low. When analyses were restricted to 
participants with a study acquired spirometry, the association between an elevated plasma 
level of IL6 and the risk to develop definite COPD remained significant (HR 3.7; 95% CI 1.19- 
11.27; p = 0.024; Table 5). Again the increase in risk was less pronounced but still significant 
in the total group of definite and probable COPD participants (HR 2.7; 95%CI 1.22-6.06; 
p=0.014). 
Table 4: Association between plasma IL6 levels and incident COPD. 
COPD No. IL6 plasma Model 1 Model 2 
Definition cohort level HR 95% CI P- HR 95% CI P-
Definite 6 / 182 < 1.40 1.0 Reference 1.0 Reference 
COPD 8 / 182 1.40 - 2.40 1.6 0.55 - 4.57 0.393 1.6 0.54 - 4.75 0.397 
 14 / 181 > 2.40 3.1 1.20 - 8.13 0.020 3.1 1.11 - 8.76 0.031 
Definite & 16 / 191 < 1.39 1.0 Reference 1.0 Reference 
Probable 17 / 191 1.39 - 2.40 1.3 0.65 - 2.55 0.469 1.2 0.61 - 2.51 0.563 
COPD 22 / 190 > 2.40 1.9 0.97 - 3.53 0.062 1.6 0.80 - 3.29 0.178 
Cox proportional hazard models were used for analyses. 
Model 1: not adjusted for confounders. 
Model 2: adjusted for age, gender, total amount of pack years smoked at the start of the study and BMI. 
Abbreviations: CI=Confidence Interval; COPD=Chronic Obstructive Pulmonary Disease; IL6= Interleukin 6; HR= 
Hazard Ratio; SNPs = Single Nucleotide Polymorphisms. 
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Table 5: Association between plasma IL6 levels and incident COPD confirmed by spirometry 
performed in the Rotterdam Study. 
COPD No. Log IL6 Model 1 Model 2 
Definition cohort level HR 95% CI P- HR 95% CI P-
Definite 6 / 66 < 1.40 1.0 Reference 1.0 Reference 
COPD* 4 /33 1.40 - 2.40 1.4 0.40 - 5.07 0.579 1.1 0.29 - 3.94 0.913 
 11 /26 > 2.40 5.6 2.07 – 15.16 0.001 3.7 1.19 -11.27 0.024 
Definite & 12 /72 < 1.39 1.0 Reference 1.0 Reference 
Probable 7 / 35 1.39 - 2.40 1.3 0.51 - 3.31 0.578 1.0 0.38 - 2.62 0.994 
COPD* 15 / 31 > 2.40 3.5 1.63 - 7.47 0.001 2.7 1.22 - 6.06 0.014 
Cox proportional hazard models were used for analyses. *Only participants with a study acquired spirometry 
were included. 
Model 1: not adjusted for confounders. 
Model 2: adjusted for age, gender, BMI and total amount of pack years smoked at the start of the study. 
Abbreviations: CI=Confidence Interval; COPD=Chronic Obstructive Pulmonary Disease; IL6= Interleukin 6; HR= 
Hazard Ratio 
 
DISCUSSION 
The results of this study demonstrate that increased IL6 plasma levels at baseline were 
associated with a higher risk to develop COPD during follow-up. This effect remained 
significant after adjustment for several confounders and despite the exclusion of incident 
cases in the first three years of follow-up. In contrast, we found no strong evidence for an 
association between various common variants in the IL6 gene and the risk of COPD. Using 
the Mendelian randomization approach previously used for the association with CRP, we 
demonstrate that also elevated plasma IL6 is not causally related to COPD.61, 64 The 
rs1800795 SNP has previously been associated with susceptibility and outcome to several 
acute and chronic inflammatory diseases, such as juvenile chronic polyarthritis, type I 
diabetes mellitus, atherosclerosis and Alzheimer disease.78, 89-91 In COPD, patients carrying 
the IL6 GG genotype of this SNP showed higher plasma levels of IL6 and higher pulmonary 
artery pressure than those carrying the CC or CG genotype.92 These results raise the 
possibility that individuals homozygous for the C-allele may have a better prognosis from 
respiratory inflammatory diseases because of a less pronounced IL6 mediated acute phase 
response. The results of our study demonstrate that the most frequently studied SNP in the 
promoter region of the IL6 gene, rs1800795, did not influence the risk of COPD. Regarding 
other common variants in the IL6 gene, the rs2056576 SNP demonstrated a small increase in 
the risk for COPD. However, the associations were no longer significant after adjustment for 
age, gender, total amount of pack years smoked and BMI. In accordance with these results, 
we recently demonstrated in a murine model of COPD that - although IL6 levels were 
significantly increased after cigarette smoke exposure - the cigarette smoke-induced 
pulmonary and systemic manifestations were IL6 independent.54 
We did not find an association between the eight investigated common variants in the IL6 
gene and the development of COPD, confirming preliminary evidence from earlier reports.80-
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82 More recently, Smolonska et al. and Castaldi et al. both published a meta-analysis 
regarding genetic association studies of COPD using the candidate gene approach. Also, in 
these meta-analysis, they could not demonstrate a significant effect of the -174 G/C IL6 
polymorphism on the risk of COPD.93, 94 In contrast, a recent study by He et al. demonstrated 
that the rs1800795 SNP was associated with an accelerated decline in FEV1 and susceptibility 
to COPD in smokers.83 In addition, Cordoba-Lanus et al. did associate another SNP 
(rs1800796) with COPD and Yanbaeva et al. showed that a haplotype of the IL6 gene was 
associated with an increased risk of moderate-to-severe smoking-induced COPD.81, 84 
However, the design of these studies has several limitations. A first limitation is the small 
sample size of both the COPD and the control groups, which may lead to spurious results and 
can compromise the power for the genetic association analysis. Secondly, several studies 
had a cross-sectional design with its difficulty to judge the sequence of cause and effect. 
Thirdly, the studies were not population-based which makes them prone to selection bias. 
Lastly, the studies of He et al. and Yanbaeva et al. only included smoking subjects.83, 84 
There was no clear functional link between the different IL6 gene variants and the plasma 
IL6 level although rs1800795 and three other SNPs (rs10499563, rs1554606 and rs10242595) 
correlated significantly with plasma hsCRP levels. IL6 plasma concentrations show 
considerable interindividual variability in acute and chronic inflammation. It has been 
speculated that these differences may be determined genetically by variations in the IL6 
gene, such as the rs1800795 polymorphism.73 However, there is disagreement concerning 
the question whether any genotype is associated with higher IL6 plasma concentrations.78, 95-
97 It is possible that the effect is dependent on interactions between several SNPs in the IL6 
gene and that one SNP is not an optimal marker in this respect. Nevertheless there is 
agreement between our results and previous data by Vickers et al. and a genome-wide 
association study of Okada et al. which also show significant associations between SNPs in 
the promoter region of IL6 and serum CRP levels.79, 98 
The strengths of our study are the prospective, population-based cohort design and the 
large number of study subjects -almost 8000- with similar data collection procedures for 
every participant. In this large ongoing cohort study, more than 900 well-defined COPD cases 
were identified over a total follow-up time of 15 years (1989-2004), as previously described.5 
All data collection during follow-up of the cohort was performed in a prospective manner, 
without knowledge of future disease or research hypothesis, making selection and 
information bias unlikely. The prospective nature of this cohort study makes the results less 
prone to bias and made it possible to adjust analyses for established risk factors and 
confounders.  
Possible limitations of the study are the limited sample size of the plasma IL6 measurements, 
since they were only analyzed in a (random) subgroup of the total cohort, the absence of 
repeated measurements of the IL6 level and the absence of a study acquired spirometry and 
high resolution computed tomography of the chest of each participant. Therefore, we 
  
Part II: COPD, systemic inflammation and cardiovascular mortality 33 
cannot completely exclude the presence of bronchiectasis and/or bronchial asthma, which 
could affect the blood IL6 levels of COPD participants and controls. The limited sample size 
of plasma IL6 measurements might explain the lack of association between the IL6 
genotypes and IL6 plasma levels in our study cohort. Still, we observed a significant 
association between hsCRP levels and the rs1800795 IL6 genotype, as previously described.79 
Regarding the genotype data, there is a chance of missing associations with variants in low 
linkage disequilibrium with the SNPs. Furthermore, the results of this study are restricted to 
an European ancestry population, since they were based on data from the HapMap CEU 
sample. 
In conclusion, previous evidence has identified the presence of increased levels of IL6 in the 
plasma and airways of patients with COPD. However, it was not known if IL6 was causally 
involved in the pathogenesis of COPD or just an innocent bystander of the disease, related to 
smoking or other risk factors. The answer to this question became of clinical relevance with 
the recent development of tocilizumab, a humanized monoclonal IL6 receptor antagonist, 
which is already successfully used in refractory rheumatoid arthritis. In this Mendelian 
randomization study, we have demonstrated that elevated plasma levels of IL6 are 
significantly associated with an increased risk of incident COPD. In contrast, there was no 
strong evidence for an association between common variants in the IL6 gene and the risk of 
developing COPD.  
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ABSTRACT 
 
Background 
Studies suggest that statins decrease mortality in COPD patients but it is unknown which 
patients might benefit most. 
 
Objectives 
We investigated whether statins were associated with reduced mortality in COPD patients 
and whether effects differed according to baseline high-sensitivity C-reactive protein 
(hsCRP) concentration, a marker of systemic inflammation. 
 
Methods 
This nested case-control study was part of the Rotterdam Study, a prospective population-
based cohort study among 7983 subjects ≥ 55 years. Using automated pharmacy records, 
we evaluated statin use of 363 cases (COPD patients who died during follow-up of 17 
years) with 2345 age and sex matched controls (COPD patients who survived the follow-up 
period of the index case). 
 
Results  
Compared to never use, long-term statin use (> 2 years) was associated with a 39% 
decreased risk of death in COPD patients. Stratified according to the level of systemic 
inflammation, long-term statin use was associated with a 78% reduced mortality if hsCRP 
level > 3 mg/L, versus a non significant 21% reduced mortality if hsCRP level ≤ 3 mg/L. 
 
Conclusions 
Statin use is associated with a beneficial effect on all-cause mortality in COPD, depending 
on the baseline level of systemic inflammation. 
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6. The role of high-sensitivity C-reactive protein in statin 
treatment 
 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of 
morbidity and mortality worldwide. In industrialized countries about 400,000 COPD deaths 
occur each year and the mortality is expected to increase further.99 The disease is 
characterized locally by a chronic inflammation of small airways and destruction of alveoli 
and systemically, in a subset of COPD patients, by increased markers of inflammation, 
including high-sensitivity C-reactive protein (hsCRP) and interleukin 6 (IL6).13, 61, 100 The 
subset of COPD patients with persistent systemic inflammation has recently been shown to 
be associated with poor clinical outcomes despite similar lung impairment.34 The chronic 
low-grade inflammation might be the key link to the occurrence of various comorbidities in 
COPD including cardiovascular diseases and lung cancer. Moreover, these comorbidities are 
the main causes of death in mild to moderate COPD; therefore, with the increased 
recognition of the prognostic role of comorbidities in COPD, all-cause mortality has become 
one of the major endpoints in the evaluation of novel therapies.29  
 
Recent observational studies suggest that statins [3-hydroxy-3-methylglutaryl coenzyme A 
(HMG-CoA) reductase inhibitors] may reduce morbidity and mortality in COPD patients.101-103 
Statins are a class of drugs mainly used to treat hypercholesterolemia and to prevent 
cardiovascular events. Statins reduce cholesterol synthesis by inhibition of HMG-CoA 
reductase in the liver and increase low density lipoprotein-cholesterol uptake from the 
circulation. In addition to their lipid-lowering effect, statins also possess pleiotropic anti-
inflammatory and immunomodulating properties, and are able to reduce levels of 
inflammatory markers such as CRP.104 CRP is a validated biomarker of systemic inflammation 
in COPD and increased CRP levels in patients with COPD are associated with increased 
mortality.105, 106 Lee et al. recently showed in a randomized controlled trial with COPD 
patients, that pravastatin treatment significantly decreased CRP and IL6 levels compared to 
placebo and that the improvement of exercise tolerance was greater in those with a greater 
decrease of hsCRP levels and higher baseline CRP levels.107 However, to our knowledge, 
studies exploring whether the beneficial effect of statins on all-cause mortality in COPD is 
greater in those with increased systemic inflammation, have not yet been published. 
 
Therefore, the objective was to investigate whether statins have a beneficial effect on 
mortality in COPD patients with increased baseline hsCRP-levels in the Rotterdam Study, a 
large prospective population-based cohort study with long-term follow-up. 
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METHODS  
Study population and design 
We performed a nested case-control analysis in all COPD cases within the Rotterdam Study, 
a population-based cohort study aimed at assessing the occurrence of and risk factors for 
chronic diseases in the elderly.108 The Rotterdam study cohort includes 7983 participants 
aged ≥ 55 years, living in Ommoord, a well-defined suburb of Rotterdam, the Netherlands. 
Almost all participants (99.8%) are of Caucasian descent. Baseline data were collected from 
1989 until 1993 and each participant visits the research center every 2 to 3 years. In 
addition, participants are continuously monitored for the onset of major events which occur 
during follow-up through automated linkage with files from general practitioners. Nearly all 
participants (99.7%) are registered at one or more of seven automated pharmacies serving 
the Ommoord area. From these pharmacies, records of all filled prescriptions were available 
as of January 1st, 1991. The medical ethics committee of the Erasmus Medical Center, 
Rotterdam, and the review board of The Netherlands Ministry of Health, Welfare and Sports, 
approved the study. Participants gave written informed consent. 
 
Definition of cases and controls 
Cases and controls were nested in all participants of the source population of whom hsCRP 
was measured at baseline and of whom COPD was diagnosed by an obstructive spirometry 
[proportion of the forced vital capacity exhaled in the first second (FEV1/FVC) < 0.7] during 
the research center or pulmonologist visits or by a general practitioner. Physician diagnosed 
asthma patients were excluded. The incident COPD date was defined as the date of COPD 
diagnosis in the medical records, or the date of a first COPD medication prescription or the 
date of obstructive lung function examination, whichever came first. To ensure at least three 
months medication history for every subject, participants of whom study follow-up started 
before April 1st, 1991 were excluded. Cases were COPD subjects who died between April 1st, 
1991 and January 1st, 2008. The mortality date was taken as the index date. Controls were 
COPD subjects matched on sex and age (+/- 1 year) who were still alive on the same day of 
follow-up as their matched case. The duration of COPD was determined as the time between 
the incident COPD date and the index date. 
 
Statin exposure 
Complete information on all filled prescriptions on a day-to-day basis was obtained in 
automated format from the pharmacies. Subjects were classified as statin users if they had 
received at least one prescription for statins between start and index date. The duration of a 
prescription was calculated as the total number of delivered units divided by the prescribed 
daily number of units. The studied statins were simvastatin, pravastatin, fluvastatin, 
atorvastatin, cerivastatin and rosuvastatin. All drugs under study are only available on 
prescription in the Netherlands. 
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All-cause mortality & primary cause of death 
Information on vital status of the Rotterdam Study participants was obtained from general 
practitioners and from municipal records. Mortality follow-up started at baseline and was 
complete until January 1st, 2008. Causes of death during follow-up in the Rotterdam Study 
were coded according to the International Classification Of Diseases (ICD)-10.109 The 
following categories were applied for description in the text: cardiac mortality (ICD-10: I21-
I73, R96), pulmonary mortality (ICD-10: J15-J44), death from bronchial carcinoma (ICD-10: 
C34), death from other malignancies (ICD-10: C15-C96 except C34) and other causes of 
death (ICD-10: all other used codes). 
 
Covariables 
The nested case-control approach makes it possible to account for age and gender by 
matching and to adjust for other drug use at the index date. Therefore, we adjusted 
mortality risk estimates for use of cardiovascular drugs (antihypertensives, diuretics, β-
blockers, calcium channel blockers and agents acting on the renin-angiotensin system, ATC 
C02, C03, C07, C08 & C09 respectively), antidiabetics (ATC A10) and corticosteroids for 
systemic use (ATC H02) on the index date. Furthermore, the duration of COPD at index date 
and the following covariables at baseline were considered as potential confounders: pack 
years of cigarette smoking, total serum cholesterol, hsCRP, systolic blood pressure, body-
mass index (BMI), diabetes mellitus and cardiovascular covariables (myocardial infarction, 
coronary artery bypass graft, percutaneous transluminal coronary angioplasty, atrial 
fibrillation and heart failure); and their assessment has been described previously.61, 100 One 
prerequisite to be a confounder is that the variable is associated with the exposure, here 
statin use. Therefore, the relationship between the potential confounder and statin use 
(yes/no) was evaluated for categorical variables with a Chi Square test and for continuous 
variables with a Mann-Whitney U test. 
 
Statistical analysis 
Crude and adjusted odds ratios for mortality were estimated using conditional logistic 
regression. All models were adjusted for covariates that were significantly related to the 
exposure and changed the point estimate by more than 10%. Statin drug use was 
categorized as no use (0 days), short-term (1-30 days), mid-term (31 days-2 year) and long-
term use (≥ 2 year). Because every participant should have the opportunity to be a long-term 
user, COPD subjects with an incident date from January 1st, 2006 onwards, were excluded 
from analyses. Never use of statins was the reference category in all analyses. To gain power 
in the subdivided cause-specific mortality analyses, the groups mid-term and long-term use 
were combined. hsCRP serum levels were categorized as high versus average and low, based 
on the American Heart Association classification.110 Total serum cholesterol levels were 
categorized as high versus borderline and desirable, based on the Adults Treatment Panel III 
classification.111 All statistical analyses were performed using SPSS version 18 (SPSS Inc, 
Chicago, IL). P-values below the conventional level of significance (p< 0.05) were considered 
as statistically significant.  
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7983 participants
6658 participants with hsCRP 
measurement at baseline
758 COPD patients with study 
start date ≥ 1.4.1991
2345 age & sex matched 
CONTROLS
= COPD patients who survived 
the follow-up period of the 
index case
363 CASES
= COPD patients who died 
during follow-up
Exclusion of 71 
patients with 
incident  COPD
date ≥ 1.1.2006
RESULTS  
Baseline characteristics of the study population 
Within the source population of 7983 subjects, hsCRP was successfully measured in 6658 
participants at baseline.(Figure 1) Of these, 758 COPD patients were identified with a study 
start date after April 1st, 1991 to ensure at least three months of medication history. The 
vast majority (82,5%) of COPD patients was confirmed by an obstructive spirometry. 
Seventy-one patients with an incident COPD date after January 1st, 2006 were excluded 
from analyses because at least two years of follow-up between incident COPD and death 
were required to study the association of long-term statin use on mortality. During the 
potential follow-up of 17 years (1991-2008), 363 COPD patients deceased and were 
determined as cases. For each case, an average of six age- and sex-matched controls with 
COPD who survived the follow-up period of their matched case, were selected for a total of 
2345 controls. Because non-deceased participants with COPD could serve as a control in 
several case-control sets, the total number of controls is larger than the total number of 
incident cases of COPD. Table 1 shows the baseline characteristics of cases and controls. 
Cases were more frequently current smokers and had a higher prevalence of cardiovascular 
disease at baseline in comparison to the controls. Although age- and sex-matched, cases 
seem older and less often males as a consequence of the fact that there were more controls 
for males and lower age-categories. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study flowchart. 
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Table 1: Baseline characteristics. 
Cases  
(n=363) 
Controls 
(n=2345) 
Age at index date (years) 81 (75-85) 78 (74-81) 
Male 249 (69%) 1722 (73%) 
Smoking behaviour   
Never smoker 39 (11%) 252 (11%) 
Current smoker 145 (40%) 820 (35%) 
Former smoker 164 (45%) 1170 (50%) 
Missing 15 (4%) 103 (4%) 
Median pack years 30 (14-50) 
 
28 (13-47) 
 Body mass index (kg/m²) 
 
25 (23-28) 
 
26 (24-28) 
 Diabetes 43 (12%) 161 (7%) 
Systolic blood pressure (mmHg) 139 (123-155) 137 (124-152) 
Cardiovascular covariables§ 163 (45%) 724(31%) 
hsCRP (mg/L) 2.1 (1.1-4.0) 2.7 (1.3-4.8) 
hsCRP categoriesa                   ≤ 3 mg/L 
                                                   > 3 mg/L 
202 (56%) 
161 (44%) 
1524 (65%) 
821 (35%) 
Total serum cholesterol (mmol/l) 6.4 (5.6-7.2) 6.4 (5.7-7.3) 
Total cholesterol categories†    < 240 mg/dL 
                                                      ≥ 240 mg/dL 
166 (46%) 
197 (54%) 
1055 (45%) 
1290 (55%) 
Drug use at index date 
Antidiabetics 
Cardiovascular drugsb 
Oral corticosteroids 
 
41 (11%) 
209 (58%) 
138 (38%) 
 
194 (8%) 
1249 (53%) 
303 (13%) 
Duration of statin use 
None 
1-30 days 
31 days-2 years 
> 2 years 
 
299 (82%) 
5 (1%) 
18 (5%) 
41 (11%) 
 
1856 (79%) 
22 (1%) 
197 (8%) 
270 (12%) Duration of COPD at index date (years) 7 (3-11) 5 (2-8) 
Categorical variables are expressed as count (percentage). Values of continuous variables are expressed as 
median (25-75 percentiles). Cases: COPD patients who deceased during follow-up; controls: COPD patients 
who survived the follow-up period of the index case. §Cardiovascular covariables included myocardial 
infarction, coronary artery bypass graft, percutaneous transluminal coronary angioplasty, atrial fibrillation 
and heart failure. a hsCRP categories based on the American Heart Association110, total cholesterol categories 
based on the Adults Treatment Panel III classification111 bCardiovascular drugs include antihypertensives, 
diuretics, β-blockers, calcium channel blockers and agents acting on the renin-angiotensin system. 
 
Mortality in COPD patients 
The cumulative survival of COPD patients (n=758) was worse in those with a baseline hsCRP 
of more than 3 mg/L than in those with an hsCRP of 3 mg/L or less (Figure 2; log-rank: p < 
0.0001). In contrary, COPD patients with a total cholesterol of 240 mg/dL or more had a 
better survival than those with less than 240 mg/dL at baseline (data not shown; log-rank: p 
= 0.008). The most frequent causes of death in COPD patients are listed in Table 2. Most 
cases died due to cardiovascular causes (38.3%), followed by pulmonary complications of 
COPD (exacerbations, emphysema or pneumonia; 19.6%) and bronchial carcinoma (10.5%). 
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Figure 2: Kaplan-Meier survival curve of COPD patients (n=758) according to the hsCRP level 
at baseline. hsCRP= high-sensitivity C-reactive protein 
 
Table 2 : Causes of death in the COPD study population.  
  n % of Total  
Pulmonary 71 19.6 
 COPD 59 16.3 
  Pneumonia 12 3.3 
Cardiovascular  139 38.3 
 Mainly Heart failure 31 8.5 
  Stroke 30 8.3 
  Sudden (cardiac) death 30 8.3 
  Cardiac arrest 18 5.0 
  Acute myocardial infarction 12 3.3 
  Chronic ischaemic heart disease 6 1.7 
Cancer 88 24.2 
 Mainly Malignant neoplasm of bronchus and lung 38 10.5 
  Malignant neoplasm of colon 8 2.2 
  Malignant neoplasm of pancreas 6 1.7 
  Malignant neoplasm of prostate 6 1.7 
Other 65 17.9 
 Mainly Other ill-defined and unspecified causes of mortality 19 5.2 
  Dementia 8 2.2 
  Fracture of femur 7 1.9 
 Total: 363  
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Statin use and the risk of mortality in COPD 
Table 3 shows the association between statin use and the risk of all-cause mortality in COPD 
in a first model which is already adjusted for age and sex by matching and in a second model 
adjusted for all confounders related to the exposure which changed the point estimate by 
more than 10%. Baseline hsCRP-level was ruled out as confounder because it was not 
associated with statin prescriptions (nor as categorical variable neither continuously); 
however, hsCRP was evaluated as a potential effect modifier. Compared to never use, long-
term statin use (> 2 years) was associated with a 39% decreased risk of (all-cause) death in 
COPD patients (95%CI, 0.38-0.99) independent of age, sex, other drug use, duration of COPD, 
pack years, total serum cholesterol, BMI and cardiovascular covariables. 
Table 3 : Association between statin use and the risk of (all-cause) death in COPD. 
 
  
Model 1 Model 2 
OR 
95% CI 
p-value OR 
95%CI 
p-value 
Lower Upper Lower Upper 
No statin use Reference Reference 
1 - 30 days 1.34 0.49 3.67 0.572 1.61 0.48 5.48 0.443 
31 days - 2 years 0.68 0.40 1.16 0.156 0.64 0.35 1.15 0.136 
> 2 years 0.82 0.55 1.22 0.331 0.61 0.38 0.99 0.045 
Model 1: adjusted for age and sex by matching. 
Model 2: adjusted for age and sex by matching; adjusted in the analyses for the use of cardiovascular drugs, 
antidiabetics, oral corticosteroids and duration of COPD at index date, and pack years of cigarette smoking, 
total serum cholesterol, body-mass index and cardiovascular covariables at baseline. 
Abbreviations : CI = confidence interval; OR = Odds ratio 
 
Regarding cause-specific mortality in COPD, statin use (>30 days) compared to never use was 
associated with a significant 64% decrease in risk of pulmonary mortality (95%CI, 0.13-0.97). 
(Table 4) In model 2, there was a trend of decrease in risk of pulmonary and cardiovascular 
mortality. Statin use did not affect cancer mortality in both, crude and adjusted analyses.  
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Table 4 : Association between statin use and the risk of cause-specific mortality in COPD. 
  
Pulmonary mortality  
Model 1 Model 2 
OR 
95% CI p-
value 
OR 
95% CI p-
value Lower Upper Lower Upper 
No statin use Reference Reference 
>30 days of statin 0.36 0.13 0.97 0.044 0.37 0.13 1.08 0.068 
Cardiovascular mortality   
No statin use Reference Reference 
>30 days of statin 0.87 0.54 1.41 0.579 0.58 0.33 1.01 0.053 
Cancer mortality   
No statin use Reference Reference 
>30 days of statin 0.89 0.49 1.61 0.700 0.92 0.48 1.75 0.790 
Model 1: adjusted for age and sex by matching. 
Model 2: adjusted for age and sex by matching; adjusted in the analyses for the use of cardiovascular drugs at 
index date, and total serum cholesterol and cardiovascular covariables at baseline. 
Abbreviations : CI = confidence interval; OR = Odds ratio 
 
Statin use and the risk of (all-cause) death in COPD according to the level of systemic 
inflammation 
When stratified according to the level of systemic inflammation, long-term statin use was 
associated with a 78% reduced risk of death in COPD patients with a hsCRP level > 3 mg/L 
(95% CI, 0.06-0.74), versus a non significant 21% reduced risk of death in COPD patients with 
a hsCRP level ≤ 3 mg/L (95% CI, 0.41-1.55).(Table 5) When we excluded COPD patients 
exclusively diagnosed by GP, the point estimator did not change substantially (OR 0.49 in 
model 1 and OR 0.31 in model 2, investigating the effect of long-term statin use compared to 
no use in COPD subjects with hsCRP > 3mg/L). A sensitivity analysis restricting the subjects to 
smoking COPD patients with a hsCRP level > 3 mg/L, confirmed that long-term statin use 
compared to no use was associated with a 85% reduced risk of death (95% CI, 0.04-0.61, 
model 2). In Table 6, analyses were stratified according to the total serum cholesterol level 
at baseline. The reduced risk of death in COPD patients by long-term statin use was 
significant in both categories (<240 mg/dl and ≥ 240 mg/dl). 
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Table 5: Association between statin use and the risk of death in COPD, stratified according to 
the serum level of hsCRP (at baseline). 
 
Model 1 Model 2 
  
OR 
95% CI p-
value OR 
95% CI p-
value Lower Upper Lower Upper 
hsCRP  
≤ 3 mg/L 
No statin use Reference Reference 
1 - 30 days 0.66 0.14 3.16 0.606 0.77 0.14 4.09 0.756 
31 days - 2 years 0.70 0.35 1.43 0.335 0.60 0.27 1.34 0.212 
> 2 years 0.87 0.51 1.50 0.620 0.79 0.41 1.55 0.496 
hsCRP  
> 3 mg/L 
No statin use Reference Reference 
1 - 30 days 1.83 0.29 11.49 0.520 NA 
31 days - 2 years 0.77 0.30 1.96 0.584 0.95 0.33 2.73 0.917 
> 2 years 0.44 0.20 0.97 0.042 0.22 0.06 0.74 0.015 
Model 1: adjusted for age and sex by matching. 
Model 2: adjusted for age and sex by matching; adjusted by model for the use of cardiovascular drugs, 
antidiabetics, oral corticosteroids and duration of COPD at index date, and pack years of cigarette smoking, 
total serum cholesterol, body-mass index and cardiovascular covariables at baseline. 
Abbreviations : hsCRP, high-sensitivity CRP; CI, confidence interval; OR, Odds ratio; NA, Not applicable (due to 
low numbers) 
 
 
Table 6: Association between statin use and the risk of death in COPD, stratified according to 
the total serum cholesterol level (at baseline). 
 
  Model 1 Model 2 
  
OR 
95% CI p-
value OR 
95% CI p-
value Lower Upper Lower Upper 
Total 
cholesterol  
< 240 
mg/dL 
No statin use Reference Reference 
1 - 30 days 1.99 0.36 10.85 0.428 5.68 0.38 84.61 0.208 
31 days - 2 years 0.32 0.07 1.40 0.130 0.17 0.02 1.42 0.102 
> 2 years 0.41 0.13 1.30 0.129 0.16 0.03 0.91 0.039 
Total 
cholesterol      
≥ 240 
mg/dL 
No statin use Reference Reference 
1 - 30 days 1.24 0.22 7.01 0.806 1.22 0.07 21.19 0.891 
31 days - 2 years 0.69 0.37 1.32 0.266 0.65 0.32 1.33 0.238 
> 2 years 0.79 0.47 1.31 0.355 0.50 0.26 0.95 0.034 
Model 1: adjusted for age and sex by matching. 
Model 2: adjusted for age and sex by matching; adjusted by model for the use of cardiovascular drugs, 
antidiabetics oral corticosteroids and duration of COPD at index date, and pack years of cigarette smoking, 
body-mass index and cardiovascular covariables at baseline. 
Abbreviations : CI, confidence interval; OR, Odds ratio
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DISCUSSION 
This is the first prospective study in a general population showing that the beneficial effect 
of long-term statin use on the risk of mortality in COPD patients is modified by the baseline 
level of systemic inflammation. The results suggest that the subset of COPD patients 
characterized by increased markers of systemic inflammation might benefit most from long-
term statin therapy. One in three COPD patients in our study died from cardiovascular 
causes - figures which have also been described by other authors.29, 112 Although the 
protective effect of statins in COPD patients could represent solely an indirect effect on the 
cardiovascular comorbidities associated with COPD, our results also suggest an effect on 
respiratory mortality by statin use compared to never use.  
Increasing insights into the pleiotropic effects of statins unravel several possible mechanisms 
for the beneficial effects seen in COPD patients. Beyond their known ability to inhibit 
endogenous cholesterol synthesis, statins exert immunomodulating effects in both systemic 
and pulmonary cytokine driven inflammation by inhibiting guanosine triphosphatase 
proteins.113 Statins down regulate the expression of adhesion molecules involved in the 
recruitment of inflammatory cells, and of chemokines which are increased in COPD, such as 
CCL2 and CXCL8.114 Furthermore, simvastatin reduces the expression of matrix 
metalloproteinases (MMPs) involved in COPD matrix remodelling, such as MMP2, MMP9 
and MMP12.115, 116 In support of a direct effect of statins in COPD, Lee et al. demonstrated in 
a rat model of smoking-induced emphysema that simvastatin ameliorated the structural and 
functional derangements of the lungs partly by suppressing inflammation and matrix MMP9 
induction.117 Statins may even reduce oxidative stress, related to their ability to scavenge 
oxygen derived free radicals.118  
The 39% reduced risk of death in COPD patients by using (long-term) statin therapy is 
consistent with findings of previous (retrospective) observational studies.102, 103 Similar to 
the retrospective study of Frost et al., we found a protective effect of statin use on the risk 
of pulmonary mortality in COPD.119 Furthermore, our results showed that having an hsCRP 
baseline level of more than 3 mg/L was associated with increased mortality and therefore 
we expected, if statins were effective, that the pre-specified subset of COPD patients with 
high hsCRP levels would benefit most of treatment. Surprisingly but consistent with other 
prospective population-based studies in the elderly, we found that COPD patients with a 
total cholesterol of 240 mg/dL or more had a better survival.120, 121 Selective survival or 
changes in the arterial wall by aging might yield individuals resistant to the effects of high 
cholesterol concentrations in the blood or high cholesterol levels might be associated with 
less frailty. 
Importantly, we demonstrate a significant interaction between statin use and the degree of 
systemic inflammation because the protective effect of statins was only significant in COPD 
patients with the highest hsCRP serum level. There was no significant effect in COPD patients 
with a low-to-moderate degree of systemic inflammation, which cannot be explained due to 
lack of power as numbers were even higher in this stratum. The same phenomenon has also 
been reported in cardiovascular studies and one RCT in COPD patients. Kinjo et al. described 
a decreased hazard by statin therapy for 1-year mortality in patients with a CRP level above 
2.9 mg/L who had an acute myocardial infarction.122 In addition, the JUPITER trial of 
apparently healthy persons without hyperlipidemia but with elevated hsCRP levels, 
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demonstrated that rosuvastatin significantly reduced the incidence of all cause mortality and 
was associated with a 60% decreased risk for cardiovascular endpoints.123 However, a recent 
RCT in persons at high risk of vascular events, could not confirm that these vascular benefits 
of statin therapy were affected by the baseline CRP concentration.116 The RCT in COPD 
patients by Lee et al. demonstrated that the improvement in exercise time by statin 
treatment is modified by plasma hsCRP-levels.107 Because both the inflammation and 
therapeutic interventions in COPD have been studied merely in (ex)smoking subjects, we 
furthermore restricted the analyses to smoking COPD patients, which confirmed the 
beneficial effects of long-term statin use in the subgroup with greater inflammation. 
Because of its observational character, a possible limitation of our study is that treatment 
with statins was not randomly assigned. Our results could therefore be flawed by 
confounding by indication. However, because statins are selectively prescribed in subjects 
who have substantial comorbidities such as diabetes mellitus and cardiovascular disease, 
this kind of confounding would only underestimate the protective effect of statins on the 
risk of death. Consequently, this would mean that the true protective effect is even stronger 
than we measured. Secondly, we cannot exclude a healthy user bias if statins are prescribed 
more readily in health-conscious, medical-attention-seeking patients or in those patients 
who are expected to live long enough to benefit from statin treatment. Importantly, 
however, this would not explain effect modification by baseline hsCRP as this measurement 
was not used for usual patient care. Finally, of a minority of COPD patients diagnosed by GP 
(17,5%), we do not have the certainty that diagnosis was confirmed by an obstructive 
spirometry. However, exclusion of this subgroup did not change the point estimator 
substantially. 
The strengths of this study are the high quality information available about exposures prior 
to outcome with a prospective data collection, the general population based setting, the 
large number of subjects that participated in the Rotterdam Study and the long duration of 
follow-up. The high response rate and virtually complete follow-up for every participant 
makes information and selection bias for these data unlikely. An important advantage is the 
availability of continuous pharmacy dispensing data with complete pharmacy records of all 
filled prescriptions on practically all members of the cohort, providing very specific and 
detailed information on drug use and thus minimizing the risk of exposure misclassification. 
Furthermore, the nested case-control approach made it possible to account for other drug 
use at index date, a major confounder in the association between statins and mortality. It is 
important that these results should be further investigated in randomized controlled trials 
before recommending widespread statin use in COPD patients. According to 
Clinicaltrials.gov, several randomized clinical trials are ongoing. 
In conclusion, statin use is associated with a decreased risk of all-cause mortality in patients 
with COPD, depending on the degree of systemic inflammation. These results suggest that in 
an older population of COPD patients, CRP levels might guide the clinician better than total 
cholesterol levels in his decision to start lipid lowering therapy. This study may provide a 
rationale for undertaking more definitive randomized clinical trials to confirm the impact of 
statin use on the outcome of COPD and to elucidate the mechanisms by which they may 
work.  
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ABSTRACT 
 
Background 
Sudden cardiac death (SCD) and chronic obstructive pulmonary disease (COPD) are both 
common conditions in the elderly. Previous studies have identified an association 
between COPD and cardiovascular disease, and with SCD in specific patient groups. 
 
Objectives 
To investigate whether there is an association between COPD and SCD in the general 
population. 
 
Methods 
The Rotterdam Study is a population-based cohort study among 14 926  subjects aged 45 
years and older with up to 24 years of follow-up. Analyses were performed with a (time-
dependent) Cox proportional hazard model adjusted for age, sex and smoking. 
 
Results  
Of the 13 471 persons included in the analysis; 1615 had a diagnosis of COPD and there 
were 551 cases of SCD. COPD increased the risk of SCD (age- and sex adjusted HR 1.34, 
95%CI 1.06-1.70). The risk particularly increased in the period 2000 days (5.48 years) 
after the diagnosis of COPD (age- and sex adjusted HR 2.12, 95%CI: 1.60-2.82) and 
increased further to a more than threefold higher risk in COPD subjects with frequent 
exacerbations during this period (age- and sex adjusted HR 3.58, 95%CI 2.35-5.44). 
Analyses restricted to persons without prevalent myocardial infarction or heart failure 
yielded similar results. 
 
Conclusions 
COPD is associated with an increased risk for SCD, independent of prevalent coronary 
heart disease. The risk especially increases in persons with frequent exacerbations five 
years after the diagnosis of COPD. This risk indicator could provide new directions for 
better-targeted actions to prevent SCD. 
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7. COPD and Sudden Cardiac Death 
INTRODUCTION 
Sudden cardiac death (SCD) forms a substantial part of cardiovascular mortality, which is the 
leading cause of death globally124, with a currently estimated incidence of 4 to 5 million 
cases worldwide per year.125 SCD is primarily caused by ventricular arrhythmias126, 127 and  
risk factors for SCD include male gender, increasing age125, a history of heart failure or cardiac 
ischemia, cardiomyopathies, long QT syndrome (LQTS) and alcohol and drug use.128 However, 
SCD is a heterogeneous outcome with multiple etiological pathways of which many have not 
been established. This complicates an adequate risk assessment and prevention plan for SCD. 
 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death.2 COPD is 
characterized by a progressive airflow limitation and is associated with a chronic 
inflammatory response in the airways and lungs. Besides these local pulmonary 
manifestations, systemic effects and comorbidities are frequently present and determine the 
prognosis of patients with COPD.1, 129, 130 Patients with COPD have a two to threefold higher 
risk of developing cardiovascular disease and half of COPD deaths can be attributed to 
cardiovascular disease.131, 132 Although the underlying mechanisms for this high 
cardiovascular morbidity and mortality in patients with COPD are not fully established to 
date, a role for the accompanied hypoxia and hypoxemia133, higher heart rate134, systemic 
inflammation133 or recurrent exacerbations has been suggested. Moreover, patients with 
COPD suffer more frequently from ventricular arrhythmias than controls.135-137 In patients 
hospitalized for an exacerbation of COPD, atrial fibrillation and ventricular arrhythmias are 
independent predictors of death at one year.138  
 
Furthermore, COPD has also been shown to be an independent predictor of SCD in high-risk 
patients after a percutaneous coronary intervention and coronary artery bypass graft.138, 139 
However, this association has not yet been assessed in the general population. Therefore, 
our objective was to assess whether COPD is an independent risk factor for SCD in the 
general population, and whether COPD exacerbations and systemic inflammation modulate 
the association between COPD and SCD.  
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METHODS 
Setting 
The Rotterdam Study is a prospective population-based cohort study in 14 926 people aged 
≥45 years, which started in 1990 in the Ommoord district, in the city of Rotterdam, the 
Netherlands.20, 21 All inhabitants of the Ommoord district, aged 55 years of age and older 
were invited to participate (n=10 215). At baseline, from 1990 through 1993, 7 983 
participants (response rate 78%) were included. In 2000, an additional 3 011 participants, 
out of 4 472 invitees, were enrolled (response rate 67%). This extension consisted of all 
persons living in the study district who had become 55 years of age or had moved into the 
study district. A second similar extension of the cohort was initiated in 2006, in which 3 932 
participants (out of 6 057 invitees; response rate 65%), aged 45 years and older were 
included. Follow-up examinations are conducted periodically, approximately every 4 to 5 
years. Examinations consist of a home interview and an extensive set of tests at a specially 
built research facility in the study district. Besides this, participants are continuously 
monitored for major morbidity and mortality through linkage of general practitioners and 
municipality records to the study base. The Rotterdam Study was approved by the medical 
ethics committee according to the Population Study Act Rotterdam Study executed by the 
Ministry of Health, Welfare and Sports of the Netherlands. The study population consisted of 
participants who gave informed consent for follow-up.  
COPD 
COPD was diagnosed by an obstructive spirometry (FEV1/FVC < 0.70) performed at the 
research center visit or, if not available, by a physician based on the combination of clinical 
history, physical examination and spirometry.140 Asthma patients were excluded. The date of 
incident COPD was defined as the date of obstructive lung function measurement, the date 
of COPD diagnosis in the medical records or the date of a first COPD medication prescription 
in someone with established COPD, whichever came first. Medication use was obtained 
through pharmacy-filled prescription data from seven pharmacies in the region which are all 
on one computer network. Moderate exacerbations were defined as needing a course of 
steroids and/or antibiotics and severe exacerbations as needing hospitalization. Frequent 
exacerbators were defined as COPD participants who had during follow-up on average two 
or more moderate or severe exacerbations a year.141 
Sudden Cardiac Death (SCD) 
SCD cases were validated independently by two researchers and confirmed by a cardiologist 
through details from the medical records. In witnessed deaths, SCD was diagnosed according 
to Myerburg’s definition endorsed by the European Society of Cardiology: “a natural death 
due to cardiac causes, heralded by abrupt loss of consciousness within one hour from onset 
of acute symptoms; pre-existing heart disease may have been known to be present, but the 
time and mode of death are unexpected”.142, 143 Unwitnessed deaths were coded as SCD if 
death was unexpected in persons found death, while they were in a stable medical condition 
24 hours before they were found and without evidence of a noncardiac cause.144 
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High-sensitivity C-reactive protein (hsCRP) serum level measurement 
HsCRP serum levels were measured as previously described.61 Non-fasting blood was 
collected at baseline and stored at -80°C until CRP measurement. Storing temperature did 
not affect stability of CRP. HsCRP measurements were performed on all blood samples using 
a rate near-infrared particle immunoassay (Immage Immunochemistry System; Beckman 
Coulter, San Diego, CA).  
Covariables 
Information on covariables was obtained through interview (i.e. smoking and alcohol use), 
laboratory, medical files, or physical examination (i.e. height, weight, systolic and diastolic 
blood pressure, myocardial infarction, heart failure, revascularization procedures, diabetes 
mellitus, atrial fibrillation, heart-rate corrected QT (QTc) interval and statin use) at the 
regular visits of the study participants to the Rotterdam Study research center. Pack years of 
cigarette smoking were computed as duration of self-reported smoking (years) multiplied by 
the number of daily smoked cigarettes, divided by 20. Body mass index was calculated as 
weight in kilograms divided by height in meters squared. Systolic (SBP) and diastolic blood 
pressure (DBP) were measured in sitting position at the right upper arm. The average of 2 
consecutive measurements was taken.  Hypertension was defined as a SBP >140 mmHg, DBP 
>90 mmHg, or use of blood pressure lowering medication for the indication hypertension. 
Myocardial infarction was adjudicated based on a combination of symptoms, ECG 
measurements and enzyme markers. Heart failure diagnosis was adjudicated in accordance 
with the guidelines of the European Society of Cardiology and included typical signs or 
symptoms of heart failure confirmed by objective evidence of cardiac dysfunction, as 
described in more detail previously.145, 146 A revascularization procedure is either a 
percutaneous coronary intervention or a coronary artery bypass graft. Diabetes mellitus was 
defined as fasting glucose above 6.9 mmol/L, non-fasting glucose above 11.0 mmol/L, the 
use of blood glucose lowering medication, or a previous diagnosis of diabetes mellitus. Atrial 
fibrillation is ascertained from electrocardiogram measurements as well as medical records. 
QTc interval according to Bazett’s formula was derived from a standard electrocardiogram. 
More detailed information on the methods of data collection and definitions of cardiac 
outcomes have been previously described.146 
 
Statistical analysis 
Differences between subjects with and without COPD were studied using Mann-Whitney U 
and Chi-Square tests. Time-dependent cox proportional hazard models were performed to 
assess the association between COPD and SCD. All models were adjusted for age and sex, 
and additionally for covariables which changed the risk estimate by more than 10%. 
Potential confounders were age, sex, height, weight, body mass index, smoking behaviour, 
pack-years, myocardial infarction, heart failure, coronary revascularisation procedures, 
systolic blood pressure, diastolic blood pressure, hypertension, total serum cholesterol, 
diabetes mellitus, atrial fibrillation, heart-rate corrected QT interval according to Bazett’s 
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formula, and statin use at baseline. High-sensitivity CRP (hsCRP) serum levels were 
categorized as high versus moderate/low, based on the American Heart Association 
classification.110 We constructed cumulative survival curves using the Kaplan-Meier method 
and used Log-rank to determine significant survival differences.  
We performed a sensitivity analysis by exclusion of persons with prevalent heart failure and 
myocardial infarction. Since we were interested in how COPD affects SCD in general terms, 
Cox models for the hazard on SCD that treat other death as censored were perfectly valid.147 
Nevertheless, with regard to the competing risk of non-SCD, we performed a sensitivity 
analysis using the data augmentation method and unstratified model described by Lunn & 
McNeil148 to estimate the hazard ratio (HR) of SCD in comparison with non-SCD. Although it 
should be mentioned that if the proportionality assumption is not satisfied, then the 
stratified Lunn-McNeil model should be used, which is identical to the Cox cause-specific 
model.149 Furthermore, since we were also interested in the incidence of SCD, we estimated 
the cumulative incidence function (CIF)150 from the competing risk data and performed the 
Gray’s test for equality of CIFs.151, 152. The CIF is a summary curve, showing the cumulative 
event rates over time due to a particular cause150, 153. The Gray’s test is developed for the 
comparison of the cumulative incidence of events among different groups151.  
Follow-up time was determined as the time between study entry (i.e. for subjects without 
COPD or with prevalent COPD) or incident COPD date (i.e. for subjects with incident COPD) 
and death or end of study (January 1st 2011). This definition includes the time at risk for 
sudden cardiac death. However, we also performed a sensitivity analysis adding the time 
between cohort entry and incident COPD to the control follow-up time. A two-sided p-value 
below 0.05 was considered statistically significant. Statistical analyses were performed using 
R Statistical Software (Foundation for Statistical Computing, Vienna, Austria) and SPSS, 
version 20.0 (IBM Corp., Somers, NY, USA). 
 
RESULTS  
General characteristics 
Table 1 shows the baseline characteristics of the study population (n=13 471) with a median 
age of 64 years (interquartile range (IQR)=16) at the start of follow-up. COPD subjects were 
older, more often male, more (current) smokers, had a slightly lower body mass index, 
higher levels of hsCRP at baseline and had more frequently a medical history of myocardial 
infarction and coronary artery bypass graft. During a median follow-up of 3 229 days (8.84 
years; IQR=3 651 days; total of 123 024 person years of follow-up), 5 197 (39%) of the 
participants died of whom 551 died suddenly. 82 (5%) COPD subjects and 469 (4%) subjects 
without COPD died due to SCD (Figure 1). The SCDs were witnessed in about half of the cases 
(54%) and the ratio of witnessed versus unwitnessed SCD was not different for COPD 
subjects versus subjects without COPD (p=0.975). 
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14 628 subjects within the Rotterdam Study
with follow-up
13 471 subjects
1 615 subjects with COPD 
11 856 subjects without COPD
551  subjects with 
sudden cardiac death
82    COPD
469  no COPD
12 920  subjects without      
sudden cardiac death
1 533    COPD
11 387  no COPD
1 157 subjects with asthma excluded
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
Figure 1: Flow chart of the study population. 
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Table 1: Baseline characteristics of the population at cohort entry (n=13 471). 
 
 
COPD  
(n= 1 615) 
No COPD  
(n=11 856) 
P-value 
Age, in years 70 (13) 63 (15) <0.001 
Males 909 (56) 4,727 (40) <0.001 
Smoking status  
        Never smoker 
Former smoker 
Current smoker 
251 (16) 
689 (44) 
632 (40) 
4,361 (38) 
4,903 (43) 
2,209 (19) 
<0.001 
Pack-years of cigarette smoking 26 (37) 3 (23) <0.001 
Height (cm) 170 (13.2) 167 (13.6) <0.001 
Weight (kg) 74.9 (17.0) 74.6 (17.8) 0.773 
BMI, in kg/m² 25.8 (4.7) 26.4 (4.9) <0.001 
hsCRP, in mg/L 1.9 (3.0) 1.5 (2.5) <0.001 
Myocardial infarction 118 (7) 581 (5) <0.001 
Heart failure 46 (3) 224 (3) 0.090 
Coronary revascularization 
        CABG* 
        PTCA* 
57 (4) 
41 (3) 
19 (1) 
334 (3) 
212 (2) 
155 (1) 
0.141 
0.048 
0.608 
Systolic blood pressure 137.0 (29.0) 137.0 (29.0) 0.399 
Total serum cholesterol (mmol/l) 6.2 (1.6) 6.1 (1.6) 0.036 
Diastolic blood pressure 75.0 (16.0) 77.0 (85.0) <0.001 
Hypertension 741 (55) 5344 (56) 0.499 
Atrial fibrillation 71 (5) 438 (4) 0.268 
QTc interval 429.5 (31.0) 429.0 (30.0) 0.618 
Diabetes mellitus 154 (10) 1196 (10) 0.488 
Categorical variables are expressed as numbers (percentage). Values of continuous variables are 
expressed as median (interquartile range). * Numbers overlap 
There were missings in baseline smoking status (n=426),  pack-years (n=728), height (n=1447), 
weight (n=1438), BMI (n=1455), hsCRP (n=1922), myocardial infarction (n=161), heart failure 
(n=297), coronary revascularization (n=583), systolic/ diastolic blood pressure (n=1317), cholesterol 
(n=1439), hypertension (n=2547), atrial fibrillation (n=1876) and QTc interval (n=1659). 
Abbreviations: BMI = body mass index; CABG=coronary artery bypass graft; COPD=chronic 
obstructive pulmonary disease; hsCRP= high-sensitivity C-Reactive Protein; QTc=heart-rate 
corrected QT interval according to Bazett’s formula; PTCA=percutaneous transluminal coronary 
angioplasty 
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Association between COPD and SCD 
Figure 2 illustrates the higher probability of SCD for COPD subjects compared to subjects 
without COPD. Adjusted for age and sex, COPD was significantly associated with an increased 
risk of dying due to SCD (HR 1.34, 95%CI: 1.06-1.70). A stratified analysis in patients without 
prevalent myocardial infarction nor heart failure nor CABG nor PCI resulted in a comparable 
age and sex adjusted HR of 1.38 (95%CI: 1.03-1.85). A sensitivity analysis using the stratified 
Lunn-McNeil method to model the competing risk effect of other causes of death, resulted in 
an age and sex adjusted HR of COPD on SCD of 1.43; 95%CI: 1.19-1.67. The cumulative 
incidence function (CIF) in the online supplement represents the higher incidence of SCD and 
other causes of death for subjects with COPD compared to subjects without COPD (see 
Figure 3). The CIFs for COPD versus no COPD were statistically significant for SCD (Gray’s 
test; p=0.0006) and for non-SCD (Gray’s test; p<0.0001). Another sensitivity analysis adding 
the time between cohort entry and incident COPD to the control follow-up time did not 
substantially change the estimate. 
 
Figure 2 further illustrates that the distinction of SCD risk according to COPD status occurred 
about 2000 days (5.48 years) after the study start (incident COPD date or cohort entry for 
participants without COPD), while the difference for other causes of death was seen much 
earlier (Figure 3). Since the proportional hazard assumption was not satisfied, we evaluated 
the effect of COPD on SCD using a time-dependent Cox regression analysis. The interaction 
between COPD and the dichotomous time indicator (more or less than 2000 days) was 
significant (p<0.001) and adjusted for age and sex, only the HR for the period 2000 days after 
the COPD incident date was significant (HR 2.12, 95%CI: 1.60-2.82; Table 2). Furthermore, 
COPD was associated with an almost twofold increased risk to develop SCD, independent of 
age, sex and pack years of cigarette smoking (HR 1.93, 95%CI 1.44-2.59; Table 2). The other 
potential confounders mentioned in the methods did not significantly influence the effect. 
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Figure 2: Kaplan-Meier curve of sudden cardiac death according to COPD status (Log-rank 
p<0.001).  
 
 
 
Figure 3: Cumulative incidence function of sudden cardiac death (Gray’s test; p=0.0006) and 
other death (Gray’s test; p<0.0001) according to COPD status. 
Abbreviations: COPD= Chronic Obstructive Pulmonary Disease; SCD= Sudden Cardiac Death  
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Table 2: COPD and the hazard on sudden cardiac death for the period >2,000 days (5.48 years) of 
follow-up.  
Model 1 Model 2 
 HR 95% CI P-value HR 95% CI 
P-
value 
COPD 2.12 1.60-2.82 <0.001 1.93 1.44-2.59 <0.001 
COPD without frequent 
exacerbations 
1.66 1.16-2.37 0.005 1.52 1.06-2.19 0.023 
COPD with frequent 
exacerbations 
3.58 2.35-5.44 <0.001 3.21 2.08-4.95 <0.001 
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex and pack years of cigarette smoking. 
Time-dependent Cox Regression analysis for the period >2,000 days of follow-up. 
Frequent exacerbations were defined as having at least two moderate or severe exacerbations a year, averaged 
over the total years of follow-up. 
Abbreviations: CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; HR= Hazard Ratio 
 
Influence of exacerbations 
Regarding the influence of COPD exacerbations, 366 (23%) of 1 615 COPD subjects had 
frequent exacerbations. 33 (9%) frequent exacerbators compared to 49 (4%) COPD subjects 
without frequent exacerbations died due to SCD. The Kaplan Meier curve for SCD in Figure 4 
illustrates the poorer survival for COPD subjects with frequent exacerbations (Log-rank 
p<0.001). Adjusted for age, sex and pack years of cigarette smoking, the COPD frequent 
exacerbator phenotype was significantly associated with a more than threefold increased 
risk of developing SCD (HR 3.21; 95%CI: 2.08-4.95; Table 2). A sensitivity analysis using the 
stratified Lunn-McNeil method to model the competing risk effect of other causes of death, 
resulted in an age and sex adjusted HR of the frequent exacerbators on SCD of 2.51 (95%CI: 
2.15-2.86). Finally, the cumulative incidence of SCD was significantly higher when COPD 
subjects had frequent exacerbations (Figure 5). 
 
Influence of baseline systemic inflammation (hsCRP) 
Among the 13 471 subjects, 11 549 (85.7%) had a baseline hsCRP measurement. A linear 
regression model adjusted for age and sex, demonstrated that the natural logarithm of 
hsCRP concentration was significantly increased in subjects with COPD and SCD compared to 
subjects with COPD without SCD (p<0.05). When stratified according to the level of baseline 
systemic inflammation, the HR for SCD was significantly increased in COPD subjects with 
frequent exacerbations having a hsCRP level > 3 mg/L (HR 3.67; 95% CI: 1.97-6.85; Table 3). 
In contrast, in all subjects with a low-to-moderate degree of systemic inflammation, the HR 
for SCD was significantly increased in COPD subjects without frequent exacerbations (HR 
1.84; 95% CI: 1.16-2.91; Table 3). 
56 
 
 
Figure 4: Kaplan-Meier curve of sudden cardiac death according to COPD status with or 
without frequent exacerbations (Log-rank p<0.001). 
 
 
 
Figure 5: Cumulative incidence function of sudden cardiac death (Gray’s test; p=0.0002) and 
other death (Gray’s test; p<0.0001) according to COPD exacerbator status (no COPD, COPD 
without frequent exacerbations, COPD with frequent exacerbations).  
Abbreviations: COPD= Chronic Obstructive Pulmonary Disease; FE= COPD frequent 
exacerbator; SCD= Sudden Cardiac Death 
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Table 3: COPD and the hazard on sudden cardiac death for the period >2 000 days (5.48 
years) of follow-up, stratified according to the serum level of hsCRP. 
  Model 1 Model 2 
 
 HR 95% CI P-value HR 95% CI P-value 
hsCRP  
≤ 3 
mg/L 
COPD 1.98 1.32-2.98 0.001 1.76 1.15-2.68 0.009 
COPD, no frequent 
exacerbations 
2.09 1.34-3.26 0.001 1.84 1.16-2.91 0.010 
COPD with frequent 
exacerbations 
1.60 0.65-3.90 0.304 1.48 0.60-3.64 0.391 
hsCRP  
> 3 
mg/L 
COPD 1.88 1.16-3.05 0.010 1.93 1.18-3.16 0.008 
COPD no frequent 
exacerbations 
1.21 0.62-2.35 0.573 1.24 0.63-2.42 0.535 
COPD with frequent 
exacerbations 
3.51 1.90-6.49 <0.001 3.67 1.97-6.85 <0.001 
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex and pack years of cigarette smoking. 
Time-dependent Cox Regression analysis for the period >2,000 days of follow-up. 
Frequent exacerbations were defined as having at least two moderate or severe exacerbations a year, 
averaged over the total years of follow-up. 
Abbreviations: CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; hsCRP= high-
sensitivity C-Reactive Protein; HR= Hazard Ratio 
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DISCUSSION 
In this population-based study in community dwelling middle-aged and elderly persons, we 
show an increased risk for SCD in subjects with COPD. The risk almost doubles in the period 2 
000 days (5.48 years) after the diagnosis of COPD and there was a more than threefold 
increase in the risk for SCD in patients with frequent exacerbations having a higher degree of 
baseline systemic inflammation. 
An increased risk for SCD has been previously described in specific patient populations at 
high risk of SCD and a diagnosis of COPD.138 From previous studies we already know that 
COPD increases the risk of ventricular arrhythmias and cardiovascular morbidity and 
mortality.131, 132, 135-137, 154-156 Our prospective cohort study for the first time demonstrates 
that COPD is associated with an increased risk of SCD in the general population. 
There are several factors in persons with COPD that could play a role in the mechanism which 
ultimately leads to SCD. COPD is associated with a prolongation of the QTc interval, currently 
the most well-known electrocardiogram-derived risk indicator for SCD.157, 158 Other factors 
that are present in persons with COPD are a higher resting heart rate, hypoxia and 
hypoxemia, cardiac ischemia and heart failure; all known risk factors for SCD.128, 131-134, 154, 159, 
160 On top of this, exacerbations could provide an additional mechanism through which SCD 
is caused. Suissa et al. recently described that with every exacerbation both the risk of 
subsequent COPD exacerbations and the risk of mortality is increased.161 Elevated 
biomarkers of cardiovascular morbidity, such as troponins, midregional-pro atrial natriuretic 
peptide and N-terminal-pro brain natriuretic peptide (the latter two are both indicators of 
heart failure) are associated with exacerbation mortality and a higher risk for myocardial 
infarction and stroke after a COPD exacerbation has been observed.162-165 Wedzicha et al. 
described that COPD exacerbations may lead to increased cardiovascular morbidity through 
systemic inflammation.25 This hypothesis is endorsed by another study that showed 
increased levels of C-reactive protein and interleukin-6 following COPD exacerbations.166 
Previous studies have also shown associations between a high CRP and cardiovascular 
disease and SCD.167-169 Interestingly, our results demonstrate that the effect of frequent 
exacerbations was modified by the baseline degree of systemic inflammation (hsCRP). In the 
absence of increased systemic inflammation, COPD without frequent exacerbations 
significantly increased the risk on SCD.  Since the Kaplan-Meier curve suggests that a latency 
period was more pronounced for COPD patients without frequent exacerbations, one might 
speculate two different mechanisms underlying SCD in COPD. Possibly, COPD patients with 
substantial systemic inflammation develop more atherosclerosis increasing the risk of 
coronary heart disease whereby each exacerbation amplifies these mechanisms an results in 
an acute increased risk on SCD. While in COPD patients without these factors, COPD might 
lead via hyperinflation to remodeling, pulmonary hypertension, cardiac arrhythmias and 
subsequently SCD.  
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The association between COPD and SCD provides various directions for further research. The 
first is to unravel the underlying mechanisms.  A second is to assess the role of respiratory 
medication in the risk for SCD.170 Thirdly, further research is needed to identify effective 
strategies to prevent SCD in COPD patients. 
Our study has several strengths and some limitations. First, in previous studies the 
association between COPD and SCD has been assessed only in specific patient populations 
who already have an increased risk of SCD, but not in a general population setting with 
adjustment for all known confounders. Second, SCD was validated by research physicians 
blinded to the COPD status of the subject. Another strength of this study is that we have 
prospectively gathered data on morbidity and mortality events, and on covariables, limiting 
the risk of information bias. However, some potential misclassification may have occurred by 
inclusion of unwitnessed deaths, though the percentage of unwitnessed deaths in our study 
was not different for COPD subjects compared to subjects without COPD. It has previously 
been suggested that participants in a prospective cohort study are more healthy than non-
participants.171, 172 The Rotterdam Study has an overall response rate of 72%. Persons with 
more severe COPD could have had lower participation rates. However, in our study this 
would have only resulted in an underestimation of the effect.   
Conclusion 
COPD is an independent risk factor for SCD in the general population, especially in the period 
2,000 days (5.48 years) after the diagnosis of COPD. The risk further increases in COPD 
patients with frequent exacerbations having a higher degree of baseline systemic 
inflammation. 
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PART III: COPD, ANGIOPATHY AND 
CEREBROVASCULAR MORBIDITY 
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ABSTRACT 
 
Increasing evidence associates lung impairment with brain disorders in the elderly. The 
most prevalent chronic lung disease in elderly is COPD, a major public health problem with 
significant economic burden. Despite the clinical relevance and the important impact of 
cerebrovascular disease and neurodegenerative disorders in respiratory impaired elderly, 
the evidence on potential explanatory mechanisms is scarce.  
 
The aim of the present review is therefore to summarize current scientific knowledge to 
provide a better understanding of the interplay between the lung and the aging brain and 
to define remaining knowledge gaps. 
 
This review article 1) provides a general overview of the epidemiology of stroke, cerebral 
small vessel disease, cognitive impairment, depression and anxiety in respiratory impaired 
elderly; 2) discusses potential underlying mechanisms including aging, smoking, systemic 
inflammation, vasculopathy, hypoxia and genetic susceptibility; and 3) highlights areas 
requiring further research. 
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8. COPD and brain disorders 
INTRODUCTION 
The main task of the lungs is to provide oxygen to the blood and eliminate carbon dioxide 
from the blood. 20% of the total body oxygen is consumed by the brain.173 Inevitably, 
impairment of the lungs will affect structure and functioning of the brain. Aging of the brain 
mainly affects high metabolic demanding neurons and the brain reserve capacity is reduced 
in elderly.44, 174 Therefore, particularly elderly are prone to a distorted supply of oxygen to 
the brains. By focusing on mortality rates rather than disability rates, the large burden of 
neurological  disorders has been underestimated in Europe.175 
Chronic Obstructive Pulmonary Disease (COPD), partially called accelerated lung aging, has 
been most extensively studied in the context of lung-brain interactions.176 Worldwide, COPD 
is the third leading cause of mortality, and the overall severity and prognosis of patients with 
COPD is strongly influenced by associated concomitant diseases.1, 2 Stroke, cognitive 
impairment, anxiety and depression are frequently described in patients with COPD.177-179 
Despite the impact on wellbeing and functional capacity, mental health in COPD is not 
frequently assessed.180 However, there is increasing recognition that COPD extends beyond 
the lungs. 
Increasing evidence demonstrates that accumulation of brain pathology associates with 
cognitive decline and can lead to clinical outcomes, such as stroke and dementia. However, a 
large part of neurological  diseases remains subclinical and may lead to subtle deficits, only 
measurable with cognitive testing and visualized with magnetic resonance imaging (MRI). 
Early clinical manifestations of these diseases include Transient Ischemic Attacks (TIAs) for 
stroke and Mild Cognitive Impairment for dementia. 
In this review article, we provide a general overview of the link between the brain and the 
lung in elderly with chronic respiratory diseases, including the epidemiology, 
pathophysiology and impact of concurrent brain disorders. We will focus on stroke, cerebral 
small vessel disease, cognitive impairment, depression, anxiety and panic disorders. These 
disease entities will be described mainly in relation to COPD. Nevertheless, information 
regarding the influence of the brain on other lung diseases including asthma, obstructive 
sleep apnea syndrome (OSAS) and interstitial lung disease is included. Lung cancer (and 
brain metastases or paraneoplastic neurological  syndromes) and pulmonary arterial 
hypertension are out of the scope of the review. Further in this review, we describe 
potential underlying mechanisms -adding the novel information on cerebral small vessel 
disease- and we summarize the impact of aging and smoking on the association between 
diseases of the brain and lung. Finally, we address the current knowledge gaps and indicate 
potential future research directions. 
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BRAIN DISORDERS AND POTENTIAL BRAIN-LUNG INTERACTIONS 
 
A) Stroke 
Stroke is one of the most common neurological  diseases worldwide. Since 2010, stroke is 
the second leading cause of death worldwide.2 A stroke is defined as the sudden death of 
brain cells in a localized area due to inadequate blood supply. The underlying cause can be a 
blockage in one of the blood vessels supplying the brain of oxygen and nutrients, called a 
ischemic stroke, or a weakened or ruptured brain vessel causing bleeding in (intracerebral) 
or around (subarachnoidal) the brain, called a hemorrhagic stroke. Ischemic strokes are 
further subtyped into large vessel stroke, small vessel stroke and cardioembolic stroke and 
they are mainly caused by atherosclerotic disease, cerebral hypoperfusion and cardiac 
embolism. A transient ischemic attack (TIA) is defined as a brief episode of neurological 
dysfunction caused by focal temporary cerebral ischemia without cerebral infarction.181  
Increasing evidence relates impaired pulmonary function, particularly COPD, to stroke and 
stroke-associated mortality.182-190 Recent studies have shown that carotid arterial plaque 
burden is increased in patients with COPD and that these plaques are more prone to 
rupture, due to an increased lipid content, leading to ischemic stroke.141, 191, 192 Also, an 
increased carotid intima-media thickness might explain the high risk of stroke in women with 
adult onset asthma.193, 194 Finally, there is some evidence of obstructive sleep apnea 
syndrome (OSAS) as a risk factor for ischemic stroke.195, 196   
 
B) Cerebral small vessel disease 
Cerebral small vessel disease refers to a group of pathological processes with various 
etiologies that affect small arteries, arterioles, venules and capillaries of the brain; and can 
be subtyped into age or hypertension-related small vessel diseases and cerebral amyloid 
angiopathy.197 Magnetic resonance imaging (MRI) is commonly used to visualize effects of 
small vessel disease. Among the MRI markers, we can distinguish the following: A. focal 
markers, such as white matter lesions, lacunar infarcts, and microbleeds (collectively called 
small vessel disease); B. atrophy markers, such as brain atrophy/lobar atrophy/hippocampus 
atrophy and C. emerging markers, such as diffusion tensor imaging (microstructural 
integrity) or amyloid imaging (using positron emission tomography [PET] tracers that bind to 
amyloid plaques). In addition, MRI can also be used to quantify total brain perfusion (e.g. 
phase-contrast MRI) or regional perfusion (e.g. arterial spin labeling).  
Small vessel disease can lead to thrombosis and subsequent stroke due to lipohyalinosis, 
fibrinoid degeneration or atheroma formation. Patients with COPD have a higher prevalence 
of neurological  disease other than stroke, including cerebral vascular disease without 
hemiplegia, peripheral neuropathy and seizure disorder.198 Elderly subjects with impaired 
pulmonary function (measured by FEV1) have decreased regional white matter volume in the 
cerebellum.199 Moreover, recent evidence has linked COPD to cerebral small vessel disease 
through an increased volume of cerebral white matter lesions200, 201 and a higher prevalence 
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of cerebral microbleeds (45% in COPD subjects compared to 31% in controls without 
COPD).141  
Cerebral small-vessel disease is common among elderly, and cerebral microbleeds are a 
relatively new suitable marker of cumulative cerebrovascular damage.197, 202, 203 
Furthermore, COPD would preferentially lead to the development of deep or infratentorial 
microbleeds which are thought to occur by arteriolosclerosis on the basis of hypertensive 
vasculopathy and lipohyalinosis.141, 202 Microbleeds occurring in strictly lobar brain sites 
which are indicative of cerebral amyloid angiopathy, were not differentially affected, 
suggesting that COPD might be less involved in beta-amyloid pathology, which also underlies 
Alzheimer's dementia.141, 202, 204  
 
C) Cognitive impairment and dementia 
Cognitive impairment is a broad term that encompasses all deficits in the intellectual process 
of information handling, attention and concentration, memory, executive functioning and 
self-control.205 Mild cognitive impairment (MCI) refers to measurable deficit(s) in cognition 
beyond normal aging in the absence of dementia, although it frequently leads to dementia. 
MCI is a clinical diagnosis based on a specified threshold on the continuum of cognitive 
impairment and subjective complaints. It is unclear from literature which cognitive domains 
are preferentially and consistently affected by lung impairment. However, cognitive 
deterioration appears to be highly prevalent in COPD, ranging from 10% to 49%.206, 207 
Approximately 42% of the patients with COPD in the nocturnal oxygen therapy trial (NOTT) 
demonstrated moderate-to-severe cognitive impairment compared to 14% amongst 
controls. Moreover, the prevalence of cognitive impairment correlated to the severity of 
COPD, ranging from 27% in COPD patients with mild hypoxemia to 62% in severe 
hypoxemia.208, 209 The association of cognitive impairment with COPD severity might be 
restricted to patients with severe to very severe COPD.210, 211 Overall, the cognitive 
functioning in patients with COPD would be impaired generally but more specifically in the 
domains of information processing and speed, memory and learning abilities, and 
coordination and motor functions.177, 205, 210 Regarding clinical diagnosed MCI, 36% of 
patients with COPD had MCI compared to 12% of healthy controls.212 Patients with COPD 
had mainly prevalent nonamnestic MCI with predominant attention and executive 
dysfunctions in this study.212 In line with these results, COPD was associated with incident 
nonamnestic MCI in a dose-dependent manner in the Mayo Clinic Study on Aging.213 Further 
research is needed to define whether patients with COPD with MCI return to normal, remain 
stable over time or mainly progress towards dementia.212 A pitfall could be the 
underdiagnosis of COPD in cognitive impaired patients, since cognitive and functional 
impairment have a negative effect on the quality of spirometry needed to confirm the 
diagnosis of COPD.214, 215 
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D) Depression 
Depression is a common mental disorder and is defined as a state of low mood characterized 
by sadness, loss of interest or pleasure, feelings of guilt or low self-worth, disturbed sleep or 
appetite, feelings of tiredness and poor concentration. Community-dwelling elderly 
demonstrate depression rates ranging from 2% to 10%.216 The prevalence of depression is 
significantly higher in COPD patients (approximately 40%) than in the general population.217 
Chronic diseases are frequently associated with psychological distress. Depression might be 
even more prevalent in patients with COPD than in patients with other chronic devastating 
illnesses such as cancer, stroke, arthritis, diabetes, heart disease, and renal disease.217-221 
However, prevalence figures of depression in COPD vary widely between 7% and 79% 
according to the studied COPD population and the method of assessment.179, 222 A meta-
analysis by Yohannes et al. reported a prevalence of depression of 40% (95% CI 36–44%), 
which is consistent with the observed 40% prevalence of depression in a large, nationally 
representative sample of COPD patients in the US population.221, 222 The prevalence of 
depression in adult asthma was found to be 10%.223, 224 Patients with idiopathic pulmonary 
fibrosis had significant levels of depressive symptoms in 24 to 49% of the patients.225, 226 
Very little is known on the causal direction between depression and respiratory diseases. 
Feelings of dyspnea and anticipatory anxiety limit physical activity in patients with COPD 
which can lead to mood changes and social impairment. Interestingly, within a large 
longitudinal cohort study, depression was recently been found to be a marker of risk for 
incident adult-onset asthma, but in contrast, prevalent asthma was not associated with 
incident adult-onset depression.227  
 
E) Anxiety 
Anxiety is an emotion characterized by feelings of tension, worried thoughts and physical 
changes like sweating, trembling, dizziness or a rapid heartbeat. Persons with anxiety or 
panic disorders usually have recurring intrusive thoughts or concerns which impact their 
behavior. The prevalence of anxiety in COPD patients in the United States was 36% (95% CI 
31–41%).228 However, as for depression, figures on the prevalence of anxious 
symptomatology ranged widely from 6% to 74%222 or even up to 100%.179 Regarding anxiety 
disorders, clinical anxiety was found in around 55% of COPD patients.222 Panic attacks or 
panic disorders occurred in 8% to 67% of COPD patients.179, 229 In patients with adult asthma, 
the prevalence of clinical anxiety was found to be 30%.224 Depression and anxiety scores 
were found to be comparable for patients with COPD and asthma, but were significantly 
higher than for patients with tuberculosis.223 In contrast, a study by Carvalho et al. observed 
that patients with asthma had significantly higher anxiety scores than COPD patients without 
recent exacerbation.230 However, this might be influenced  by a much higher presence of 
females in the asthma group, since females are more likely to have an anxiety disorder than 
men. Information on the incidence of anxiety and panic disorders and longitudinal 
population-based studies to explore the direction of the associations are lacking. 
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PATHOPHYSIOLOGY  
Multiple interconnected factors associated with lung impairment, specifically COPD, might 
lead to brain dysfunction and/or damage.(Figure 1) Some factors (i.e. genetic susceptibility, 
smoking and aging) might be causally related with COPD and can induce a multimorbidity 
state affecting both lung and brain. Other factors (i.e. physical inactivity, inflammation, 
atherosclerosis, disturbed oxygenation and cardiovascular disease) might be instead 
aggravated by COPD. 
 
 
Figure 1: Potential mechanisms contributing to clinical and subclinical brain dysfunction 
and/or damage in elderly subjects with COPD.  
COPD = Chronic Obstructive Pulmonary Disease 
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Effects of aging and smoking on brain and lung  
Aging and smoking are common risk factors for brain disorders and lung diseases. Although 
the prevalence of some brain disorders was still higher in COPD after controlling for aging 
and smoking141, 200, 201, 231-235, it remains to be further investigated whether COPD enhances 
the development of brain disorders independent of any combined risk factors. Since few 
studies adequately control for the total amount of smoking or environmental tobacco 
smoke, residual smoking confounding could still exist. Undisputably, both aging and smoking 
have an influence on the associations and can accelerate or amplify contributing 
mechanisms. Firstly, pulmonary and vascular inflammation may develop simultaneously in 
response to smoking, as with aging. Accumulating cellular defects during aging can initiate a 
vicious circle of inflammatory reactions further increasing damage.236 Moreover, local and 
systemic inflammation activate microglial cells in the brain which become hyperresponsive 
with aging.37  
Secondly, glucocorticoid concentrations are chronically elevated during aging and the 
hippocampus might lose its ability to repress glucocorticoid release through the 
hypothalamus, which exposes the entire organism to elevated stress hormone 
concentrations.44 Through reduced glucocorticoid sensitivity, the aging brain might be a 
regulator of organismal aging, including accelerated lung aging.44, 176 Thirdly, at the cellular 
level, several hallmarks of the aging process have been associated with impaired lung 
function or an increased risk of COPD, including telomere shortening, epigenetic alterations, 
loss of proteostasis and an altered intercellular communication.176, 237, 238 The proteostasis 
might also be impaired in OSAS due to an activation of endoplasmic reticular stress 
pathways in the brain.239 Importantly, the ability to handle proteostatic stress caused by 
environmental stressors like smoking declines with age.176, 239 
Several studies have associated cigarette smoking to an altered brain structure.199, 240-246 
However, whilst smoking appears to be an independent risk factor in cognitive dysfunction, 
studies have found associations between impaired lung function and cognition that were 
independent of current and lifetime smoking status.247-249 Smoking can exacerbate cerebral 
hypoxia due to chronically elevated carbon monoxide levels causing a leftward shift of the 
oxyhaemglobin dissociation curve.208 In addition, cigarette smoke components such as heavy 
metals and nicotin are thought to have a direct neuromodulating effect.250, 251 Nicotin 
upregulates nicotinic cholinergic receptors 252 and makes the cerebellum, believed to be rich 
in nicotinic cholinergic receptors253, vulnerable to the chronic effects of smoking.199 Nicotine 
might also affect mood via cholinergic receptors.254 On the other hand, acetylcholine might 
act as a systemic mediator between lung and brain.255 Both affective disorders and airway 
constriction have been associated with cholinergic activation.227, 256 Hypoxemia can elevate 
brain choline levels which are associated with brain tissue breakdown, myelin damage and 
increased turnover of neuronal membrane precursors.257-259 Since white matter 
microstructural damage was already observed in stable nonhypoxemic patients with COPD, 
these manifestations might not be limited to advanced COPD.200 Finally, the biomarker 
plasma clusterin or apolipoprotein J might be a mediator of the relationship between COPD 
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and MCI since clusterin levels have been shown to be elevated in patients with COPD and are 
associated with cognitive decline in elderly.260, 261 
 
Effects of systemic inflammation, vasculopathy and hypoxia on brain and lung 
The mechanisms underlying the link between lung impairment and brain disorders have not 
yet entirely been elucidated, although different hypotheses encompass systemic 
inflammation, vasculopathy and hypoxia (hypoxemia) and hypercapnia. In patients with 
COPD, the hypoxia due to progressive airflow limitation and emphysema, as well as the 
chronic low-grade systemic inflammation might contribute to vessel wall changes resulting in 
endothelial dysfunction, stiffening of arteries and arterioles, and an impaired vascular 
reactivity.32, 141, 232, 262-265 The inflamed endothelium overexpresses surface adhesion 
molecules, such as vascular cell adhesion molecule-1 (VCAM-1), facilitating the adherence of 
white blood cells to damaged endothelial surfaces.29  
In addition, interleukin 6 can stimulate the release of acute phase proteins by hepatocytes 
including C Reactive Protein (CRP), serum amyloid A, fibrinogen, and procoagulant factors 
which further promote or amplify the inflammatory process.29, 266 CRP fosters the uptake of 
low density lipoproteins (LDL) by macrophages, which can contribute to the increased 
prevalence of arterial plaques containing a lipid core in patients with COPD.29, 232 Progression 
of atherosclerosis and instability of plaques in the carotid arteries can thereby lead to stroke.  
In OSAS, the increased risk of stroke is thought to result from an accelerated atherogenesis, 
impaired endothelial function, and a prothrombotic and proinflammatory state in addition 
to blood pressure swings, reduction in cerebral blood flow and an altered cerebral 
autoregulation.195 Similarly, a vascular inflammation state is hypothesized to lead to 
microvascular dysfunction or cerebral small vessel disease which results in observable 
cerebral microbleeds.32, 197, 202 Arteriolosclerotic microangiopathy or cerebral small-vessel 
disease is linked with (vascular) depression, cognitive and functional impairment.177, 178, 197 
Moreover, the role of vascular pathology including atherosclerosis is increasingly being 
recognized in the etiology of dementia and Alzheimer’s disease in addition to beta-amyloid 
and tau pathology.267 The fact that COPD is preferably associated with nonamnestic MCI also 
suggests a role of inflammation and vascular disease.213 Cerebral small vessel disease is 
known to cause cognitive decline and functional loss in the elderly.197 Vascular risk factors 
and chronic ischemic brain changes are associated with vascular dementia and vascular 
depression.268-271 Patients with COPD who had cognitive impairment showed an altered 
cerebral perfusion.272 Especially brain regions fed by the posterior cerebral circulation (e.g. 
cerebellum, hippocampus, and deep nuclei) are more vulnerable to hypoxia, which is 
consistent with the preferential deep or infratentorial cerebral microbleeds seen in patients 
with COPD.141, 273, 274 Hypoxia is moreover thought to cause an altered brain bioenergetic 
metabolism, brain dysfunction and hippocampal atrophy as well as generalized cerebral 
atrophy.275-277 However, in order to draw more definitive conclusions on COPD, depression 
and dementia and its subtypes, further research is required.  
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Effects of genetic susceptibility and epigenetic mechanisms on brain and lung  
Shared genetic factors might predispose subjects to COPD and brain disorders.278, 279 Most 
respiratory and neurological diseases in the elderly are complex and involve interactions 
between genetic susceptibility, decreased reserve capacity by aging and cumulative 
exposure to environmental factors such as smoking, air pollution, unhealthy diet or lifestyle. 
Although research into common genetic and epigenetic mechanisms underlying lung and 
brain diseases is still in its infancy, several clues are emerging. 
First, subjects with lung disease and stroke might share genetic variations that lead to an 
altered histone deacetylase (HDAC) expression.280-283 In addition, sirtuines (type III HDACs) 
are associated with aging, neurodegenerative diseases and COPD.284, 285 Especially sirtuin 1 
(SIRT1) is of interest since it is downregulated in COPD and the posttranslational 
modification is modified by smoking and oxidative stress.286 Downregulation of SIRT1 is 
involved in proinflammatory pathways, impairs mechanisms of neuronal repair and limits 
cognitive function processes.280, 285-287  
Second, genome-wide association studies of asthma and depression both suggested 
involvement of Retinoic Acid Receptor-Related Orphan Receptor Alpha (RORα).288, 289 
Moreover, RORα has been suggested to play a role in chronic inflammation, hypoxia 
signaling and the pathogenesis of emphysema and premature aging. 290-292 
Finally, genetic variations affecting serotonin and nicotinic acetylcholine pathways are 
associated with COPD, nicotine dependence and depression.11, 279, 293 An increased genetic 
risk of nicotine addiction might therefore indirectly link COPD to depression, on top of the 
psychosocial effects of a chronic debilitating disease as COPD. 
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IMPACT OF THE BRAIN DISORDERS ON LUNG DISEASE 
The impact of brain damage on the quality of life in survivors of a clinical stroke is clearly 
observable through the functional loss of body parts or abilities (e.g. hemiparesis, sensory 
deficits, dysphagia or aphasia, Figure 1). The impact of subclinical events on the quality of 
life such as silent stroke, brain atrophy or small vessel disease can be more subtle and 
become only clinically apparent after a certain amount of damage has been reached. Early 
assessment of cerebrovascular diseases, cognitive impairment and mental illness in 
respiratory impaired patients is a first important step to favorably influence the large health 
burden. A reduced pulmonary function is associated with an increased risk of stroke and 
stroke-associated mortality, but even in stroke survivors the lung function is often affected 
due to weakness of respiratory muscles associated with stroke or central diaphragmatic 
impairment.183, 186, 294, 295 Furthermore, stroke survivors are at increased risk of dysphagia  
and aspiration pneumonia.296  
Several studies in mostly selected patient populations show that cognitive dysfunction 
reduces the level of functioning as assessed by activities of daily living 297-300 and is 
associated with increased length of hospital stay, mortality, discharge destination 301 and 
poor compliance with both medication and oxygen therapy.302 This poor compliance in turn 
increases the risk of acute exacerbation.303, 304 During an exacerbation of COPD, cognitive 
function is further impaired but the impairment and excitability changes may be (initially) 
reversible.177, 305  
Several associations between cognitive dysfunction in COPD and health outcomes were not 
consistent between studies.177, 306-310 Methodological limitations of the performed studies 
including limited or self-reported assessment of COPD and/or cognitive dysfunctioning, 
might explain the discrepancies.205  Depressive symptoms and anxiety have been associated 
with reduced functional capacity, increased risk of COPD exacerbations and increased 
mortality.311-317 Depression and cognitive impairment can place COPD patients in a vicious 
cycle since it may influence their attempt to stop smoking, make them less compliant to the 
maintenance medication and raise the exacerbation and mortality risk.313, 318-320  
Finally, multiple comorbidities in elderly with respiratory impairment result in 
polypharmacy.321 Regarding the brain-lung interaction, it is important to note that some 
drugs affecting the central nervous system (like opiates, narcotics and tranquillizers) might 
conversely cause lung injury or respiratory depression (http://www.pneumotox.com). 
Especially elderly COPD patients are at increased risk of adverse drug reactions due to 
polypharmacy and overdosage of drugs with renal clearance.322 
 
  
72 
 
FUTURE RESEARCH DIRECTIONS 
Because the influence of comorbidities on disability and mortality is especially important at 
an older age, prevalence figures should be more precisely estimated and large prospective 
studies conducted to estimate the incidence of brain disorders in elderly with lung 
impairment. Unified definitions of both brain disorders and respiratory diseases herein are 
crucial. In addition to COPD, brain disorders in lung disease entities as obstructive sleep 
apnea syndrome (OSAS), interstitial lung disease and frequently underdiagnosed asthma in 
the elderly should be investigated too.323 Many different definitions are used for cognitive 
dysfunction and many different strategies for screening (using different cut-offs) exist for 
cognitive impairment and diagnosis of depression in patients with chronic lung diseases such 
as COPD.210, 324, 325 This makes it difficult to ascertain the consequences of cognitive 
dysfunction and depression on the daily living in respiratory impaired patients. 
Definitely, more research is needed to investigate the relation between COPD and dementia. 
Regarding the underlying mechanisms, a link with the different subtypes of dementia might 
be interesting to explore. Another interesting topic might be research into emerging MRI 
markers as diffusion tensor imaging to investigate associations with early microstructural 
white matter changes. 326 
In addition, there is need for studies further investigating the mechanisms contributing to 
the development or influencing the course of the described brain disorders, including ethnic 
or gender differences, epigenetic mechanisms and genetic predisposition.327 Longitudinal 
studies are required to elucidate the pathophysiological mechanisms underlying brain-lung 
diseases in elderly and clinical trials are awaited to evaluate potential preventive or 
treatment strategies for the brain disorders resulting from the brain-lung interaction. The 
routinely exclusion of COPD patients with cognitive impairment, depression, physical 
limitations or comorbidities in general from large pharmacological trials, precludes optimal 
daily care for the majority of elderly COPD patients.322 Besides pharmacological therapies, 
more research is needed to explore the potential benefits of cognitive behavioral therapy or 
pulmonary rehabilitation in this population. 
  
In conclusion, increasing evidence associates lung impairment with brain disorders in the 
elderly. Considering that neurological disorders have a major impact on the daily lives of 
patients with respiratory diseases, time is running for more investigations towards 
interactions between the lung and the brain in the elderly. 
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ABSTRACT 
 
Background 
Chronic obstructive pulmonary disease (COPD) is an independent risk factor for ischemic 
stroke and the risk increases with severity of airflow limitation. Even though vulnerable 
carotid artery plaque components, such as intraplaque hemorrhage and lipid core, place 
persons at high risk for ischemic events, the plaque composition in COPD patients has 
never been explored. 
 
Objectives 
To investigate the prevalence of carotid wall thickening, the different carotid artery plaque 
components, and their relations with severity of airflow limitation in elderly patients with 
COPD. 
 
Methods 
This cross-sectional analysis was part of the Rotterdam Study, a prospective population-
based cohort study performed in subjects aged 55 years and older. Diagnosis of COPD was 
confirmed by spirometry. Participants with carotid wall intima-media thickness (IMT) ≥ 2.5 
mm on ultrasonography underwent high-resolution magnetic resonance imaging (MRI) for 
characterization of carotid plaques. Data were analyzed using logistic regression. 
 
Results  
COPD cases (n = 253) had a twofold increased risk (OR 2.0, 95%CI 1.44-2.85, p<0.0001) of 
presentation with carotid wall thickening on ultrasonography compared to controls with a 
normal lung function (n = 920). Moreover, the risk increased significantly with severity of 
airflow limitation.  On magnetic resonance imaging, vulnerable lipid core plaques were 
more frequent in COPD cases than in control subjects (OR 2.1, 95%CI 1.25-3.69, p=0.0058). 
 
Conclusions 
Carotid artery wall thickening is more prevalent in COPD patients than in controls. In 
elderly subjects with carotid wall thickening, COPD is an independent predictor for the 
presence of a lipid core, and therefore of vulnerable plaques. 
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9. COPD and macroangiopathy: carotid artery plaques 
INTRODUCTION  
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow 
limitation and various systemic manifestations which significantly impact mortality.325, 328, 329 
Increasing evidence demonstrates that COPD is an independent risk factor for ischemic 
stroke and that the risk increases by severity of airflow limitation.183, 184 Moreover, the risk of 
stroke-associated mortality has also been shown to correlate with degree of airflow 
limitation.184 The main underlying causes of cerebral ischemia are atherosclerotic disease 
and cardiac embolism.  
 
Vulnerable carotid artery plaques place persons at high risk for ischemic stroke through 
thromboembolism arising from a disrupted plaque surface. Besides size and degree of 
obstruction, plaque properties are recognized to be crucial to identify high risk patients.330 
Unlike the extensively used ultrasound and Computed Tomography (CT), high-resolution 
magnetic resonance imaging (MRI) has the ability to distinguish between lipid and 
hemorrhagic components in plaques and is therefore very powerful to reveal noninvasively 
the composition of atherosclerotic plaque.331 Regarding the different carotid artery plaque 
components, calcified plaques are generally known to be more stable than noncalcified 
plaques. Intraplaque hemorrhage and lipid core are both recognized as vulnerable plaque 
components and associated with the risk of cerebrovascular disease.332 Intraplaque 
microhemorrhages initiate phagocytosis of erythrocytes which may lead to lipid 
accumulation in macrophages.333 Plaques with a lipid core contain fat-laden macrophages 
and extracellular lipids and are along with a thin fibrous cap more prone to rupture.334  
 
Even though increasing evidence indicates that impaired lung function is an important risk 
factor for the formation of carotid plaques on ultrasonography, the association between 
COPD and the different plaque components on MRI has not yet been investigated. 
Therefore, the aim of this study was to examine in a large, prospective population-based 
cohort study of elderly, whether carotid atherosclerosis is indeed more prevalent in subjects 
with COPD compared to subjects with a normal lung function, whether plaque components 
differ between both groups, and whether plaque prevalence or components relate to 
severity of airflow limitation. 
 
METHODS  
Study design  
This cross-sectional analysis was part of the Rotterdam Study, a population-based cohort 
study aimed at assessing the occurrence of, and risk factors for chronic diseases in the 
elderly.108 The study started in 1990 among 7983 persons aged ≥ 55 years, and all 
participants are invited every 3 to 4 years to the research center for follow-up examinations, 
including spirometry and carotid ultrasonography. The medical ethics committee of the 
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Erasmus Medical Center, Rotterdam, and the review board of The Netherlands Ministry of 
Health, Welfare and Sports, approved the study. Participants gave written informed consent. 
 
Carotid artery atherosclerosis 
Ultrasonography of the common carotid artery, bifurcation and internal carotid artery of the 
left and right carotid arteries was performed using a 7.5-MHz linear-array transducer. 
Participants, in whom ultrasonography revealed carotid intima-media wall thickness (IMT) ≥ 
2.5 mm in the left, right or both carotid arteries, were selected for carotid MRI scanning 
from October 2007 till August 2010. MRI of the carotid arteries was performed on a 1.5-T 
MRI scanner with a bilateral phased-array surface coil. Participants were recorded as 
positive for the presence of any plaque component if the component was identified in one 
or both carotid arteries. The ultrasonography and carotid MRI protocol, reading and 
reproducibility were previously described.331, 335  
 
In detail, ultrasonography was performed by careful searching all interfaces of the near and 
far walls of the distal common carotid artery, the carotid bifurcation and the internal carotid 
artery of the left and right carotid arteries using a 7.5-MHz linear-array transducer in 
accordance with the Rotterdam Study ultrasound protocol.335, 336 Optimal longitudinal, two-
dimensional ultrasound images of the carotid artery were frozen on the R-wave of the ECG 
and stored on videotape. The actual measurements of intima–media thickness were 
performed off-line, averaged from three frozen images of each arterial segment from the 
videotape. The interfaces of the common carotid artery, the carotid bifurcation and the 
internal carotid artery were marked across a length of 10 mm. Then the maximum carotid 
intima–media thickness value was determined as the mean of the maximum intima–media 
thickness over the marked length of anterior (near)- and posterior (far)-wall measurements 
of both the left and right side arteries for each of the three arterial segments. When an 
atherosclerotic plaque was present at the measurement site, it was included in the 
measurement. If data on one of the walls or one of the sides was missing, maximum 
thickness of the available wall and side was used. Readers of the ultrasound images were 
unaware of the case status of the subject.  
 
Results from a reproducibility study of ultrasound intima-media thickness measurements of 
the common carotid artery among 80 participants of the Rotterdam Study who underwent a 
second ultrasound of both carotid arteries within 3 months of the first scan, showed low 
mean differences (SD) in far-wall intima–media thickness of the common carotid artery 
between paired measurements of sonographers, readers, and visits of 0.005 mm (0.09), 
0.060 mm (0.05), and 0.033 mm (0.12), respectively.337  
 
MRI high-resolution images were obtained using a standardized protocol.331 First, both 
carotid bifurcations were identified by means of two-dimensional (2D) time-of-flight MR 
angiography. Thereafter, high-resolution MRI sequences were planned to image the carotid 
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bifurcations on both sides: four sequences in the axial plane: (1) a proton density weighted 
(PDw)-fast spin echo (FSE)-black blood (BB) sequence; (2) a PDw-FSE-BB with an increased in-
plane resolution; (3) a PDw-echo planar imaging (EPI) sequence, and (4) a T2w-EPI sequence; 
and two 3D sequences: (1) a 3D-T1w-gradient echo (GRE) sequence; and (2) a 3D phased-
contrast MR angiography. 
 
Carotid plaque characteristics were assessed with an online PACS viewer. All scans were 
reviewed by a trained physician with three years of experience in carotid MRI under 
supervision of a neuro-radiologist with more than six years of experience in MRI plaque 
analysis, who were both unaware of the research hypothesis. Calcification was defined as 
the presence of a hypointense region in the plaque on all sequences.331, 338, 339 Intraplaque 
haemorrhage was defined as the presence of a hyperintense region in the atherosclerotic 
plaque on 3D-T1w-GRE.331, 340, 341 Lipid core presence was defined as a hypointense region, 
not classified as intraplaque haemorrhage or calcification, in the plaque on PDw-FSE or PDw-
EPI and T2w-EPI images, or a region of relative signal intensity drop in the T2w-EPI images 
compared with the PDw-EPI images.331, 338, 339, 342 Results from a reproducibility study of MRI 
measured plaque composition among 40 participants of the Rotterdam Study who 
underwent a second MRI scan (average time between scans 15±9 days), showed excellent 
inter-observer and intra-subjects agreement.331 The Kappa values for inter-observer 
agreement were 0.86 (95% CI 0.72-0.99) for intraplaque hemorrhage; 0.86 (95% CI 0.72-
0.99) for lipid core presence and 0.94 (95% CI 0.86-0.99) for calcification. The Kappa values 
for intra-subjects agreement were 0.95 (95% CI 0.88-0.99) for presence of intraplaque 
hemorrhage; 0.85 (95% CI 0.74-0.96) for lipid core and 0.91 (95% CI 0.82-0.99) for 
calcification. Furthermore, the non-contrast-enhanced MRI technique for plaque 
characterization has been shown to have good accuracy and reproducibility in other 
validation studies.338, 339, 342 
Diagnosis and staging of COPD 
The diagnosis of COPD was based on an obstructive spirometry examination according to the 
modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria [proportion of 
the forced vital capacity exhaled in the first second (FEV1/FVC) < 0.7] and classified into mild, 
moderate or severe by forced expiratory volume in one second (FEV1)% predicted of ≥ 80%, 
50-80% or < 50% respectively. Participants with a spirometry report suggestive of restrictive 
respiratory disease [FEV1/FVC ≥ 0.7 and forced expiratory vital capacity (FVC) and/or FEV1 < 
80% predicted], and patients with asthma were excluded. No reversibility tests were 
conducted. Spirometry was performed between March 2009 and January 2011 using a 
Master Screen® PFT Pro (CareFusion, San Diego, CA) by trained paramedical personnel 
according to the ATS/ERS guidelines.22  
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Statistical analyses 
Differences between COPD and control subjects were compared using t-test or Mann-
Whitney U test for continuous variables and Chi-Square test for categorical variables. Wilson 
score method for a binomial proportion was used to calculate prevalence plus 95% 
confidence intervals. A logistic regression model was used to calculate the risk of COPD on 
carotid artery wall thickening and the different plaque components. Age, sex, body mass 
index (BMI), smoking behaviour, hypertension, hypercholesterolemia [total serum 
cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides], anemia [haemoglobin, 
hematocrit], diabetes mellitus, kidney function [creatinin] and maximum wall thickness were 
considered as potential confounders and comprise the previously identified risk factors for 
the different plaque components.331 Information on smoking behaviour was collected using 
home interviews. Smoking status was thus self-reported and classified as current, past, and 
never. Cigarette pack years were computed as duration of smoking (years) multiplied by the 
number of smoked cigarettes, divided by 20. Hypertension was identified as the use of 
antihypertensive medication and/or an average systolic blood pressure of 160 mmHg or 
above and/or an average diastolic blood pressure of 100 mmHg or above (Grade 2 according 
to European Society of Cardiology criteria).343 Medication use was assessed through 
automated linkage to pharmacies with computerized records. Blood pressure, total 
cholesterol, HDL cholesterol, and triglycerides were measured at study center visits as 
described previously.344 Diabetes mellitus was defined as the use of blood glucose-lowering 
medication and/or a non-fasting serum glucose level of ≥11.1 mmol/L and/or fasting serum 
glucose levels ≥7 mmol/L. 
 
Covariables were included in the models if they changed the risk estimate by more than 10% 
or if they were biologically plausible according to previous literature. Statistical analyses 
were performed using SPSS, version 20.0 for Windows (IBM, North Castle, NY). 
 
RESULTS  
Subject flow and baseline characteristics 
Until February 2011, 1386 participants of the Rotterdam study had an interpretable 
spirometry test.(Figure 1) Of them, 253 (18.3%) COPD patients and 920 (66.4%) controls 
underwent ultrasonography of both carotid arteries. Table 1 shows the baseline 
characteristics of the study population (n=1173) with median age 78 (IQR=6). COPD subjects 
were more often male and (current) smokers. 694 out of 1173 participants (59.2%) 
participants had carotid wall thickening (IMT ≥ 2.5 mm in the left, right or both carotid 
arteries) determined by ultrasonography.(Figure 1) 216 subjects were not invited for carotid 
MRI scanning due to contraindications for MRI (n=17), dementia (n=3), physical immobility 
(n=19), history of carotid endarterectomy (n=3), living in a nursing home or because they 
moved outside the area (n=30) or could not be scheduled during the study period (n=144). 
Of the 478 subjects who were invited during the study period, 407 agreed to participate 
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(response rate 85.1%). Due to physical inabilities (e.g. back pain) or claustrophobia, imaging 
could not be performed or completed in 26 individuals (6.4%). In total, 358 subjects of the 
381 participants who underwent a complete scan, had scans of good quality (94.0%); 88 
patients were COPD cases and 270 control subjects with normal lung function. Table 2 shows 
that the clinical, demographic and physiological characteristics of the subjects excluded from 
the MRI examination were similar to those from the 358 subjects included in the MRI 
examination. 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Study profile. 
1386 subjects with interpretable spirometry 
255 subjects with obstructive lung function without asthma (=COPD)
922 subjects with normal lung function (=controls)
209 subjects with restrictive lung function or asthma
1173 subjects with ultrasonography of both carotid arteries
253 COPD
920 controls
694 subjects with carotid 
wall thickening (≥2.5 mm)
189 COPD
505 controls
358 with an interpretable MRI
88 COPD
270 controls
336 subjects excluded
216 not invited due to contraindications for MRI, dementia, 
physical immobility, carotid endarterectomy, moved to 
nursing home or outside the area or  study period.
71 invited but not willing to participate
26 MRI could not be performed or completed due to 
physical inabilities
23 scan of bad quality          
479 subjects without 
carotid wall thickening
64 COPD
415 controls
213 subjects excluded 
77 spirometry report suggestive of 
restrictive respiratory disease 
132 asthma subjects 
4 subjects without ultrasonography 
of both carotid arteries
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Table 1: Baseline characteristics of the study population (n=1173). 
 
 
COPD 
(n=253) 
Controls 
(n= 920) 
p-value 
Age (years) 79 (7) 78 (6) 0.006 
Males 142 (56.1) 366 (39.8) <0.001 
Smoking status1 
Never  smoker 
Former  smoker 
Current  smoker 
 
50 (19.8) 
159 (62.8) 
44 (17.4) 
 
345 (37.5) 
520 (56.5) 
55 (6.0) 
<0.001 
Pack years for smokers 27.5 (36.0) 14.4 (25.2) <0.001 
Body mass index (kg/m²) 25.9 (5.0) 27.0 (4.8) 0.001 
Hypertension2 136 (53.8) 468 (50.9) 0.416 
Myocardial infarction 20 (7.9) 64 (7.0) 0.610 
Coronary revascularization3 23 (9.1) 80 (8.7) 0.852 
Diabetes4 40 (15.8) 122 (13.3) 0.301 
Glucose (serum, mmol/l) 5.5 (0.9) 5.5 (0.9) 0.378 
Total cholesterol (serum, mmol/l) 5.2 (1.4) 5.3 (1.5) 0.299 
HDL-cholesterol (serum, mmol/l) 1.4 (0.5) 1.4 (0.5) 0.648 
Creatinin (serum, µmol/l) 79.5 (27.0) 80.0 (23.5) 0.156 
Hemoglobin (mmol/l) 8.6 (1.1) 8.5 (0.9) 0.173 
Hematocrit (%) 44 (5) 43 (4) 0.025 
Leucocytes (#,*103) 
 
7.1 (2.3) 6.8 (2.0) 0.004 
Granulocytes (#,*103) 
 
4.4 (1.8) 4.1 (1.5) <0.001 
FEV1 (% predicted) 80.5 (27.6) 111.6 (24.1) <0.001 
FEV1/FVC (%) 65.6 (8.8) 78.1 (6.2) <0.001 
Categorical variables are expressed as numbers (percentage). Values of continuous variables are expressed as 
median (IQR). 1Smoking status was self-reported. 2Hypertension was defined as antihypertensive medication 
use and/or an average systolic blood pressure of ≥ 160 mmHg and/or an average diastolic blood pressure of ≥ 
100 mmHg. 3Coronary revascularization was defined as coronary artery bypass grafting and percutaneous 
coronary intervention. 4Diabetes mellitus was defined as blood glucose-lowering medication use and/or a 
non-fasting serum glucose level of ≥11.1 mmol/L and/or fasting serum glucose levels ≥7 mmol/L. 
Abbreviations: COPD=Chronic Obstructive Pulmonary Disease; FEV1= forced expiratory volume in one second; 
FEV1/FVC= proportion of the forced vital capacity exhaled in the first second; HDL= High-Density Lipoprotein 
 
  
  
Part III: COPD, angiopathy and cerebrovascular morbidity 81 
Table 2: Comparison of the subjects included in the MRI component and excluded from the 
MRI component. 
 
IMT ≥ 2.5 mm, 
MRI performed 
(n=358) 
IMT ≥ 2.5 mm, 
MRI not 
performed 
(n=336) 
p-value 
Age (years) 78 (6) 79 (7) 0.127 
Males 169 (47.2) 178 (53.0) 0.129 
Smoking status1 
Never  smoker 
Former  smoker 
Current  smoker 
 
91 (25.4) 
236 (65.9) 
31 (8.7) 
 
89 (26.5) 
215 64.0) 
32 (9.5) 
0.853 
Pack years for smokers 21 (31.7) 17 (32.0) 0.585 
Body mass index (kg/m²) 27.0 (5.0) 27.0 (5.4) 0.374 
COPD 88 (24.6) 101 (30.1) 0.105 
Hypertension2 204 (57.0) 204 (60.7) 0.318 
Myocardial infarction 37 (10.4) 32 (9.5) 0.703 
Coronary revascularization3 51 (14.3) 35 (10.4) 0.119 
Diabetes4 57 (15.9) 52 (15.5) 0.885 
Glucose (serum, mmol/l) 5.6 (0.8) 5.6 (1.1) 0.455 
Total cholesterol (serum, mmol/l) 5.1 (1.6) 5.2 (1.7) 0.701 
HDL-cholesterol (serum, mmol/l) 1.4 (0.5) 1.4 (0.5) 0.529 
Creatinin (serum, µmol/l) 
 
82.0 (25.3) 82.0 (24.0) 0.540 
Hemoglobin (mmol/l) 8.5 (1.1) 8.6 (1.1) 0.446 
Hematocrit (%) 43.5 (5) 43.0 (5) 0.538 
Leucocytes (#,*103) 
 
7.0 (1.9) 6.9 (2.2) 0.702 
Granulocytes (#,*103) 
 
4.4 (1.7) 4.3 (1.6) 0.939 
FEV1 (% predicted) 103.9 (27.4) 101.3 (31.0) 0.172 
FEV1/FVC (%) 76.1 (10.1) 74.9 (10.6) 0.042 
Categorical variables are expressed as numbers (percentage). Values of continuous variables are expressed as 
median (IQR). 1Smoking status was self-reported. 2Hypertension was defined as antihypertensive medication 
use and/or an average systolic blood pressure of ≥ 160 mmHg and/or an average diastolic blood pressure of ≥ 
100 mmHg. 3Coronary revascularization was defined as coronary artery bypass grafting and percutaneous 
coronary intervention. 4Diabetes mellitus was defined as blood glucose-lowering medication use and/or a 
non-fasting serum glucose level of ≥11.1 mmol/L and/or fasting serum glucose levels ≥7 mmol/L. 
Abbreviations: COPD=Chronic Obstructive Pulmonary Disease; FEV1= forced expiratory volume in one second; 
FEV1/FVC= proportion of the forced vital capacity exhaled in the first second; HDL= High-Density Lipoprotein 
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Carotid artery wall thickening as determined by ultrasonography 
The prevalence of carotid artery wall thickening was higher in participants with COPD (189 
out of 253; 74.7%; 95% CI: 69.0 to 79.7%) than in those without COPD (505 out of 920 
controls; 54.9%; 95% CI: 51.7 to 58.1%) (p<0.0001). The prevalence of carotid wall thickening 
(≥ 2.5 mm in the left, right or both carotid arteries) was significantly associated with severity 
of airflow limitation.(Figure 2) Subjects with severe airflow limitation had a more than sixfold 
increased risk of carotid wall thickening compared to control subjects, independent of age, 
sex, BMI, smoking status, hypertension, HDL-cholesterol, triglycerides, hemoglobin, diabetes 
and serum creatinin.(Table 3) Evaluating the continuous measures FEV1 and FEV1/FVC, Table 
3 shows that per 10% predicted increase in FEV1 the risk of carotid artery atherosclerosis 
decreases by 14% and that per percentage increase in FEV1/FVC, the risk of carotid artery 
atherosclerosis decreases by 4%. Stratified on smoking status, the prevalence of carotid wall 
thickening (≥2.5 mm in the left, right or both carotid arteries) in COPD cases was significantly 
higher in both never, former, and current smokers compared to controls.(Figure 3) 
Additionally, a plaque score was measured on ultrasonography and reflects the total number 
of sites with plaques (left- and right-sided common carotid artery, bifurcation, and internal 
carotid artery); the score was significantly higher in subjects with COPD compared to 
controls (p<0.001). Volume of plaques was also measured on ultrasonography and 
categorically defined as stenosis more or less than 50%; 20.2% of subjects with COPD had a 
stenosis ≥50% left-, right- or both-sided compared to 13.7% of controls (p=0.011). 
 
Figure 2: Prevalence (%) of carotid artery wall thickening (≥ 2.5 mm in the left, right or  
both carotid arteries) determined by ultrasonography, according to severity of airflow 
limitation. * p < 0.005 ; ** p < 0.0001 by Pearson Chi-Square  
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Table 3: 
A) Risk of carotid artery wall 
thickening determined by 
ultrasonography. 
Model 1 (n=1173) Model 2 (n=1145) 
Categorical, all versus no COPD OR 95% CI P-value OR 95% CI P-value 
COPD 2.1 1.53-2.90 <0.0001 2.0 1.44-2.85 <0.0001 
COPD, mild 1.6 1.09-2.46 0.0174 1.6 1.06-2.49 0.0258 
COPD, moderate 2.6 1.57-4.27 0.0002 2.4 1.42-4.04 0.0011 
COPD, severe 6.1 1.36-26.95 0.0180 6.4 1.37-29.81 0.0180 
COPD, dyspnea score <2 1.6 1.09-2.44 0.0175 1.6 1.04-2.46 0.0328 
COPD, dyspnea score ≥2 3.1 1.89-5.04 <0.0001 2.8 1.71-4.71 <0.0001 
COPD, no chronic bronchitis  2.0 1.42-2.77 <0.0001 1.9 1.35-2.73 0.0003 
COPD, chronic bronchitis 4.0 1.35-11.80 0.0122 3.7 1.21-11.46 0.0218 
Continuous, lung function 
parameters 
OR 95% CI P-value OR 95% CI P-value 
FEV1 (per 10% predicted increase) 0.8
5 
0.80-0.90 <0.0001 0.8
6 
0.81-0.92 <0.0001 
FEV1/FVC (per 1 % increase) 0.9
6 
0.95-0.98 <0.0001 0.9
6 
0.94-0.98 <0.0001 
B) Risk of lipid core carotid 
plaques determined by MRI. 
Model 1 (n=358) Model 2 (n=353) 
Categorical, all versus no COPD OR 95% CI P-value OR 95% CI P-value 
COPD 2.2 1.31-3.58 0.0025 2.1 1.25-3.69 0.0058 
COPD, mild 2.0 1.07-3.93 0.0306 2.0 0.97-3.98 0.0598 
COPD, moderate 2.1 1.04-4.31 0.0398 2.3 1.08-4.94 0.0317 
COPD, severe 3.8 0.72-20.17 0.1173 2.6 0.44-15.58 0.2930 
COPD, dyspnea score <2 1.6 0.79-3.04 0.2006 1.7 0.81-3.47 0.1680 
COPD, dyspnea score ≥2 2.9 1.52-5.66 0.0013 2.7 1.33-5.49 0.0062 
COPD, no chronic bronchitis  2.3 1.37-3.99 0.0018 2.5 1.40-4.45 0.0019 
COPD, chronic bronchitis 1.2 0.37-3.95 0.7595 0.7 0.17-2.52 0.5382 
Continuous, lung function 
parameters 
OR 95% CI P-value OR 95% CI P-value 
FEV1 (per 10% predicted increase) 0.8
9 
0.81-0.99 0.0256 0.8
9 
0.80-0.99 0.0248 
FEV1/FVC (per 1 % increase) 0.9
6 
0.94-0.99 0.0037 0.9
6 
0.94-0.99 0.0142 
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex, Body Mass Index, smoking status, hypertension, High-Density Lipoprotein-
cholesterol (serum, mmol/l), triglycerides (serum, mmol/l), hemoglobin (mmol/l), diabetes and creatinin 
(serum, µmol/l). 
COPD: defined as FEV1/FVC < 0.7 and categorized according to the modified Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) criteria into mild COPD (GOLD1; FEV1≥80%pred), moderate COPD (GOLD2; 
50%≤FEV1<80%pred) & severe COPD (GOLD3; FEV1<50%pred) 
Dyspnea score: based on 5 dyspnea-questions and scored from 0 (all questions negative) to 5 (all positive) 
Chronic bronchitis: defined as the self-reported presence of cough and sputum for at least 3 months in each 
of two consecutive years (http://www.goldcopd.org) 
Abbreviations: OR= Odds Ratio; CI=Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; FEV1= 
forced expiratory volume in one second; FEV1/FVC = proportion of the forced vital capacity exhaled in the first 
second; MRI= magnetic resonance imaging 
Bold values indicate significance at P < 0.05. 
84 
 
 
Figure 3: Prevalence (%) of carotid artery wall thickening (≥2.5 mm in the left, right or both 
carotid arteries) determined by ultrasonography, according to smoking status.  
* p = 0.0284; ** p = 0.0032 ; *** p = 0.0004 by Pearson Chi-Square 
 
Carotid artery plaque components as determined by MRI 
358 subjects with carotid wall thickening on ultrasonography had an interpretable MRI scan 
result. The median maximum wall thickness on MRI was 3.6 mm (IQR: 1.1 mm) in 88 COPD 
subjects and 3.3 mm (IQR : 1.0 mm) in 270 controls (p=0.04). Median stenosis was 16.7% 
(IQR: 32.2 %) in COPD subjects and 12.6% (IQR: 25.6 %) in controls (p=0.102). The different 
prevalence of intraplaque hemorrhage, lipid core, and calcification between COPD subjects 
and controls is shown in Figure 4. Carotid artery plaques with a lipid core were significantly 
more prevalent in COPD subjects than in controls. No significant associations between COPD 
and the risk of intraplaque hemorrhage or calcification were observed.(Table 4). COPD cases 
have a more than twofold increased risk to present lipid core compared to control subjects 
independent of age, sex, BMI, smoking status, hypertension, HDL-cholesterol, triglycerides, 
hemoglobin, diabetes, creatinin, and maximum wall thickness.(Table 3) Especially COPD 
subjects with a dyspnea score ≥ 2 had a significantly increased risk of a lipid core plaque 
compared to control subjects (OR 2.7, 95%CI 1.33-5.49, p=0.0062). The risk of lipid core 
plaques was significantly inversely related to both FEV1% predicted and FEV1/FVC.  
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Figure 4: Prevalence of carotid artery plaque components (%) determined by magnetic 
resonance imaging (MRI) . * p = 0.0092 ; ** p = 0.0040 by Pearson Chi-Square 
 
 
 
Table 4: COPD versus control subjects and the risk of different carotid artery plaque 
components (intraplaque hemorrhage, lipid core or calcification). 
 
 Model 1 (n=358) Model 2 (n=353) 
 OR 95% CI P-value OR 95% CI P-
COPD and risk of intraplaque 
hemorrhage 
1.0 0.61-1.72 0.9386 0.8 0.45-1.50 0.5184 
COPD and risk of lipid core 
2.2 1.31-3.58 0.0025 2.1 1.25-3.69 0.0058 
COPD and risk of calcification 
0.6 0.31-1.27 0.1965 0.6 0.27-1.24 0.1637 
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex, Body Mass Index, smoking status, hypertension, High-Density Lipoprotein-
cholesterol (serum, mmol/l), triglycerides (serum, mmol/l), hemoglobin (mmol/l), diabetes, creatinin (serum, 
µmol/l) and maximum wall thickness (mm). Abbreviations: OR= Odds Ratio; CI=Confidence Interval; COPD= 
Chronic Obstructive Pulmonary Disease. Bold values indicate significance at P < 0.05.  
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DISCUSSION 
This population-based study in elderly demonstrates that COPD subjects have a twofold 
increased risk of carotid artery wall thickening on ultrasonography compared to controls 
with a normal lung function, and that COPD is an independent determinant for the presence 
of a lipid core, an indicator of a vulnerable plaque, as determined by high-resolution MRI. To 
our knowledge, the association between COPD and the presence of intraplaque hemorrhage, 
lipid core, and calcification has never been studied before. Therefore, our MRI-based results 
give more insight into COPD as an independent risk factor for stroke by progression of 
atherosclerosis. Since the risk of stroke and stroke-associated mortality is related with 
severity of airflow limitation, identification of risk factors for stroke is crucial to identify the 
subgroup of COPD patients at high risk, and to develop preventive, more personalized 
treatment strategies.184, 345, 346 
 
Few studies have investigated the association between COPD and/or severity of airflow 
limitation and carotid wall thickening on ultrasound.191, 192, 347-350 Consistent with our results, 
a study performed in vascular surgery patients detected an association between COPD and 
carotid wall thickening (IMT ≥ 1.25 mm) independent of age and smoking status.347 Frantz et 
al. recruited participants of a respiratory questionnaire survey and observed a higher 
prevalence of COPD in subjects with than without plaques (IMT ≥ 2 mm), although they 
could not confirm that COPD was an independent predictor of carotid plaques.348 In 
accordance with our lung function parameter results, an inverse association between FEV1, 
FEV1/FVC and internal carotid IMT has been recently reported.192 Three other studies also 
found that the severity of airflow limitation measured by FEV1 was significantly associated 
with continuously increased IMT.191, 349, 350 In line with these three studies, our population-
based study performed in older subjects demonstrates a significant association between 
severity of airflow limitation and carotid wall thickening (IMT ≥ 2.5 mm). Although severity of 
airflow limitation may not entirely reflect disease activity, it previously correlated well with 
clinical important outcomes as hospitalizations due to exacerbations, cardiovascular 
comorbidity, and mortality.33, 351-353 Furthermore, our study adds to all previous studies that 
the risk of carotid wall thickening further increases when COPD subjects have clinical 
symptoms of dyspnea or chronic bronchitis, that plaques are more lipid-rich in COPD 
subjects compared to controls, and that lipid core plaques also relate to the severity of 
airflow limitation.  
 
The regulatory pathway responsible for the association between COPD and plaque 
progression has not yet been elucidated, although several hypotheses have been proposed. 
COPD and plaque formation may coexist as a result of common risk factors such as smoking. 
However, our results demonstrate that COPD cases have an increased risk of carotid wall 
thickening independent of smoking status and that the prevalence of carotid wall thickening 
was consistently higher in COPD cases compared to controls, even in never smokers. In line 
with our results, two studies in smoking men found an increased susceptibility for 
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asymptomatic carotid and leg atherosclerosis by a higher degree of lung function 
impairment, independently of tobacco consumption, and a significantly higher mean carotid 
IMT in smokers with airflow limitation compared to smokers without airflow limitation.191, 354 
Furthermore, ex-smokers retain an increased risk of atherosclerosis even after a long period 
of smoking cessation.355 Since the atherogenic effect proceeds despite smoking cessation, an 
associated process such as COPD might be causative.356 COPD and plaque remodelling to 
vulnerable plaques can result from increased numbers of macrophages, interferon(IFN)-γ 
secreting Th1 lymfocytes, and metalloproteinase (MMP)-9 and MMP-12, observed in both 
disorders.13, 325, 330, 357 Our observation that there was a gradual association between COPD 
and lipid core plaques, but not between COPD and intraplaque hemorrhage, suggests that 
the underlying mechanism differentially affects the presence of the two vulnerable plaque 
characteristics. 
 
The strengths of this study are the high quality information derived from state of the art 
diagnostic imaging techniques, the prospective data collection, the general population based 
setting and the large number of elderly subjects that participated in the Rotterdam Study. 
Possible limitations are the lack of computed tomography findings of the lungs to 
corroborate emphysema in those with airflow limitation and the cross-sectional design. The 
latter implies that we cannot infer causal mechanisms between COPD and carotid plaques. 
However, the association is biologically plausible and the risk of carotid plaques increased 
according to severity of airflow limitation. As we were not able to administer contrast 
material because of the population-based setting, a fibrous cap of carotid artery plaques 
could not be identified. Although this could have provided additional information on 
assessing plaque stability, it is known that the size of lipid core and the presence of 
hemorrhage are both independently associated with a worse fibrous cap status.358 In 
addition, contrast material would have improved lipid core detection.331 Because 
misclassification by underestimation is often random, the association with COPD may be 
higher than we found.  
 
In conclusion, this study shows an increased risk of carotid artery plaque formation and of 
presence of vulnerable plaques with a lipid core in population-based elderly patients with 
COPD. Clinicians should be aware that asymptomatic carotid atherosclerosis is more 
prevalent in subjects with COPD and that COPD as a systemic inflammatory disease might 
lead to vulnerable plaques by inducing or aggravating the presence of a lipid core. This 
important observation may advance further research in the prevention of ischemic strokes, a 
devastating complication of carotid atherosclerosis. 
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ABSTRACT 
 
Background 
Chronic obstructive pulmonary disease (COPD) is a common, complex multisystem 
disease in the elderly with multiple comorbidities that significantly impact morbidity and 
mortality. Although cerebral small-vessel disease is an important cause of cognitive 
decline and age-related disability, it is a poorly investigated potential systemic 
manifestation of patients with COPD. 
 
Objectives 
To examine whether COPD relates to the development and location of cerebral 
microbleeds, a novel marker of cerebral small-vessel disease. 
 
Methods 
Cross-sectional and longitudinal analyses were part of the Rotterdam Study, a 
prospective population-based cohort study in subjects aged ≥55 years. Diagnosis of 
COPD was confirmed by spirometry. Cerebral microbleeds were detected using high-
resolution Magnetic Resonance Imaging (MRI). 
 
Results  
Subjects with COPD (n = 165) had a higher prevalence of cerebral microbleeds 
compared to subjects with normal lung function (n = 645) independent of age, sex, 
smoking status, atherosclerotic macroangiopathy, antithrombotic use, total cholesterol, 
triglycerides, and serum creatinin (OR 1.7, 95%CI 1.15-2.47, p=0.007). Regarding the 
specific microbleed location, COPD subjects had a significantly higher prevalence of 
microbleeds in deep or infratentorial locations (OR 3.3, 95%CI 1.97-5.53, p<0.001), 
which increased with severity of airflow limitation and are suggestive of hypertensive or 
arteriolosclerotic microangiopathy. Furthermore, in longitudinal analysis restricted to 
subjects without microbleed at baseline, COPD was an independent predictor of 
incident cerebral microbleeds in deep or infratentorial locations (OR 7.1, 95%CI: 2.1-
24.5, p=0.002). 
 
Conclusions 
Our findings are compatible with an increased risk of COPD on the development of 
cerebral microbleeds in deep or infratentorial locations. 
 
 
 
 
 
 
 
Reprinted with permission of the American Thoracic Society.  
Copyright © 2014 American Thoracic Society.  
Lahousse L, Loth DW, Vernooij MW, Darweesh SKL, Akoudad S, Joos GF, Hofman A, Stricker BH, Ikram MA, 
Brusselle GG. 2013 Chronic Obstructive Pulmonary Disease and cerebral microbleeds: the Rotterdam 
Study. Am J Respir Crit Care Med. 188(7):783-8 
Official Journal of the American Thoracic Society. 
 
  
Part III: COPD, angiopathy and cerebrovascular morbidity 89 
10. COPD and microangiopathy: cerebral microbleeds 
INTRODUCTION  
Chronic obstructive pulmonary disease (COPD) is a multisystem disease characterized 
primarily by persistent airflow limitation that is associated with an abnormal inflammatory 
response of the lungs to noxious particles or gases.13 Worldwide, COPD is a leading cause of 
morbidity and mortality, and the frequent comorbidities further impact the overall severity 
and prognosis of patients with COPD.1 Depression, postural instability, cognitive and 
functional impairment are known consequences of cerebral small-vessel disease, and are 
frequently described extrapulmonary manifestations in patients with COPD.177, 178, 197, 359 
However, it is unclear whether COPD is associated with incident cerebral small-vessel 
disease. 
 
Cerebral small-vessel disease is common among elderly, and cerebral microbleeds are a 
relatively new marker of the condition.197, 202 These microbleeds, which consist of 
hemosiderin deposits in macrophages, can be visualized on Magnetic Resonance Imaging 
(MRI) as small areas of hypointensity.360 Microbleeds rarely disappear, making them suitable 
markers for cumulative cerebrovascular damage.203 The location of a cerebral microbleed 
appears to be associated with its underlying disease mechanism: microbleeds in deep or 
infratentorial locations are suggestive of hypertensive or arteriolosclerotic microangiopathy, 
whereas those occurring in strictly lobar brain sites are indicative of cerebral amyloid 
angiopathy.202, 204  
 
Detection of cerebral microbleeds in patients with COPD and studying their location might 
increase insight into the pathology substantially. Furthermore, it might also pave the path 
for better prevention of cognitive and functional impairment in these vulnerable patients. 
The aim of this study was therefore to investigate whether cerebral microbleeds were more 
prevalent in subjects with (more severe) COPD and whether microbleed location differed 
compared to subjects without COPD. Moreover, we wanted to confirm our cross-sectional 
results into longitudinal analyses to further explore causality. We examined our hypotheses 
in a large, prospective population-based cohort study of elderly using state of the art MRI. 
 
METHODS  
Study design  
The present study is embedded within the Rotterdam Study, a population based cohort 
study comprising almost 15.000 participants aimed at assessing the occurrence of, and risk 
factors for chronic diseases in the elderly.108 The study started in 1990 and all participants 
are invited every 3 to 4 years to the research center for follow-up examinations, including 
spirometry. As a part of the Rotterdam Study, the Rotterdam Scan Study is investigating age-
related brain changes on MRI from 2005 onwards.55 The present study comprises a cross-
sectional analysis performed within all participants taking part of the Rotterdam Scan Study 
90 
 
where spirometry was performed around the same time (2009-2010); and a longitudinal 
analysis performed within all participants with complete and reliable baseline (2005-2006) 
and follow-up MRI examinations (2008-2010).55, 203 In the longitudinal analysis, only subjects 
without any microbleed at the time of the first MRI scan were included. The medical ethics 
committee of the Erasmus Medical Center, Rotterdam, and the review board of The 
Netherlands Ministry of Health, Welfare and Sports, approved the study. All participants 
gave written informed consent.  
 
Assessment of COPD 
Diagnosis of COPD was spirometry based as described previously.232 Spirometry and 
diffusing capacity were performed using a Master Screen® PFT Pro (CareFusion, San Diego, 
CA) by trained paramedical personnel according to the ATS/ERS guidelines.22, 23 The diffusing 
capacity of the lungs measured using carbon monoxide was corrected for the haemoglobin 
concentration (DLCO,c).23 The diagnosis of COPD was based on an obstructive spirometry 
examination according to the modified Global Initiative for Chronic Obstructive Lung Disease 
(GOLD) criteria [proportion of the forced vital capacity exhaled in the first second (FEV1/FVC) 
< 70%] and classified into mild, moderate, or severe airflow limitation by forced expiratory 
volume in one second (FEV1)% predicted of ≥ 80%, 50-80% or < 50% respectively.24  
 
In addition, according to the GOLD 2011 update, the influence of respiratory symptoms was 
evaluated.1 Dyspnea score was based on the following five dyspnea-questions: 1. Are you 
troubled by shortness of breath when climbing stairs? (i.e. at a normal speed) 2. Are you 
troubled by shortness of breath when walking on level ground? 3. Do you have shortness of 
breath? (i.e. during normal/daily life activities) 4. Are you troubled by shortness of breath 
when lying down, while this improves when you sit up or when you sleep on more pillows? 
5. Are you short of breath at rest? Based on these five dyspnea questions, a dyspnea score 
was added from 0 (all questions negative, never dyspneic) to 5 (all positive, even dyspneic at 
rest).232 Chronic bronchitis was defined as the self-reported presence of cough and sputum 
for at least 3 months in each of two consecutive years.  
 
Participants with a spirometry report suggestive of a restrictive syndrome [FEV1/FVC ≥ 70% 
and forced expiratory vital capacity (FVC) < 80% predicted], and asthma patients were 
excluded. No reversibility tests were conducted. Two COPD subjects within the longitudinal 
analysis had no interpretable spirometry at the research center within the study period, 
however, diagnosis was made by a pulmonologist. In longitudinal analyses, subjects who 
developed COPD between both MRIs, were excluded, and subjects who developed COPD 
after the second MRI were treated as controls.  
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Assessment of cerebral microbleeds on MRI 
As described previously, all participants of the Rotterdam Scan Study underwent a 
multisequence MRI protocol on a 1.5-T scanner (GE Healthcare).55 A custom-made 
accelerated three-dimensional T2*-weighted gradient-recalled echo sequence with high 
spatial resolution and long echo time was used for cerebral microbleed detection.361 MRI 
scans were viewed by research physicians blinded to the COPD status of the subject, and 
presence, number and location of microbleeds was rated. Individuals who had dementia or 
MRI contraindications were not eligible. Furthermore, participants who had claustrophobia 
or motion artifacts or susceptibility artifacts on their MRI scans, were excluded from the 
study population. 
Microbleeds were defined as focal areas of very low signal intensity on T2*-weighted 
imaging that were not accompanied by evident signal abnormality on other structural 
sequences.55, 202 Intraobserver and interobserver reliabilities for microbleed rating were very 
good (κ = 0.85–0.87) and review of the initial ratings by an experienced neuroradiologist 
yielded a very high accordance.204  
In accordance with previous literature, microbleed location was classified as lobar (cortical 
gray matter and subcortical or periventricular white matter), deep (deep gray matter: basal 
ganglia and thalamus, and the white matter of corpus callosum, internal, external, and 
extreme capsule) or infratentorial (brainstem and cerebellum).202, 362, 363 According to the 
presumed underlying disease mechanism, microbleeds were classified as occurring in strictly 
lobar brain sites, or occurring in deep or infratentorial locations (whether or not additional 
to lobar microbleeds).203  
 
Statistical analyses  
Differences between subjects with and without COPD were studied using Mann-Whitney U 
test for continuous variables and Chi-Square test for categorical variables. Logistic regression 
models were performed to assess the effect of COPD on cerebral microbleeds, both overall 
and per location class (strictly lobar versus deep or infratentorial). All models were adjusted 
for age and sex, and additionally, for covariables which changed the risk estimate by more 
than 5%. Following covariables were considered as potential confounders: age, sex, body 
mass index (BMI), smoking behaviour, pack years, APOE genotype, hypertension 
[antihypertensive medication, systolic and diastolic blood pressure], hypercholesterolemia 
[total serum cholesterol, high-density lipoprotein (HDL)-cholesterol, triglycerides], diabetes 
mellitus [blood glucose-lowering medication, glucose], kidney function [creatinin], 
atherosclerotic macroangiopathy [carotid intima-media wall thickness ≥ 2.5mm in the left, 
right or both carotid arteries on ultrasonography] and use of drugs for obstructive airway 
diseases, antithrombotic, and lipid lowering agents. These covariables include previously 
identified risk factors for cerebral microbleeds.232, 364 Medication use was obtained through 
automated linkage with pharmacy filled prescription data. For the other factors, information 
was obtained through interview, laboratory, or physical examination at the latest regular visit 
of the study participant to the Rotterdam Study research center preceding the most recent 
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MRI in the cross-sectional analyses, and preceding the baseline MRI in the longitudinal 
analyses.365  
 
With regard to cerebrovascular disease status, a known history of stroke was assessed on 
entry of study participants into the Rotterdam Study.366 Subsequently, participants have 
been continuously monitored for incident stroke through automated linkage of the study 
database with files from general practitioners, and hospital discharge information. For all 
cases of stroke, subsequent validation by research physicians and neurologists was 
performed on the basis of clinical details from medical records as described earlier.367 
 
Sensitivity analyses were done by re-examining the associations after exclusion of 
participants with a history of stroke, in order to assess the confounding effect of previously 
existent cerebrovascular disease. Individuals with at least one microbleed were consistently 
compared to individuals without any microbleed. Statistical analyses were performed using 
SPSS, version 20.0 for Windows (IBM, North Castle, NY). 
 
RESULTS  
Cross-sectional study of COPD, severity of airflow limitation and cerebral microbleeds 
944 participants of the Rotterdam study had both an interpretable spirometry and brain MRI 
during the last center visit.(Figure 1) After exclusion of 134 subjects with asthma or a lung 
function suggestive of a restrictive syndrome, 165 subjects with COPD and 645 subjects 
without COPD were evaluated.  
  
Table 1 shows the baseline characteristics of the cross-sectional study population (n=810) 
with a total median age of 78 years (inter-quartile range[IQR]=6). COPD subjects were 
slightly older, more often male, (current) smokers, had a lower body mass index and worse 
lung function. Of the 79 (47.9%) COPD subjects who took drugs for obstructive airway 
diseases (Anatomical Therapeutic Chemical (ATC) classification R03), 50 (63.3%) used inhaled 
anticholinergics (R03BB), 48 (60.8%) inhaled β2-sympathomimetics (R03AC), 33 (41.8%) 
inhaled corticosteroids (R03BA), 55 (69.6%) inhaled fixed combinations (R03AK), and 13 
(16.5%) COPD subjects were on treatment with other agents for obstructive airway diseases 
including xanthines (R03BC, R03C and R03D). Because 57 (72.2%) COPD subjects were on 
multiple treatments, summed percentages exceed hundred percent.  
 
The 165 COPD subjects were categorized according to the modified Global Initiative for 
Chronic Obstructive Lung Disease (GOLD) classification of airflow limitation 24 into 84 (50.9%) 
mild, 73 (44.2%) moderate and 8 (4.8%) severe COPD; and according to the updated GOLD 
group categorization1 into 81 (49.1%) group A, 58 (35.2%) group B, 7 (4.2%) group C and 19 
(11.5%) group D. COPD categories did not vary significantly by age or sex.   
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1082 subjects with brain MRI
944 subjects with spirometry
810 subjects with brain MRI & spirometry
165 subjects with obstructive lung function (=COPD)
645 subjects with normal lung function (=no COPD)
276  subjects with 
cerebral microbleeds
74    COPD
202  no COPD
534  subjects without      
cerebral microbleeds
91    COPD
443  no COPD
134 subjects excluded with asthma 
or restrictive syndrome
 
 
  
  
 
 
 
 
 
 
  
 
 
   
  
 
 
 
 
 
 
  
  
  
  
  
  
  
  
  
  
  
Figure 1: Study profile of cross-sectional analysis. 
 
 
 
The prevalence of cerebral microbleeds was significantly higher in participants with COPD 
(74 out of 165; 44.8%; 95% CI: 37.5 to 52.5%) than in those without COPD (202 out of 645; 
31.3%; 95% CI: 27.9 to 35.0%) (p=0.001). The difference remained statistically significant 
after controlling for age, sex, smoking status, carotid artery wall thickening, antithrombotic 
use, total cholesterol, triglycerides, and serum creatinin (OR 1.7, 95%CI 1.15-2.47, p=0.007). 
The prevalence of cerebral microbleeds in (ever) smoking COPD subjects (47.8%; 95% CI: 
39.5 to 56.2%) was significantly higher than in (ever) smoking subjects without COPD (32.8%; 
95% CI: 28.4 to 37.5%), even after controlling for age, sex, and pack years (p=0.003). 
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Location of cerebral microbleed  
Because the location of a cerebral microbleed tends to be associated with its underlying 
pathogenetic mechanism, we further investigated the association of COPD with microbleeds 
occurring in strictly lobar brain sites (amyloid angiopathy), and with microbleeds in deep or 
infratentorial locations (arteriolosclerotic microangiopathy).(Figure 2) Out of 276 subjects 
who had a cerebral microbleed detected on MRI (Figure 1), 177 (64%) had microbleed(s) 
with a strictly lobar location. In addition, 99 (36%) subjects had microbleed(s) which were 
located deeply. COPD was not significantly associated with microbleeds occurring in strictly 
lobar brain sites.(Figure 2)  
 
Table 1: Baseline characteristics of the cross-sectional study population (n=810). 
 COPD  
(n=165) 
No COPD  
(n= 645) 
p-value 
Age, years 79 (7) 77 (6) 0.023 
Males 101 (61.2) 265 (41.1) <0.001 
Smoking status1  
        Never  smoker 
Former  smoker 
Current  smoker 
 
31 (18.8) 
107 (64.8) 
27 (16.4) 
 
242 (37.5) 
368 (57.1) 
35 (5.4) 
<0.001 
Pack years of cigarette smoking1 16.8 (36.6) 3.3 (19.1) <0.001 
Body mass index, kg/m² 25.9 (5.6) 26.9 (4.8) 0.034 
Hypertension2 87 (52.7) 318 (49.4) 0.443 
Mean systolic blood pressure, mmHg 152.0 (23.0) 153.0 (28.0) 0.472 
Mean diastolic blood pressure, mmHg 83.0 (15.0) 84.0 (14.0) 0.664 
Diabetes3 27 (16.4) 80 (12.4) 0.182 
Glucose in serum, mmol/l 5.5 (0.9) 5.5 (0.8) 0.178 
Total cholesterol  in serum, mmol/l 5.3 (1.4) 5.3 (1.5) 0.446 
HDL-cholesterol in serum, mmol/l 1.4 (0.6) 1.4 (0.5) 0.200 
Triglycerides in serum, mmol/l 1.2 (0.6) 1.2 (0.7) 0.152 
Creatinin in serum, µmol/l 81.0 (27.5) 81.0 (25.0) 0.150 
APOE ε3/ε3 genotype 89 (53.9) 365 (56.6) 0.724 
Hematocrit, % 44.0 (4.0) 44.0 (5.0) 0.085 
Antithrombotic use ever 93 (57.8) 325 (51.5) 0.156 
Lipid reducing agent use ever 57 (34.5) 217 (33.6) 0.827 
FEV1, % predicted 81.2 (25.5) 111.5 (24.1) <0.001 
FEV1/FVC, % 65.6 (7.6) 78.0 (6.4) <0.001 
DLCO,c ,% predicted 87.9 (26.0) 99.3 (22.4) <0.001 
Categorical variables are expressed as numbers (percentage). Values of continuous variables are expressed as 
median (IQR). 1Smoking status and pack years were self-reported. 2Hypertension was defined as 
antihypertensive medication use and/or an average systolic blood pressure of ≥ 160 mmHg and/or an average 
diastolic blood pressure of ≥ 100 mmHg. 3Diabetes mellitus was defined as blood glucose-lowering medication 
use and/or a non-fasting serum glucose level of ≥11.1 mmol/L and/or fasting serum glucose levels ≥7 mmol/L. 
Abbreviations: COPD=Chronic Obstructive Pulmonary Disease; DLCO,c = diffusing capacity of the lungs 
measured using carbon monoxide and corrected for the hemoglobin concentration; FEV1= forced expiratory 
volume in one second; FEV1/FVC= proportion of the forced vital capacity exhaled in the first second; HDL= 
High-Density Lipoprotein 
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Figure 2: Prevalence (%) of subjects without a cerebral microbleed, with strictly lobar 
cerebral microbleed(s) and with deep or infratentorial cerebral microbleed(s) subdivided by 
no COPD, mild COPD or moderate to severe COPD. 
 
 
In contrast, COPD was significantly associated with deep or infratentorial microbleeds, 
independent of age, sex, smoking status, and pack years.(Table 2) The odds ratio was highest 
and comparable for COPD subjects with severe airflow limitation, COPD subjects with 
frequent exacerbations, and COPD subjects belonging to GOLD group D.(Table 2) Since the 
airflow limitation in COPD is caused by a combination of small airways disease (bronchiolitis) 
and loss of elastic recoil due to parenchymal destruction (emphysema), we evaluated 
continuous lung function parameters. Table 2 shows that per 10% predicted increase in FEV1, 
the prevalence of deep or infratentorial microbleeds decreased by 17%. Furthermore, per 
percentage increase in FEV1/FVC and diffusing capacity, the prevalence of deep or 
infratentorial microbleeds decreased by 5% and 2% respectively. Regarding the effect of 
COPD independent of smoking effects, the prevalence of deep or infratentorial cerebral 
microbleeds was significantly higher in (ever) smoking COPD subjects (32.7%; 95% CI: 24.4 to 
42.2%) compared to (ever) smoking subjects without COPD (10.0%; 95% CI: 7.1 to 13.9%), 
even after controlling for age, sex, and pack years  (p<0.001).   
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Table 2: COPD and the risk on cerebral microbleeds in deep or infratentorial locations (n=633). 
 
 Model 1 Model 2 
Categorical, all versus no COPD OR 95% CI P-value OR 95% CI P-value 
COPD (n=129) 2.7 1.68-4.36 <0.001 3.3 1.97-5.53 <0.001 
COPD, mild (n=65) 2.2 1.17-4.13 0.015 2.6 1.34-5.00 0.005 
COPD, moderate (n=57) 3.2 1.71-5.96 <0.001 4.1 2.11-8.00 <0.001 
COPD, severe (n=7) 4.4 0.94-20.30 0.060 6.8 1.31-34.87 0.023 
COPD, group A (n=61) 1.8 0.91-3.54 0.090 2.1 1.05-4.31 0.036 
COPD, group B (n=45) 3.6 1.83-7.11 <0.001 4.4 2.19-9.02 <0.001 
COPD, group C (n=6) 2.9 0.52-16.66 0.224 3.9 0.66-23.48 0.134 
COPD, group D (n=17) 4.4 1.59-12.08 0.004 6.6 2.20-20.00 0.001 
COPD, dyspnea score <2 (n=67) 1.9 0.99-3.60 0.053 2.2 1.15-4.39 0.018 
COPD, dyspnea score ≥2 (n=62) 3.8 2.10-6.88 <0.001 4.9 2.58-9.28 <0.001 
COPD, exacerbations <2 (n=112) 2.5 1.51-4.15 <0.001 3.0 1.77-5.19 <0.001 
COPD, exacerbations ≥2 (n=17) 4.3 1.57-12.01 0.005 6.2 2.09-18.10 0.001 
COPD, no chronic bronchitis (n=109) 2.7 1.66-4.53 <0.001 3.3 1.93-5.60 <0.001 
COPD, chronic bronchitis (n=18) 3.0 1.05-8.32 0.040 4.3 1.39-13.40 0.012 
Continuous, lung function OR 95% CI P-value OR 95% CI P-value 
FEV1 (per 10% predicted increase) 0.85 0.77-0.94 0.002 0.83 0.74-0.92 0.001 
FEV1/FVC (per 1 % increase) 0.95 0.93-0.98 <0.001 0.95 0.92-0.97 <0.001 
DLCO,c (per 1% predicted increase) 0.98 0.97-0.99 0.005 0.98 0.96-0.99 0.003 
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex, smoking status, and pack years. 
COPD was defined as FEV1/FVC < 70% and categorized according to the modified Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification of airflow limitation 200724 into mild COPD (GOLD1; 
FEV1≥80%pred), moderate COPD (GOLD2; 50%≤FEV1<80%pred) & severe COPD (GOLD3; FEV1<50%pred) and 
according to the updated GOLD group categorization 20131 A (low risk, less symptoms), B (low risk, more 
symptoms), C (high risk, less symptoms) and D (high risk, more symptoms). 
Dyspnea score was based on 5 dyspnea-questions and scored from 0 (never dyspneic) to 5 (even dyspneic at 
rest) Exacerbations were defined as the total number of moderate and severe exacerbations in the year prior 
to the MRI examination.  
Chronic bronchitis was defined as the self-reported presence of cough and sputum for at least 3 months in each 
of two consecutive years (http://www.goldcopd.org). 
Abbreviations: OR= Odds Ratio; CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease; FEV1= 
forced expiratory volume in one second; FEV1/FVC = proportion of the forced vital capacity exhaled in the first 
second; DLCO,c = diffusing capacity of the lungs measured using carbon monoxide and corrected for the 
hemoglobin concentration 
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Figure 3 demonstrates the prevalence (%) of subjects without a cerebral microbleed, with 
strictly lobar cerebral microbleed(s) and with deep or infratentorial cerebral microbleed(s) 
subdivided by non-smoking control, (ever) smoking control or COPD. A sensitivity analysis 
excluding the participants with a history of stroke to assess the confounding effect of 
previously existent cerebrovascular disease, did not change the point estimate of the risk of 
COPD on cerebral microbleeds nor on deep or infratentorial microbleeds. In 39 well-defined 
elderly asthmatics and the 645 controls, no significant associations were noted between 
asthma and (all) cerebral microbleeds, deep or infratentorial microbleeds, or strictly lobar 
microbleeds (data not shown). In an age and sex-adjusted model of 45 subjects with a 
spirometry suggestive of restrictive respiratory disease compared to the 645 controls, a 
restrictive spirometric pattern was significantly associated with (all) cerebral microbleeds 
(OR 2.6, 95% CI 1.4-4.9 , p=0.002), deep or infratentorial microbleeds (OR 3.8, 95% CI 1.7-
8.4, p=0.001) and strictly lobar microbleeds (OR 2.1, 95% CI: 1.0-4.3, p=0.041). The 
associations with cerebral microbleeds (OR 2.9, 95% CI 1.5-5.6, p=0.002) and deep or 
infratentorial microbleeds (OR 6.1, 95% CI 2.5-15.1, p<0.001) remained significant after 
adjustment for age, sex, BMI, smoking status, hematocrit, HDL cholesterol, triglycerides, 
glucose and serum creatinin (and borderline significant for strictly lobar microbleeds (OR 2.1, 
95% CI 1.0-4.6, p=0.064)).  
 
Figure 3: Prevalence (%) of subjects without a cerebral microbleed, with strictly lobar 
cerebral microbleed(s) and with deep or infratentorial cerebral microbleed(s) subdivided by 
non-smoking control, (ever) smoking control or COPD. 
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827 subjects with baseline and follow-up brain MRI 
553 subjects with two brain MRIs without microbleed at baseline
161    subjects excluded with microbleed 
at time of first brain MRI
106    subjects excluded with asthma, 
or restrictive syndrome
7       subjects excluded with incident 
COPD between both MRIs
Longitudinal analyses of COPD and incident cerebral microbleeds 
In order to investigate causality, longitudinal analyses were performed in 553 participants of 
the Rotterdam Study who had two MRI brain scans and no cerebral microbleed at the time 
of the first MRI scan.(Figure 4) The median time interval between the two MRI scans was 
3.42 years (IQR: 79.5 days) and was not significantly different between subjects with or 
without COPD (p=0.663). Table 3 in the Online Data Supplement shows the baseline 
characteristics of the longitudinal study population. COPD subjects were more often male, 
diabetic, and current smokers. During follow-up, 54 subjects without cerebral microbleeds at 
the time of the first MRI scan developed a cerebral microbleed, 18 of them at a deep or 
infratentorial location.(Figure 4)  
Of the 46 COPD subjects without cerebral microbleeds at the time of the first MRI scan, 5 
(10.9%) subjects developed a deep or infratentorial microbleed, compared to 13 (2.6%) of 
the 507 subjects without COPD. Adjusted for age, sex, and pack years, COPD was associated 
with a significantly increased risk of developing a deep or infratentorial microbleed (OR 7.1, 
95%CI: 2.1-24.5; p=0.002). No significant association was noted for COPD and incident 
strictly lobar cerebral microbleeds.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4: Study profile of longitudinal analysis. 
 
Baseline brain MRI
46 COPD without microbleed
507 no COPD without microbleed
3 years
Follow-up brain MRI
8 (17%) COPD with microbleed
5 in deep or infratentorial location
46 (9%) no COPD with microbleed
13 in deep or infratentorial location
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Table 3: Baseline characteristics of the longitudinal study population (n=553). 
 
Covariable measured at baseline  
(=first MRI) 
COPD (n=46) No COPD (n= 507) P-value 
Age, years 66 (9) 66 (6) 0.122 
Males 30 (65.2) 248 (48.9) 0.034 
Smoking status1  
       Never  smoker 
Former  smoker 
Current  smoker 
 
5 (11.1) 
23 (51.1) 
17 (37.8) 
 
181 (36.1) 
276 (55.1) 
44 (8.8) 
<0.001 
Pack years cigarette smoking1 28.1 (33.7) 2.5 (17.3) <0.001 
Body mass index , kg/m² 26.3 (3.6) 27.0 (4.8) 0.529 
Mean systolic blood pressure , mmHg 147.0 (29.5) 141.5 (22.0) 0.171 
Mean diastolic blood pressure , mmHg 84.0 (16.0) 81.5 (12.1) 0.315 
Diabetes2 8 (17.8) 38 (7.6) 0.019 
Glucose in serum, mmol/l 5.4 (1.5) 5.4 (0.7) 0.252 
Total cholesterol  in serum, mmol/l 5.5 (1.2) 5.7 (1.3) 0.119 
HDL-cholesterol in serum, mmol/l 1.3 (0.5) 1.4 (0.5) 0.219 
Antihypertensive use  19 (41.3) 177 (34.9) 0.385 
Antithrombotic use  10 (21.7) 82 (16.2) 0.332 
Lipid reducing agent use  7 (15.2) 100 (19.7) 0.459 
Categorical variables are expressed as numbers (percentage). Values of continuous variables are expressed as 
median (IQR). 1Smoking status and pack years were self-reported. 2Diabetes mellitus was defined as blood 
glucose-lowering medication use and/or a non-fasting serum glucose level of ≥11.1 mmol/L and/or fasting 
serum glucose levels ≥7 mmol/L. 
Abbreviations: COPD= Chronic Obstructive Pulmonary Disease; HDL= High-Density Lipoprotein 
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DISCUSSION 
This large population based study in elderly demonstrates that COPD is associated with a 
higher prevalence of cerebral microbleeds, a marker of cerebral small-vessel disease 
determined by MRI.202 These findings tend to be driven by a greater occurrence of 
microbleeds in deep or infratentorial locations in subjects with COPD. Furthermore, follow-
up analyses within subjects without a cerebral microbleed at baseline, demonstrated that 
COPD is an independent risk factor to develop deep or infratentorial cerebral microbleeds. 
Our results are in line with two previous cross-sectional studies which showed that patients 
with COPD had a significantly increased volume of cerebral white matter lesions, which is 
another marker of cerebral small vessel disease, and known to be associated with 
microbleeds in a deep or infratentorial region.200, 201  
 
The location of cerebral microbleeds might give more insight into the underlying mechanism 
of the association between COPD and cerebral microbleeds. In our population, the 
association of cerebral microbleeds with COPD was especially strong for microbleeds in deep 
or infratentorial locations, which are thought to occur by arteriolosclerosis on the basis of 
hypertensive vasculopathy and lipohyalinosis.202 Recently, we have demonstrated that COPD 
subjects had a significant increased prevalence of atherosclerotic macroangiopathy as 
evidenced by the increased prevalence of carotid artery wall thickening in subjects with 
COPD.232 Therefore, carotid artery wall thickening was taken into account as potential 
confounder in the present study. The current results suggest that COPD might affect large 
and small blood vessels simultaneously. The systemic inflammation present in a subset of 
COPD patients, as well as the hypoxia due to progressive airflow limitation and emphysema, 
might contribute to vessel wall changes resulting in stiffening of arteries and arterioles.232, 
262, 263 Although severity of airflow limitation may not entirely reflect disease activity, our 
results suggest that cerebral small vessel disease is more present in COPD patients with 
more severe airflow limitation.351 In addition, the prevalence of deep or infratentorial 
microbleeds was more pronounced in COPD subjects with respiratory symptoms or frequent 
exacerbations. Interestingly, the effect size of GOLD group B did not seem to be lower than 
group C. Previously, a higher mortality risk for group B than C was established.26, 27 The high 
percentage of subjects in group A and the very small number in group C are in line with 
other general population studies.26-28  
 
In order to investigate the potential impact of emphysema on the prevalence of cerebral 
microbleeds, we examined the influence of the diffusing capacity, a measure of the rate of 
CO uptake by the lungs.23 The diffusing capacity was significantly associated with the 
prevalence of deep or infratentorial microbleeds.  
 
The impact of smoking is of particular importance since most COPD patients are current or 
former smokers, and smoking was previously identified as a risk factor for the presence of 
cerebral microbleeds.201 Therefore, we compared the prevalence of microbleeds between 
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COPD subjects who had ever smoked and smoking subjects without airflow limitation. We 
found that smoking COPD subjects had a significantly higher prevalence of deep or 
infratentorial microbleeds than smoking subjects without COPD, suggesting that the 
association between COPD and deep or infratentorial microbleeds could not be explained by 
smoking solely. These results are in line with previous findings that oxidative stress persists 
in patients with COPD despite smoking cessation, and has a crucial role in the perpetuation 
of the inflammation.13 Previously, the association between impaired lung function and 
cerebral small vessel disease (white matter lesions) on the one hand and macrovascular 
disease (carotid intima-media thickness, arterial stiffness) on the other hand, was found to 
be independent of smoking.200, 231-233 Although smoking tends to increase the prevalence of 
cerebral microbleeds within COPD subjects of our study, our results suggest that an interplay 
with, or a certain susceptibility for COPD seems necessary before the harmful effect of 
smoking on deep or infratentorial microbleeds becomes apparent. Potentially, there might 
be a phenotype more sensitive to smoking, simultaneously developing cardiovascular, 
pulmonary and cerebral abnormalities. Further research is warranted to explore whether a 
general phenotype of ‘systemic COPD’ exists and might benefit from more tailored 
treatment options.368 Although the reported longitudinal association is more compatible 
with a causative role for COPD in the development of cerebral small vessel disease, we 
cannot exclude that pulmonary manifestations present themselves earlier than 
cerebrovascular abnormalities.  
 
Aging is another important determinant since cerebral microbleeds gradually increase with 
age.201 COPD subjects within the cross-sectional study population were slightly older and 
therefore all analyses were adjusted for age. However, it is unlikely that the small difference 
in age could explain the much higher prevalence of cerebral microbleeds compared to the 
controls, or compared to the age-specific prevalence of cerebral microbleeds described by 
Poels et al.201 
 
Strengths of this study are the high quality information derived from state of the art 
diagnostic imaging techniques which allowed highly sensitive detection of cerebral 
microbleeds, and the prospective data collection. The population based setting and large 
sample size of our cohort allowed us to examine COPD patients with a range of disease 
severity. Furthermore, we made a distinction between different locations of microbleeds in 
the brain, enabling us to separately assess the prevalence of microbleeds in deep or 
infratentorial regions versus strictly lobar regions, which embodies a different etiology.202 
 
A first potential limitation of this observational study is the cross-sectional design of our 
main analysis. However, the gradual increase in prevalence of deep or infratentorial 
microbleeds according to severity of airflow limitation, suggests a potential causal 
mechanism between COPD and cerebral microbleeds. Therefore, we further examined the 
association longitudinally involving 553 participants of the Rotterdam Study with two MRI 
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scans of the brain and without cerebral microbleeds at the time of the first scan. These 
results showed that COPD is significantly associated with an increased risk of developing 
deep or infratentorial microbleeds in the subsequent three years, which further 
substantiates the plausibility of a causal association between COPD and microbleeds in deep 
and infratentorial locations. A second consideration is that although COPD is primarily a lung 
disease, the disease is very heterogeneous and associated with multiple comorbid 
conditions. The specific role of COPD as a risk factor for cerebral small-vessel disease in 
patients with multiple comorbidities could therefore be difficult to ascertain. However, the 
associations between COPD and cerebral microbleeds in our population were independent 
of known other physiological and cardiovascular risk factors. Finally, we did not perform 
computed tomography (CT) of the lungs in our population to corroborate emphysema. 
Although diffusing capacity correlates fairly with lung CT density and loss of alveolar 
membrane surface area (in emphysema) is one of the primary causes of a low DLCO, it is not 
the gold standard to measure emphysema.369 
 
In conclusion, the results of this study are compatible with an increased risk of COPD on the 
development of cerebral microbleeds in deep or infratentorial locations. Given the 
importance of cognitive and functional consequences, our results might lead to a better 
recognition of vulnerable patient groups, and enhance research into necessary preventive 
strategies. 
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ABSTRACT 
 
Background 
Worldwide, chronic obstructive pulmonary disease (COPD) and stroke are leading 
causes of death. Moreover, increasing evidence suggests an association between both 
diseases, potentially caused by an increased atherosclerosis risk in patients with COPD. 
 
Objectives 
To examine the associations between COPD and the different subtypes of stroke in the 
general population. 
 
Methods 
Within the prospective population-based Rotterdam Study, we followed 13 115 
participants without history of stroke or asthma for occurrence of stroke. Follow-up 
started in 1990-2008 and finished in 2012. COPD was related to stroke using a time-
dependent Cox proportional hazard model adjusted for age, sex and smoking. 
 
Results  
1250 of the 13115 participants incurred a stroke, of whom 701 an ischemic stroke. 
Adjusted for age and sex, COPD was significantly associated with all stroke (HR 1.22; 
95%CI 1.03-1.46), ischemic stroke (HR 1.34; 1.07-1.67), and hemorrhagic stroke (HR 
1.79; 1.07-2.99). Additionally adjusting for smoking attenuated the effect sizes (HR 1.12 
(0.93-1.33) for all stroke, HR 1.19 (0.93-1.49) for ischemic stroke, and HR 1.63 (0.97-
2.76) for hemorrhagic stroke). 
 
Conclusions 
COPD is associated with incident stroke, both ischemic and hemorrhagic. Associations 
were mainly, but not completely driven by smoking, suggesting that clinicians should be 
aware of the higher risk of both ischemic and hemorrhagic stroke in persons with COPD. 
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11. COPD and stroke 
INTRODUCTION 
Chronic obstructive pulmonary disease (COPD) is primarily characterized by persistent 
airflow limitation that is associated with an abnormal inflammatory response of the lungs to 
noxious particles or gases and leads to many extrapulmonary manifestations.13 A stroke is 
characterized as a neurological deficit lasting 24 hours or leading to death, due to an acute 
focal injury of the central nervous system by a vascular cause.370 This can be either an 
infarction or intracerebral hemorrhage. COPD and stroke are both leading causes of 
morbidity and mortality worldwide 2, 371 and evidence for an association between both 
diseases is increasing.35 This association could be causal, since some studies showed that the 
risk of stroke correlates with the degree of airflow limitation.183, 188 Especially during COPD 
exacerbations, pulmonary inflammation can lead to systemic inflammation30, which plays a 
role in the forming of instable atherosclerotic plaques.372 Recent studies showed that in 
COPD patients carotid arterial plaque burden is increased and more prone to rupture, 
leading to an increased risk of stroke.191, 192, 232 However, any associations between COPD 
and stroke might also emerge due to shared etiology. COPD and stroke are both associated 
with cardiovascular risk factors as diabetes, hypertension, and particularly smoking.232, 373, 374 
Whether associations are independent from these cardiovascular risk factors is still unclear. 
Some previous population-based found associations between COPD and stroke131, 190, 375-377, 
but only few had information about smoking.190, 375, 377 Furthermore, previous studies only 
examined associations with all subtypes of stroke combined. However, if associations are 
due to a higher risk of atherosclerosis, associations will be mainly present for ischemic 
stroke. Still, we previously showed an increased risk of microbleeds in persons with COPD, 
suggesting that COPD might also be associated with intracerebral hemorrhage.141  
Therefore, the aim of our prospective population-based study was to examine the 
associations between COPD and stroke, taking into account the different subtypes of stroke. 
Furthermore, we investigated the role of cardiovascular risk factors on these associations.  
 
METHODS 
Setting and study population 
This study was conducted within the population-based Rotterdam Study, which has as aim to 
assess incidence and risk factors of chronic diseases in the elderly. Initially, from 1990 
onwards 7983 persons aged 55 years and older and living in the Ommoord district in the city 
of Rotterdam were included (Rotterdam Study I). The cohort was extended in 2000 with 
3011 participants who moved into the study district or had become 55 years or since the 
start of the study (Rotterdam Study II). In 2006, the study was further extended with 3932 
persons that were aged 45-54 years (Rotterdam Study III). Details regarding the objective 
and design of the Rotterdam Study have been described elsewhere.20 
The study population consisted of participants who gave informed consent for follow-up and 
had no history of stroke at baseline. Patients with physician diagnosed asthma or asthma-
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COPD overlap syndrome (ACOS) were excluded. The Rotterdam Study has been approved by 
the medical ethics committee according to the Population Study Act Rotterdam Study, 
executed by the Ministry of Health, Welfare and Sports of the Netherlands. A written 
informed consent was obtained from all participants. 
 
Assessment of COPD 
COPD was diagnosed by an obstructive spirometry (proportion of the forced vital capacity 
exhaled in the first second (FEV1/FVC) < 0.7) during the research centre visit or by a 
pulmonologist or general practitioner.5 The incident COPD date was defined as the date of 
COPD diagnosis in the medical records, the date of a first COPD medication prescription or 
the date of obstructive lung function examination, whichever came first. Medication use was 
obtained through automated linkage with pharmacy filled prescription data.378  
 
Assessment of stroke 
Stroke was defined according to the World Health Organization criteria as syndrome of 
rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with 
symptoms lasting 24 hours or leading to death, with no apparent cause other than of 
vascular origin.379  Prevalent stroke at baseline was assessed using the home interview and 
verified by reviewing medical records. From baseline onwards, all participants were 
continuously followed-up for occurrence of stroke through automatic linkage of general 
practitioners’ medical records with the study database. Additionally, nursing home 
physicians’ medical records and medical records from general practitioners of participants 
who moved out of the Ommoord district were inspected on a regular basis. Research 
physicians reviewed potential strokes using hospital discharge letters and information from 
general practitioners and an experienced neurologist verified the stroke diagnoses.366 
Strokes were subclassified in ischemic or hemorrhagic based on neuroimaging reports. If no 
neuroimaging was performed, strokes were classified as unspecified. Strokes were further 
subclassified in cortical or lacunar, based on clinical symptoms. Furthermore, strokes were 
subclassified according to TOAST criteria.380 The follow-up was complete until January 1st, 
2012 for 96.3% of potential person-years. 
 
Covariates 
Covariates were measured at baseline of each cohort. Smoking status and medication use 
were assessed during a home interview. Smoking was categorized into current, past, and 
never smoking. Additionally, cardiovascular risk factors were measured during a visit at the 
study center.381 Blood pressure was measured two times in sitting position on the right arm 
with a random-zero sphygmomanometer. The average of the two consecutive 
measurements was used in the analyses. Total cholesterol, high-density lipoprotein (HDL) 
cholesterol, and C-reactive protein (CRP) were measured in serum. Diabetes mellitus was 
defined as having an overnight fasting glucose level 7.0 mmol/L or higher, a non-fasting 
glucose level of 11.0 mmol/L or higher, or using antidiabetic medication.  
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14235 subjects within the Rotterdam Study
without prevalent stroke and with follow-up
13115 subjects at risk for first stroke
1120 subjects with asthma excluded
Statistical analyses 
Analysis of covariance was used to study differences in baseline characteristics between 
subjects with and without COPD and between persons with prevalent or incident COPD, 
adjusted for age and sex. Associations between COPD and stroke were evaluated using Cox 
proportional hazards regression. COPD was added as time-varying covariate in the analysis, 
which captured persons that developed COPD during follow-up. Participants were censored 
at date of stroke, date of death, last date of follow-up, or January 1st, 2012, whichever came 
first. Furthermore, we examined associations of COPD with different subclassifications of 
stroke. All models were adjusted for age and sex, and additionally for potential confounders, 
such as smoking, systolic blood pressure, diastolic blood pressure, blood pressure-lowering 
medication, total cholesterol, HDL cholesterol, lipid-lowering medication, diabetes mellitus, 
and BMI. Missing data on covariates (for all covariates 14.1% or less) were imputed based on 
the other covariates using multiple imputation with 5 imputation sets. All analyses were 
done using IBM SPSS Statistics version 21.0 (IBM Corp., Armonk, NY). 
 
RESULTS  
Participants that did not give informed consent for collection of follow-up data (n=238), had 
history of stroke at baseline (n=453), or had history of asthma or ACOS at baseline (n=1120) 
were excluded. Consequently, 13 115 participants were eligible for analysis.(Figure 1) During 
9.6 (±6.0 SD) years of follow-up, 1250 subjects suffered a stroke, of whom 701 an ischemic 
stroke, 107 a hemorrhagic stroke, and 442 an unspecified stroke. 
  
Figure 1: Flow chart of the study population. 
 
  
Baseline
538 subjects with COPD
12577 subjects without COPD 
22 years
End of Follow-up
1250 subjects with stroke
12920 subjects without stroke
108 
 
The baseline characteristics of the study population are presented in Table 1. 538 
participants had COPD at baseline and 1028 participants developed COPD during follow-up. 
The mean age (±SD) was 67.0 years (±9.3) for persons with COPD at baseline, 65.2 (±7.4) for 
persons that developed COPD during follow-up, and 65.7 (±10.3) for persons without COPD. 
Persons with COPD were more often male and more (current) smokers.(Table 1) 
 
Table 1: Baseline characteristics of the study population (n=13 115). 
 
 Prevalent COPD Incident COPD No COPD 
N=538 N=1028 N=11549 
Age, years 67.0 (9.3)*† 65.2 (7.4) 65.8 (10.6) 
Female 250 (46.5%)* 449 (43.7%)* 6971 (60.4%) 
Smoking    
Never 80 (15.0%)* 151 (14.8%)* 4052 (35.9%) 
Past 240 (44.9%)† 410 (40.2%)* 4797 (42.5%) 
Current 214 (40.1%)* 459 (45.0%)* 2449 (21.7%) 
Systolic blood pressure, mmHg 139 (21) 137 (21) 138 (22) 
Diastolic blood pressure, mmHg 77 (12)† 76 (12)* 77 (12) 
Use of blood pressure-lowering 
medication 
182 (34.0%) 288 (28.1%) 2436 (29.8%) 
Total cholesterol, mmol/L 6.1 (1.2)† 6.3 (1.2)* 6.2 (1.2) 
HDL-cholesterol, mmol/L 1.43 (0.44)*† 1.34 (0.36) 1.37 (0.39) 
Use of lipid-lowering medication 62 (11.6%)*† 74 (7.2%)* 1047 (9.1%) 
Diabetes mellitus 55 (11.9%)† 67 (7.1%)* 922 (9.1%) 
Body mass index 26.4 (4.1)* 26.0 (3.8)* 26.9 (4.0) 
hsCRP, mg/L 3.8 (5.7)* 3.1 (5.1) 2.8 (6.0) 
Data are presented as mean (standard deviations) or counts (percentages). 
* Significantly different between persons with and without COPD, after sex and age adjustment – if applicable. 
† Significantly different between persons with prevalent and incident COPD at baseline, a>er sex and age 
adjustment – if applicable. 
Abbreviations: COPD= Chronic Obstructive Pulmonary Disease; HDL= High-Density Lipoprotein; hsCRP = high-
sensitivity C-reactive protein; N= number of persons included in study;  
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In Table 2 we show associations of COPD and the risk of stroke. When we adjusted for age 
and sex, we found a significant association of COPD with all stroke (HR 1.22; 95%CI 1.03 – 
1.46), ischemic stroke (HR 1.34; 1.07 – 1.67), and hemorrhagic stroke (HR 1.79; 1.07 – 2.99). 
However, additionally adjusting for smoking attenuated the associations. Further adjusting 
for systolic blood pressure, diastolic blood pressure, blood pressure-lowering medication, 
total cholesterol, HDL cholesterol, lipid-lowering medication, diabetes mellitus and BMI 
hardly changed the estimates.(Table 2) 
Associations between COPD and ischemic stroke were mainly present for persons with a 
cortical stroke (HR adjusted for age, sex, and smoking 1.40; 1.00 – 1.96) and persons with a 
stroke based on large artery atherosclerosis (HR adjusted for age, sex, and smoking 1.94; 
1.11-3.38). 
 
 
Table 2: COPD and the hazard on stroke. 
All stroke 
n/N 1250/13115 
Ischemic stroke 
n/N 701/13115 
Hemorrhagic stroke 
n/N 107/13115 
Model 1 1.22 (1.03; 1.46) 1.34 (1.07; 1.67) 1.79 (1.07; 2.99) 
Model 2 1.12 (0.93; 1.33) 1.19 (0.95; 1.49) 1.63 (0.97; 2.76) 
Model 3 1.12 (0.93; 1.33) 1.19 (0.95; 1.49) 1.57 (0.93; 2.65) 
Values are hazard ratios with 95% confidence intervals.  
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex and smoking. 
Model 3: adjusted for age, sex, systolic blood pressure, diastolic blood pressure, blood pressure-lowering 
medication, total cholesterol, HDL cholesterol, lipid-lowering medication, diabetes mellitus, BMI, and smoking. 
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DISCUSSION 
In this large population-based cohort study, we found that COPD was associated with a 
higher risk of stroke, both ischemic stroke and hemorrhagic stroke. Associations between 
COPD and stroke attenuated after adjusting for smoking.  
 
Other studies found age and sex adjusted odds ratios for the association of COPD with stroke 
varying between 1.24 and 1.51, which is comparable to the HR of 1.22 (1.03 – 1.46) that we 
found.131, 190, 376, 377 One study found a larger effect size, with a HR of 3.34 (3.21 – 3.48), but 
this was driven by the younger age groups until 54 years.375 We found associations for both 
ischemic and hemorrhagic stroke. None of the previous studies examined associations with 
ischemic or hemorrhagic stroke separately.  
 
The most likely explanation for the higher risk of ischemic and hemorrhagic stroke in 
subjects with COPD is the shared risk factor smoking. Associations attenuated after adjusting 
for smoking. In a previous nested case-control study, a similar attenuation in effect on all 
stroke was found after adjusting for smoking.190 Two other studies that also adjusted for 
smoking found a stronger and significant effect, but one only in younger age groups 375 and 
the other only in the elderly.377 However, not all of our findings can be explained by smoking. 
Associations with hemorrhagic stroke were still borderline significant after adjusting for 
smoking and for ischemic stroke we found larger associations in persons with cortical stroke 
or strokes due to large artery atherosclerosis, which suggests that part of the association is 
influenced by effects of COPD itself. For instance due to the systemic inflammation occurring 
in COPD, especially during exacerbations. Inflammation in the systemic circulation leads to 
forming of instable atherosclerotic plaques and a pro-thrombotic state, which could lead to 
ischemic stroke.372, 382, 383 Another causal mechanism might be hypoxia. Previous studies 
found an increased risk of stroke with decreasing lung function.182, 183, 188 Hypoxia could lead 
to endothelial dysfunction which might predispose to stroke.384, 385  
 
The strengths of our study are the longitudinal design with long-term follow-up, the 
population-based setting, and the thorough collection of COPD, exacerbations and stroke 
information during follow-up. This study also has limitations. We adjusted for baseline 
covariates, whereas the status of those variables might change during follow-up. Another 
limitation is that not all strokes could be classified into ischemic or hemorrhagic stroke due 
to lack of imaging data. Furthermore, we could not subclassify all ischemic strokes into 
lacunar or cortical and could not subclassify all ischemic strokes according to the TOAST 
criteria, because we were limited by the information from medical records.  
 
In conclusion, we found that COPD was associated with stroke, both ischemic and 
hemorrhagic. Associations were mainly, but not completely driven by smoking, suggesting 
that in persons with COPD clinicians should be aware of the higher risk of both ischemic and 
hemorrhagic stroke.  
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ABSTRACT 
 
Objectives 
To investigate the prevalence of frailty in a Dutch elderly population and to identify adverse 
health outcomes associated with the frailty phenotype independent of the comorbidities. 
 
Methods 
Cross-sectional and longitudinal analyses within the Rotterdam Study (the Netherlands), a 
prospective population-based cohort study in persons aged ≥55 years. Frailty was defined as 
meeting three or more of five established criteria for frailty, evaluating nutritional status, 
physical activity, mobility, grip strength and exhaustion. Intermediate frailty was defined as 
meeting one or two frailty criteria. Comorbidities were objectively measured. Health 
outcomes were assessed by means of questionnaires, physical examinations and continuous 
follow-up through general practitioners and municipal health authorities for mortality. 
 
Results  
Of 2833 participants (median age 74.0 years, IQR 9) with sufficiently evaluated frailty 
criteria, 163 (5.8%) participants were frail and 1454 (51.3%) intermediate frail. Frail elderly 
were more likely to be older and female, to have an impaired quality of life and to have 
fallen or to have been hospitalized. 108 (72.0%) frail participants had ≥2 comorbidities, 
compared to 777 (54.4%) intermediate frail and 522 (44.8%) non-frail participants. Adjusted 
for age, sex and comorbidities, frail elderly had a significantly increased risk of dying within 
3 years (HR 3.4; 95% CI 1.9 to 6.4), compared to the non-frail elderly. 
 
Conclusions 
This study in a general Dutch population of community-dwelling elderly able to perform the 
frailty tests, demonstrates that frailty is common and that frail elderly are at increased risk 
of death independent of comorbidities. 
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12. Frailty in the elderly 
INTRODUCTION 
Elderly people of the same chronological age demonstrate that there is a large 
heterogeneity in terms of biological age.58, 386 Some are still fit and energetic while a 
relatively large number of elderly people has an accelerated decline in well-being and 
resilience.37 Given the expanding elderly population and the major impact on health and 
social care, the identification of this frail group of elderly, which could benefit from more 
adequate interventions, becomes of increasing interest.37 Frailty is defined as a biological 
syndrome in which a progressive, cumulative decline in the reserve capacity of multiple 
physiological systems elicits an abnormal vulnerability to common stressors.38 In short, 
frailty could be defined as the disability to compensate function loss. Increasing evidence 
suggests that frail elderly are at an increased risk of adverse health outcomes (disability, falls, 
hospitalizations, institutionalizations and death).38-42 Conceptually, it is important to 
distinguish “frailty” from “disability” and “comorbidity” and therefore, not to use an 
instrument integrating disability or comorbidity items to measure frailty.57 In the 
Cardiovascular Health Study, more than a quarter of the elderly categorized as frail 
according to the Fried frailty criteria were not disabled and had no comorbidity.38 However, 
these three different entities are related.37 Those who are frail have a higher prevalence of 
concomitant chronic diseases and of disability than those who are non-frail. Moreover, 
comorbidity is a risk factor for frailty, whereas disability is an adverse outcome of frailty and 
disability may aggravate frailty.56 Because of the complex relationship between comorbidity 
and frailty, it is not always clear whether frailty is a predictor of mortality independent of 
comorbidities. To our knowledge, the very few studies who investigated the association 
between frailty and mortality only adjusted for some selected, mainly self-reported, chronic 
diseases.38, 40-42, 387 
An unambiguous definition of frailty is of great importance for clinicians to identify those at 
an increased risk of adverse health outcomes, but also for policy makers to make cost-
effective decisions in health care.58 Since there is no distinct uniform definition of frailty, 
reported prevalences vary greatly from 5% to 58%.388 Generally, two different definitions of 
frailty are most commonly used:58 a broader definition of frailty taking into account more 
social and psychological aspects;39 and one based on predominantly physical criteria.38 
Within the latter definition based on physical aspects, frailty is defined as meeting three or 
more of five established criteria for frailty, namely evaluating: i) nutritional status 
(unintentional weight loss), ii) physical activity, iii) mobility (slow walking speed), iv) 
weakness (reduced grip strength), and v) exhaustion (self-reported).38 Elderly individuals 
with one or two criteria are defined as intermediate frail or pre-frail and have been found to 
be at increased risk of becoming frail.38 The physical frailty definition by Fried et al. is 
associated with a lower prevalence and less variable prevalence rates.38 Although it is 
suggested that frailty is more than a decline in physical functions, the model based on 
physical aspects is more practical for fundamental research since the criteria are limited in 
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number, has clear cut-offs between frail versus non frail and constitutes a more objective 
measure.58, 388 Moreover, the frailty phenotype by Fried et al. is the most widely used 
instrument in frailty research, allowing comparisons with other studies, and has been most 
extensively tested for its validity, including the external validity of adverse health 
outcomes.38, 57  
 
The aim was to investigate the prevalence of physically frail elderly in a Dutch population-
based cohort study and the impact on adverse health outcome including all-cause mortality 
independent of comorbidity. 
 
METHODS  
Study population and design 
This study was embedded within cohort I and II (RSI and RSII) from the Rotterdam Study, a 
prospective population-based cohort study ongoing since 1990.108 The rationale and design 
of the Rotterdam Study have been extensively described.20, 21, 55, 85, 108, 389 In short, all 
inhabitants aged 55 years and older of one district of Rotterdam (Ommoord) were invited to 
the original cohort (RSI). Names and addresses were drawn from the municipal register 
which is reliable, complete and up to date.21 7 983 subjects participated (78% of 10,215 
invitees). 3 011 participants (out of 4 472 invitees) who had become 55 years of age or 
moved into the study district since the start of the study were added as RSII in 1999. Almost 
all participants are from Caucasian descent. All participants are invited every 3 to 5 years to 
the research center for follow-up examinations, including physical examination and blood 
sampling. Moreover, the participants are continuously monitored for clinically meaningful 
outcomes. The assessment of the study participants’ characteristics and frailty criteria used 
in this study took place from March 2009 until March 2012 among 4027 participants. The 
follow-up period started at the time of the frailty-assessment until death or end of the study 
period (January 1st, 2013). This study was approved by the medical ethics committee of the 
Erasmus Medical Center, Rotterdam, and the review board of The Netherlands Ministry of 
Health, Welfare and Sports. Participants gave written informed consent.  
 
Definition of frailty 
Frailty was determined using the physical definition of frailty, which has been developed in 
the population-based Cardiovascular Health Study and is since then the most widely used 
and validated instrument in frailty research.38, 57, 390 Frailty was defined as meeting three or 
more of the five established frailty criteria. Grip strength was assessed using a handgrip 
dynamometer and the grip strength was defined as the highest value (kg) of three trials 
performed in the non-dominant hand.108 Weakness was defined as having a grip strength for 
men ≤29 kg (if body mass index (BMI)≤24, or ≤30 kg if BMI≤24.1-28, or ≤32 kg if BMI>28) and 
for women ≤17 kg (if BMI≤23, or ≤17.3 kg if BMI≤23.1-26, or ≤18 kg if BMI≤26.1-29, or ≤21 kg 
if BMI>29).38 Weight loss was defined as losing more than 5% body weight compared to the 
previous examination (six years earlier). Exhaustion was defined as answering “frequently” 
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or “mostly” to one of the following two statements from the Center for Epidemiological 
Studies Depression (CES-D) scale: (a) I felt that everything I did was an effort; (b) I could not 
get going.391 Physical activity was determined from an extensive questionnaire about leisure 
time and sports; the physical activities were weighted by their intensity and all awarded 
kilocalories per week were summed.38, 392 Low physical activity was defined as expending 
less than 383 kcal per week for men and less than 270 kcal per week for women.38 Finally, 
slowness was defined as walking at a velocity of less than 0.76 m/s if height was more than 
173 cm for men or more than 159 cm for women (otherwise less than 0.65 m/s).38 
Assessment of gait was performed in all participants using the GAITRite walkway (CIR 
Systems, Inc., Sparta, New Jersey). Only participants who had a sufficient number of criteria 
to confirm or to exclude frailty were included (e.g. at least three concordant positive or 
negative criteria evaluated). Participants with one or two criteria were defined as 
intermediate frail or pre-frail.38  
Characteristics, comorbidities and adverse health outcomes 
Standardized questionnaires including information on smoking status, pack years, falls and 
hospitalizations, were completed at the time of the frailty-assessment in the research 
center. Participants were asked “Did you fall in the past 12 months?” and “Have you been 
hospitalized in the past 12 months?”. Mortality information was obtained from the 
municipal health authorities in Rotterdam in addition to computerized reports from the 
general practitioners.108 Smoking status was distinguished into never, former, and current 
smoking. Cigarette pack years were computed as duration of smoking (years) multiplied by 
the number of smoked cigarettes, divided by 20. The BMI was calculated as weight divided 
by height squared.  
Diabetes mellitus was defined as the use of blood glucose-lowering medication based on 
automated pharmacy records.393 Chronic obstructive pulmonary disease (COPD) was 
assessed by spirometry, performed at the research center. The participants were classified 
as having COPD when the ratio of forced expiratory volume in 1 second (FEV1) to forced vital 
capacity (FVC) was less than 70%, in the absence of asthma.232 Hypertension was defined as 
the use of antihypertensive medication during follow-up, and/or a systolic brachial blood 
pressure of ≥160 mmHg, and/or a diastolic brachial blood pressure of ≥100 mmHg (Grade 2 
according to European Society of Cardiology criteria).343 Coronary revascularization was 
defined as coronary artery bypass grafting and percutaneous coronary intervention. 
Myocardial infarction, heart failure, stroke and cancer were clinically validated. Osteoporosis 
was defined using femoral neck bone mineral density measured by Dual-energy X-ray 
absorptiometry applying World Health Organization (WHO) criteria.394 Kidney disease was 
defined according to the National Kidney Foundation guidelines as having a glomerular 
filtration rate (GFR) <60 mL/min/1.73m or as having markers of kidney damage (i.e. a urine 
albumin – creatinine ratio greater than 17 mg/g in men and greater than 25 mg/g in women) 
395. The GFR was calculated using the Modification of Diet in renal Disease Study Equation of 
Levy et al.396 Anemia was defined according to the WHO guidelines <120 g/L for women and 
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<130 g/L for men.397 The comorbidity count which distinguishes between none, one and two 
or more comorbidities, was calculated for all participants of whom we had complete 
information on all ten diseases. Blood samples for determination of levels of serum glucose, 
creatinin, hemoglobin (Hb), cholesterol, and white blood cell (WBC) count were obtained at 
the research center.  
Statistical analyses 
For the baseline characteristics, logistic regression models, adjusted for age and sex, were 
performed. Cox proportional hazard ratios were calculated to evaluate the risk of mortality 
for frail elderly. The following variables were considered as potential confounders: age, sex, 
body mass index, smoking status, pack years and the comorbidity-index. Models were 
adjusted for co-variables that changed the point estimate by more than 5%. Kaplan-Meier 
survival analysis was used to illustrate the percentage of participants who died during 
follow-up. The Log rank test was used to determine whether the difference in survival 
between frail elderly and intermediate and non-frail elderly was significant. Stratification for 
sex was performed and individual Kaplan-Meier curves were depicted. Proportionality of 
hazards was checked for the Cox-regression models. The influence of the use of age as time 
scale instead of the use of the standard survival analysis corrected for age, was evaluated 
using R Statistical Software (Foundation for Statistical Computing, Vienna, Austria). All other 
statistical analyses were performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM 
Corp, Armonk, NY). P-values below the conventional level of significance (p<0.05) were 
considered as statistically significant. 
RESULTS 
Characteristics of the study population 
Within the Rotterdam Study, the frailty status could be determined in 2833 (71.6%) of the 
4027 participants who recently visited the research center. Of these, 1585 participants 
(55.9% of the study population) were women and the median age was 74 years (IQR 9). The 
prevalence of the individual frailty criteria was: 1) 1113 (40.3%) out of 2765 participants had 
reduced grip strength, 2) 534 (19.4%) out of 2753 evaluated participants had ≥5% weight 
loss over the past six years, 3) 61 (3.6%) out of 1688 participants exhibited a slow walking 
speed, 4) 118 (4.4%) out of 2695 participants had a low physical activity, and 5) 366 (13.0%) 
out of 2816 participants reported exhaustion (Figure 1). No walking speed measurement was 
available in 1145 (40.4%) participants due to a postponed start period of the gait 
assessment. Three or more of the five frailty criteria were present in 163 participants, 
implicating that the prevalence of frailty in the Rotterdam Study is 5.8% (95% CI: 5.0 to 6.7%; 
4.1% in males, 7.1% in females). 1216 (42.9%) and 1454 (51.3%) participants were non-frail 
and intermediate frail, respectively.  
Frail participants were older and more frequently female compared to participants with less 
than three frailty criteria (Table 1). In addition, adjusted for age and sex, frail participants 
had a significantly impaired quality of life (QoL) and were more frequently current smokers 
with a higher number of pack years. 
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Compared to the participants in whom the frailty status could be determined (n=2833), the 
participants with incomplete information (n=1194) were older and more frequently female, 
had a worse quality of life, higher mortality and more comorbidities (Table 2). In a sensitivity 
analysis using multiple imputation, the prevalence of frailty was not significantly higher in 
the participants with incomplete information (6.9% compared to 5.8% in the participants 
where the frailty status could be determined; p=0.177). 
Table 1: Baseline characteristics. 
 Non-frail 
Intermediate 
Frail 
Frail P-value 
Number 1216 (42.9%) 1454 (51.3%) 163 (5.8%)  
Age (years) 73 (7) 75 (9) 81 (8) <0.001 
Female 623 (51.2%) 850 (58.5%) 112 (68.7%) 0.001 
QoL 80 (15) 80 (15) 70 (20) <0.001 
BMI 26.6 (4.5) 27.4 (5.3) 27.0 (6.6) 0.811 
Pack years 5.4 (23.1) 5.0 (23.0) 6.5 (35.3) <0.001 
Smoking status     
  Never 393 (32.3%) 497 (34.2%) 60 (36.8%)  
  Former 715 (58.8%) 832 (57.2%) 84 (51.5%) 0.913 
  Current 108 (8.9%) 125 (8.6%) 19 (11.7%) 0.035 
Lab results     
  Hb (mmol/l) 8.8 (0.9) 8.7 (0.9) 8.4 (0.9) <0.001 
  WBC (count/mm3) 6,700 (1,900) 6,900 (2,200) 7,200 (2,600) 0.007 
  Cholesterol (mmol/l) 5.4 (1.5) 5.3 (1.5) 5.0 (1.5) <0.001 
  Glucose (mmol/l) 5.5 (0.9) 5.6 (1.0) 5.5 (1.1) 0.881 
  Creatinin  (µmol/l) 79 (22.0) 78 (24.8) 78 (26.0) 0.288 
Comorbidity     
  Coronary disease 29 (2.4%) 75 (5.2%) 5 (3.1%) 0.280 
  Heart failure 21 (1.7%) 60 (4.1%) 18 (11.0%) 0.006 
  Hypertension 865 (71.1%) 1124 (77.3%) 140 (85.9%) 0.034 
  Stroke 10 (0.8%) 13 (0.9%) 4 (2.5%) 0.001 
  Diabetes 72 (5.9%) 122 (8.4%) 17 (10.4%) 0.095 
  Osteoporosis 121 (10.2%) 181 (12.4%) 40 (25.0%) 0.001 
  Cancer 159 (13.1%) 206 (14.2%) 29 (17.8%) 0.160 
  COPD 172 (14.1%) 238 (16.4%) 47 (28.8%) <0.001 
  Anemia 45 (3.8%) 127 (8.9%) 30 (19.9%) <0.001 
  Kidney disease 306 (25.5%) 470 (32.6%) 66 (43.1%) 0.380 
Comorbidity count     
  0 173 (14.8%) 151 (10.6%) 7 (4.7%)  
  1 471 (40.4%) 501 (35.1%) 35 (23.3%) 0.601 
  ≥2 522 (44.8%) 777 (54.4%) 108 (72.0%) 0.057 
Falls in preceding year 180 (21.2%) 298 (26.8%) 53 (39.8%) 0.001 
Hospitalization in preceding year 60 (10.6%) 144 (17.4%) 27 (24.5%)  0.006 
Categorical variables are expressed as numbers (percentages). Values of continuous variables are expressed as 
median (interquartile range (IQR)). P-values comparing the frail group against the non-frail and intermediate 
frail group combined, are age and sex adjusted (age and sex adjusted for one another). Comorbidity count 
determined in participants without missing comorbidities (n=2745; coronary disease was missing in 6 
participants, heart failure in 12, osteoporosis in 29, anemia in 58 and kidney disease in 37 participants). 
Abbreviation: QoL = Quality of Life, BMI = Body Mass Index, Hb = Hemoglobin, WBC = White Blood Cells, COPD 
= Chronic Obstructive Pulmonary Disease 
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Table 2: Baseline characteristics of the included (Frailty status determined) and excluded 
group (No frailty status determined). 
 
Frailty status 
determined 
No frailty status 
determined 
P-value 
Number 2833 (70.4%) 1194 (29.6%)  
Age (years) 74 (9) 80 (11) <0.001 
Female 1585 (55.9%) 796 (66.7%) <0.001 
QoL 80 (15) 70 (15) <0.001 
BMI 27.0 (5.0) 27.4 (5.9) 0.103 
Pack years 5.2 (23.6) 4.5 (24.5) 0.222 
Smoking status    
  Never 950 (33.5%) 444 (37.2%)  
  Former 1631 (57.6%) 600 (50.3%)  
  Current 252 (8.9%) 150 (12.6%) <0.001 
Lab results    
  Hb (mmol/l) 8.7 (1.0) 8.5 (1.1) <0.001 
  WBC (count/mm3) 6,800 (2,000) 7,300 (2,300) <0.001 
  Cholesterol (mmol/l) 5.4 (1.5) 5.3 (1.5) 0.109 
  Glucose (mmol/l) 5.5 (0.9) 5.6 (1.2) 0.116 
  Creatinin (µmol/l) 78 (23.0) 77 (26.0) 0.404 
Comorbidity    
  Coronary disease 109 (3.9%) 67 (5.7%) 0.010 
  Heart failure 99 (3.5%) 124 (10.5%) <0.001 
  Hypertension 2129 (75.2%) 841 (71.3%) 0.012 
  Stroke 27 (1.0%) 20 (1.7%) 0.051 
  Diabetes 302 (12.4%) 64 (18.6%) 0.001 
  Osteoporosis 342 (12.2%) 65 (13.9%) 0.297 
  Cancer 433 (17.4%) 68 (19.0%) 0.464 
  COPD 457 (16.1%) 200 (16.8%) 0.627 
  Anemia 202 (7.3%) 59 (12.6%) <0.001 
  Kidney disease 841 (30.1%) 201 (41.6%) <0.001 
Comorbidity count    
  0 287 (11.8%) 22 (6.5%)  
  1 806 (33.2%) 90 (26.5%)  
  ≥2 1337 (55.0%) 227 (67.0%) <0.001 
Falls in preceding year 531 (25.3%) 294 (33.6%) <0.001 
Hospitalization in preceding 
year 
231 (15.4%) 155 (19.8%)  0.008 
Frailty (imputed) 163 (5.8%) 82 (6.9%) 0.177 
Deaths 118 (4.2%) 198 (16.6%) <0.001 
Categorical variables are expressed as numbers (percentages). Values of continuous variables are expressed 
as median (interquartile range (IQR)). Abbreviation: QoL = Quality of Life, BMI = Body Mass Index, Hb = 
Hemoglobin, WBC = White Blood Cells, COPD = Chronic Obstructive Pulmonary Disease 
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Frailty and comorbidities 
72.0% of those who were frail had two or more comorbidities compared to 44.8% of the 
non-frail participants (Table 1). Frail participants had a significantly higher prevalence of 
heart failure, hypertension, stroke, osteoporosis, COPD and anemia independent of age and 
sex than those who were non-frail and intermediate frail (Table 1). Furthermore, frail 
participants had lower blood levels of hemoglobin and cholesterol, whereas they had an 
increased white blood cell count, even when adjusted for age, sex, BMI, smoking status, pack 
years and the comorbidity count (p=0.001, p=0.003 and p=0.040 respectively). There were 
no remarkable differences regarding BMI, blood glucose or creatinin levels. 
Frailty and adverse health outcomes 
More than one third of the frail participants had fallen in the preceding year and one quarter 
had been hospitalized in the previous year, compared to approximately one fifth and one 
tenth of the non-frail participants respectively (Table 1, Figure 2). In Figure 2A the 
percentage of participants who fell is depicted per frailty category; Figure 2B shows the 
percentage of participants who were hospitalized. 
 
During the more than three years of follow-up between March 2009 and January 2013 
(average follow-up 805 days, SD 310 days), 118 (4.2%) of the 2831 participants with follow-
up died. 26 (16.0%) among the frail, 63 (4.3%) among the intermediate frail and 29 (2.4%) 
among the non-frail. Survival was significantly worse for frail elderly compared to the other 
two groups (Log rank p<0.001; Figure 3A). The Kaplan-Meier curves stratified by sex suggest 
a different survival pattern for men (immediate decline) compared to women (steady 
progressive decline) (Figure 3B,C).  
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Figure 1: The frailty flower. 
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Figure 2: Falls (A) and hospitalizations (B) in the preceding year according to frailty status. 
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Figure 3: Kaplan-Meier survival curves overall (A), in men (B) and in women (C). 
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When adjusting for age, sex and the comorbidity count in the Cox hazard proportion model, 
frail elderly had a more than threefold increased risk of mortality (HR 3.43, 95% CI 1.85 to 
6.36; p<0.001, Table 3). Importantly, the addition of all enumerated potential confounders 
and the ten diseases of the comorbidity count to the model, did not change the 
independency of the frailty effect on mortality (p=0.002). A trend towards an increased 
mortality risk could be noticed in the (male) pre-frail group (intermediate frail elderly); 
however, this was no longer significant after adjustment (Table 3). The use of age as time 
scale did not substantially influence the frailty point estimate (data not shown). Stratified by 
sex and adjusted for age and comorbidity, frail men had a 4.3 fold increased risk of mortality 
and frail women a 2.5 fold increased risk of mortality (Table 3). However, confidence 
intervals largely overlapped and the interaction term between frailty and sex was non-
significant. 
Table 3: Cox proportional hazard model of frailty on the risk of mortality. 
 Mortality 
Crude model (n=2831) Adjusted model (n=2745) 
HR 
95% CI P-
value 
HR 
95% CI P-
value Lower Upper Lower Upper 
All Non-frail Reference Reference 
 Intermediate frail 1.63 1.05 2.54 0.029 1.31 0.81 2.10 0.267 
Frail 5.77 3.39 9.80 <0.001 3.43 1.85 6.36 <0.001 
Males Non-frail Reference Reference 
Intermediate frail 1.93 1.10 3.37 0.022 1.50 0.81 2.75 0.196 
Frail 7.25 3.49 15.08 <0.001 4.25 1.84 9.78 0.001 
Females Non-frail Reference Reference 
 Intermediate frail 1.44 0.70 2.94 0.318 1.04 0.49 2.22 0.919 
 Frail 6.08 2.76 13.40 <0.001 2.49 1.00 6.22 0.051 
Adjusted model: adjusted for age, sex and comorbidity count. 
Abbreviations: HR = Hazard Ratio; CI = Confidence Interval. 
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DISCUSSION 
Overall, we observed a prevalence of frailty of almost 6 percent within the Rotterdam Study. 
Compared to the non-frail, frail participants were more likely to be older and female. Frail 
elderly people had more falls and hospitalizations in the previous year and had an increased 
risk of mortality independent of age, sex and comorbidity. 
  
Our observed frailty prevalence is in line with the 6.9% prevalence estimate that Fried et al. 
found in the Cardiovascular Health Study.38 In addition, a review by Collard et al. reported an 
overall prevalence of frailty of 9.9% in studies using physical frailty definitions.58 The results 
in our study confirm the consistency of the Fried frailty criteria. In the Cardiovascular Health 
Study, 68.0% of the frail elderly had 2 comorbidities or more and 7.3% had none of 9 co-
morbidities.38 Consistently, we found that 72.0% of the frailty group had two or more, and 
4.7% had none of the co-morbidities, respectively. This indicates that frailty is not identical 
to comorbidity. It is more likely that these entities frequently coexist, and that comorbidity 
only partly explains the presence of frailty.56  
 
Notably, the body mass index did not differ significantly between frailty groups, which is 
similar to previous findings.387, 398 Although frail people in our study had a significantly lower 
weight, they were also significantly shorter. As the BMI is a ratio, both parameters are 
important. Furthermore, not only weight loss, but also ‘sarcopenic obesity’ might be a risk 
factor of frailty.399 Sarcopenia is a syndrome characterized by a progressive and generalized 
loss of skeletal muscle mass and muscle function (strength) with an increased risk of adverse 
health outcomes. ‘Sarcopenic obesity’ is the condition where lean body mass is lost, while 
fat mass may be preserved or even increased.400 Thus not only loss of body weight, through 
loss of muscle tissue, but also intramuscular and visceral fat accumulation, are important for 
developing muscle weakness.400  
Interestingly, in our study we found an increased WBC count and low hemoglobin levels to 
be associated with frailty. Chaves et al. found that the risk of being frail in community-
dwelling older women progressively declined with increasing hemoglobin levels up to what 
is currently considered mid-normal levels (13.5 g/dL).401 In the Women’s Health and aging 
Study, higher WBC counts and IL6 levels were independently associated with prevalent 
frailty.51 Possibly, IL6 contributes to unexplained anemia in elderly people by inhibiting 
erythropoietin production or by interaction with the erythropoietin receptor.47 This supports 
the assumption of an association between frailty and a state of chronic systemic 
inflammation.37 
 
In the Rotterdam Study, frail elderly had an increased risk of death compared to non-frail 
participants, independent of age, sex and co-morbid disease. Fried and others have also 
found an increased risk of mortality in the frail group, although the mean follow-up period in 
these studies ranges from 3 to 9.7 years.38, 42, 387 Puts et al. stated that men appeared to die 
more suddenly, while women had a more steady progressive decline.40 Although our survival 
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pattern for men compared to women seemed to confirm this statement, the mortality 
hazards were not significantly influenced by time in the Cox regression model. In our study, 
the short-term mortality risk was not significantly increased for the intermediate frail group 
independently of age, sex and comorbidity. Fried et al. found that intermediately frail elderly 
were at an increased risk of becoming frail.38 This is in accordance with the concept that the 
frailty syndrome is a dynamic process, where transitions to states of greater frailty are more 
common, than transitions to states of lower frailty.402 Thus, intermediate frailty could be 
considered as a state where the process of decline in multiple physiologic systems has 
already been set in motion, but reserves are still sufficient to withstand most stressors. This 
stage would therefore be suited for secondary prevention, including chronic disease 
management and geriatric assessment, fall prevention, exercise and nutritional 
modifications.388, 403 Frailty, on the other hand, is often considered to be irreversible and 
tends to progress to an end-stage condition.38, 404 This is shown in the study of Gill et al. 
where, over a 54 months period, the probability of transition from being frail to non-frail 
was very low (rates 0% to 0.9%).402 Moreover, in an interventional trial the benefit of the 
intervention (physical training) was observed only among the participants with moderate 
frailty, but not among those with more severe frailty. Note that in this trial moderately frail 
elderly were defined as having only 1 physical criterion, and the severe frail as having 2.405  
 
The strengths of our study are the high quality and detail of medical information, the 
prospective mortality data collection, objective measurement of comorbidities and the 
general population-based setting of the Rotterdam Study. A potential limitation is that 
measurement of walking speed was only recently introduced. Because solely participants 
with at least three concordant positive or negative criteria were included in the study (e.g. 
the result of the missing gait assessment no longer mattered to conclude frailty), it is unlikely 
that this alone has caused misclassification of frail participants within the study. However, 
the percentage of intermediate frail participants within the study might have been 
underestimated. Second, falls and hospitalizations were assessed retrospectively. The recall 
of any fall in the previous year is relatively specific (91–95%) but somewhat less sensitive 
(80–89%) than intensive prospective data collection and individuals with poorer cognitive 
function may be less likely to recall falling (or hospitalization) in the previous 12 months.406  
Thirdly, weight loss was not self-reported but directly measured without asking whether any 
weight loss was intentional. Although we believe that the objective weight measurement is a 
strength, we cannot exclude the possibility that the actual prevalence might be lower due to 
intentional weight loss. In contrast, it is important to note that the true prevalence of frailty 
might be higher than measured if frail people do not feel fit enough to perform physical tests 
or complete questionnaires. The comparison of participants in whom the frailty status could 
be determined with those participants with incomplete information, seemed to point in the 
direction that the more vulnerable people are less able to perform the physical frailty tests.  
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Consequently, the impact of frailty on mortality may be even larger if this phenomenon is 
limited to the most vulnerable frail people. In conclusion, frailty is common in those 
participants of the Rotterdam Study able to perform the frailty tests, and more prevalent in 
females than males. Frail elderly are at an increased risk of dying within three years 
independent of comorbidity. We suggest that clinicians should focus on intermediate frail 
elderly to implement preventive measures.  
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ABSTRACT 
 
Background 
With the longevity of our population, the prevalence of chronic illnesses such as Chronic 
Obstructive Pulmonary Disease (COPD) and geriatric syndromes such as frailty increases. 
 
Objectives 
To investigate whether COPD is an independent risk factor for frailty. 
 
Methods 
This study was part of the Rotterdam Study, a prospective population-based cohort study 
performed in subjects aged ≥ 55 years. Diagnosis of COPD was confirmed by spirometry. 
Frailty was defined as meeting 3 or more of five established criteria for frailty, evaluating 
nutritional status, physical activity, mobility, strength and energy. 
 
Results  
Of the 2142 subjects with frailty and lung function assessments, 100 subjects were frail 
including 41 of the 402 (10.2%) subjects with COPD compared to 59 of the 1740 (3.4%) 
subjects without COPD. The prevalence of frailty was significantly increased in subjects 
with COPD, especially in those with severe airflow limitation, dyspnea and frequent 
exacerbations. Subjects with mild airflow limitation were more frequently pre-frail. 
Independent of age, sex, smoking, cumulative use of systemic corticosteroids and other 
confounders, subjects with COPD had a more than twofold increased prevalence of frailty 
(OR 2.2, 95% CI 1.34-3.54, p=0.002). 
 
Conclusions 
This population-based cohort study in elderly demonstrates that COPD is associated with 
frailty, independent of common risk factors and comorbidities. 
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13. COPD, comorbidities and frailty 
INTRODUCTION  
With the aging of our population and the reduction in early deaths from acute illnesses and 
infections, more people are living longer but frequently suffer from chronic illnesses such as 
Chronic Obstructive Pulmonary Disease (COPD). COPD is characterized by various systemic 
manifestations in addition to the progressive chronic airflow limitation.24 The most prevalent 
known comorbidities are cardiovascular disease, metabolic syndrome, osteoporosis, 
depression, and lung cancer.24 Other systemic manifestations of COPD include skeletal 
muscle wasting, cachexia and normocytic anemia.373, 407 These comorbid conditions have a 
clear impact on the clinical presentation and prognosis of patients with COPD and the 
identification and treatment of comorbid diseases are key elements in COPD management.1 
 
In contrast to organ-specific diagnoses and treatment, frailty points more to a holistic 
viewpoint of the elder patient and their predicament.37 The definition of frailty describes a 
biological syndrome in which a progressive, cumulative decline in the reserve capacity of 
multiple physiological systems elicits an abnormal vulnerability to common stressors.38 
Frailty is a distinct syndrome associated with functional decline, loss of independence, and 
mortality, and is characterized by the disability to compensate function loss.38 Frailty is 
defined as meeting 3 or more of five established criteria for frailty, evaluating nutritional 
status, physical activity, mobility, strength and energy.38 Individuals with one or two criteria 
are defined as intermediate frail or pre-frail and have been found to be at increased risk of 
becoming frail.38 Previously, we have demonstrated that frailty is common in the general 
elderly population.408 Moreover, we demonstrated that frail elderly subjects had more falls 
and hospitalizations and an increased risk of mortality independent of age, sex and 
comorbidity.408 Distinction of frail elderly people from those who are not frail is essential in 
an aging population to better outweigh benefits and risks of invasive procedures or 
potentially harmful medication in vulnerable elderly.37 
 
The demographic change is a great challenge for social welfare systems and healthy aging is 
becoming increasingly important. Both COPD and frailty are prevalent syndromes in the 
elderly, associated with substantial morbidity, disability and mortality. Although smoking 
and aging are the main risk factors for COPD, and have been associated with an increased 
risk of frailty, the link between COPD and frailty remains insufficiently investigated. Frailty 
might identify those COPD subjects at high risk of adverse health events including mortality. 
Moreover, frailty -especially the intermediate stage- might be more reversible than COPD 
itself. Therefore, the identification and risk stratification of frailty in patients with COPD 
might be the first step towards improved COPD management and prolonged healthy aging in 
general.409 Therefore, we have investigated the interrelationship between COPD and frailty 
in a large population-based cohort study. 
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METHODS  
Study population and design 
This study was embedded within the Rotterdam Study, a population-based cohort study in 
the city of Rotterdam aimed at assessing the occurrence of, and risk factors for chronic 
diseases in the elderly.108 The study started in 1990 and all participants are invited every 3 to 
5 years to the research centre for follow-up examinations, including physical examination, 
blood sampling and spirometry. In addition, information is obtained by questionnaires on 
health status, medical history, smoking, socio-economic status, drug use, dietary habits, 
physical activity, exhaustion and respiratory symptoms. The participants are moreover 
continuously monitored for the onset of major events which occur during follow-up. This 
current study was embedded within cohort I and II (RSI and RSII) from the Rotterdam Study. 
The Rotterdam Study was approved by the medical ethics committee of the Erasmus 
Medical Center, Rotterdam, and the review board of The Netherlands Ministry of Health, 
Welfare and Sports. All participants gave written informed consent.  
 
Frailty assessment 
The definition and assessment of frailty within the Rotterdam Study have been extensively 
described.408 In short, frailty was determined using the physical definition of frailty by Fried 
et al. which has been the most widely used and validated instrument in frailty research.38, 57, 
390 Frailty was defined as meeting three or more of the five established frailty criteria 
evaluating nutritional status (weight loss), physical activity (low physical activity), walking 
speed (slow gait velocity), weakness (reduced grip strength), and self-reported exhaustion.38 
First, weakness was defined as having a grip strength for men ≤29 kg (if body mass index 
(BMI)≤24, or ≤30 kg if BMI≤24.1-28, or ≤32 kg if BMI>28) and for women ≤17 kg (if BMI≤23, 
or ≤17.3 kg if BMI≤23.1-26, or ≤18 kg if BMI≤26.1-29, or ≤21 kg if BMI>29).38 Weight loss was 
defined as losing more than 5% body weight compared to the previous examination. 
Exhaustion was defined as answering “frequently” or “mostly” to one of the following two 
statements from the Center for Epidemiological Studies Depression (CES-D) scale: (a) I felt 
that everything I did was an effort; (b) I could not get going.391 Low physical activity was 
defined as expending less than 383 kcal per week for men and less than 270 kcal per week 
for women.38 Finally, slowness was defined as walking at a velocity of less than 0.76 m/s if 
height was more than 173 cm for men or more than 159 cm for women (otherwise less than 
0.65 m/s).38 Only participants who had a sufficient number of criteria to confirm or to 
exclude frailty were included (e.g. at least three concordant positive or negative criteria 
evaluated). Participants with one or two criteria were defined as intermediate or pre-frail.38  
COPD assessment and classification 
COPD cases and controls were nested in all participants of the source population with an 
interpretable lung function measurement at the last research centre visit of whom sufficient 
criteria were examined to confirm or to exclude frailty. The diagnosis of COPD was based on 
a spirometry examination conducted between March 2009 and March 2012. No reversibility 
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tests were conducted. However, asthma patients and participants with a spirometry report 
suggestive of restrictive respiratory disease [FEV1/FVC ≥ 0.7 and forced expiratory vital 
capacity (FVC) and/or FEV1 < 80% predicted] were excluded. Spirometry was performed 
using a Master Screen® PFT Pro (Care Fusion, the Netherlands) by trained paramedical 
personnel according to the ATS/ERS guidelines.22 Spirometry results which did not meet 
ATS/ERS criteria for acceptability and reproducibility were classified as not interpretable. 
COPD was defined by an obstructive spirometry [proportion of the forced vital capacity 
exhaled in the first second (FEV1/FVC) < 0.7] and classified as mild, moderate or severe COPD 
by forced expiratory volume in one second (FEV1)% predicted of ≥ 80%, 50-80% and < 50% 
respectively. 
 
In addition, COPD subjects were classified according to the recent GOLD update (2011) 
which includes the evaluation of symptoms and the history of exacerbations next to the 
severity of airflow limitation. GOLD Group A consists of patients with a low risk and less 
symptoms (i.e. mild or moderate airflow limitation), (n)one exacerbation a year and a 
dyspnea score of 0 or 1. Group B includes patients with a low risk but with more symptoms 
(dyspnea score ≥ 2). Group C gathers patients with high risk (severe or very severe airflow 
limitation and/or ≥ 2 exacerbations a year) but less symptoms. Finally, group D consists of 
patients with a high risk and more symptoms. The dyspnea score was based on the following 
five dyspnea-questions: 1. Are you troubled by shortness of breath when climbing stairs? 
(i.e. at a normal speed) 2. Are you troubled by shortness of breath when walking on level 
ground? 3. Do you have shortness of breath? (i.e. during normal/daily life activities) 4. Are 
you troubled by shortness of breath when lying down, while this improves when you sit up 
or when you sleep on more pillows? 5. Are you short of breath at rest? Based on these five 
dyspnea questions, a dyspnea score was added from 0 (all questions negative, never 
dyspneic) to 5 (all positive, even dyspneic at rest).232  
 
Comorbidity assessment 
Nine comorbidities were chosen and assessed as prescribed previously.(Ref) Hypertension 
was defined as the use of antihypertensive medication during follow-up, and/or a systolic 
brachial blood pressure of ≥160 mmHg, and/or a diastolic brachial blood pressure of ≥100 
mmHg (Grade 2 according to European Society of Cardiology criteria).343 Coronary 
revascularization was defined as coronary artery bypass grafting and percutaneous coronary 
intervention. Myocardial infarction, heart failure, stroke and cancer were clinically validated. 
Diabetes mellitus was defined as the use of blood glucose-lowering medication based on 
automated pharmacy records.393 Osteoporosis was defined using femoral neck bone mineral 
density measured by Dual-energy X-ray absorptiometry applying World Health Organization 
(WHO) criteria.394 Kidney disease was defined according to the National Kidney Foundation 
guidelines as having a glomerular filtration rate (GFR) <60 mL/min/1.73m or as having 
markers of kidney damage (i.e. a urine albumin – creatinine ratio greater than 17 mg/g in 
men and greater than 25 mg/g in women) 395. The GFR was calculated using the Modification 
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of Diet in renal Disease Study Equation of Levy et al.396 Anemia was defined according to the 
WHO guidelines <120 g/L for women and <130 g/L for men.397 The comorbidity count which 
distinguishes between none, one and two or more comorbidities, was calculated for all 
participants of whom we had complete information on all nine diseases. Blood samples for 
determination of levels of serum glucose, creatinin, hemoglobin (Hb), cholesterol, and white 
blood cell (WBC) count were obtained at the research center. Medication use was assessed 
through automated linkage with the serving pharmacies of filled prescriptions. 
Statistical analyses 
Differences between subjects with and without COPD were studied using Mann-Whitney U 
test for continuous variables and Chi-Square test for categorical variables. Logistic regression 
models were performed to assess the effect of COPD on frailty. Following variables were 
considered as potential confounders: age, sex, body mass index, smoking status, pack-years, 
and the comorbidity count. All models were adjusted for covariates that changed the point 
estimate by more than 5%. Finally, a stepwise regression with backward elimination 
(probability for stepwise entry was 0.05 and for removal 0.10) was performed including all 
comorbidities, lab values and medication use. All statistical analyses were performed using 
SPSS, version 20.0 for Windows (IBM, North Castle, NY). P-values below the conventional 
level of significance (p< 0.05) were considered as statistically significant.  
 
RESULTS  
Study flow and baseline characteristics of the study population 
Of the 2833 subjects with frailty assessment, 2489 had performed an interpretable lung 
function test.(Figure 1) After the exclusion of 229 subjects with asthma and 118 subjects 
with a spirometry suggestive for a restrictive syndrome, 2142 subjects were included in the 
analyses. 100 subjects were frail defined as having three or more of the following 
characteristics: weak grip strength, weight loss, exhaustion, physical inactivity or slow 
walking time. 1074 subjects were intermediate or pre-frail defined as having one or two 
frailty characteristics. 968 subjects were non-frail defined as having none of the frailty 
characteristics. COPD subjects were significantly older, more frequently male and (current) 
smokers, had smoked more pack-years and had a slightly lower BMI than participants 
without COPD.(Table 1) Subjects with COPD had higher white blood cell counts, whereas 
they had lower serum levels of cholesterol compared to subjects without COPD. Regarding 
comorbidities, subjects with COPD had more prevalent coronary disease, heart failure, 
stroke, osteoporosis and kidney disease. 
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2833 subjects with assessment of frailty
2489 subjects with interpretable spirometry
2142 subjects with frailty assessment & spirometry
402 subjects with obstructive lung function (=COPD)
1740 subjects with normal lung function (=no COPD)
100  frail subjects
41  COPD (10.2%)
59  no COPD (3.4%)
1074  intermediate frail  
subjects 
206  COPD (51.2%)
868  no COPD (49.9%)
968  non-frail subjects
155  COPD (38.6%)
813  no COPD (46.7%)
118 subjects excluded with a 
spirometry suggestive 
for a restrictive syndrome 
and 229 subjects with asthma
  
  
 
 
 
 
 
 
  
 
 
   
Figure 1: Study profile. 
  
134 
 
Table 1: Baseline characteristics. 
 COPD (n=402) No COPD (n=1740) P-value 
Age (years) 75 (9) 74 (8) <0.001 
Female 173 (43.0%) 990 (56.9%) <0.001 
BMI 26.0 (4.6) 27.0 (4.8) <0.001 
Pack years 22.0 (37.5) 3.0 (19.5) <0.001 
Smoking status    
 Never 62 (15.4%) 646 (37.1%)  
 Former 259 (64.4%) 985 (56.6%)  
 Current 81 (20.1%) 109 (6.3%) <0.001 
FEV1% predicted 79.6  (25.2) 89.4 (29.3) <0.001 
FEV1/FVC 65.6 (7.8) 76.1 (8.1) <0.001 
Lab results    
  Hemoglobin (mmol/l) 8.8 (1.1) 8.7 (1.0) 0.010 
  WBC (count/mm3) 7,100 (2,300) 6,600 (1,900) <0.001 
  Cholesterol (mmol/l) 5.2 (1.4) 5.4 (1.5) <0.001 
  Glucose (mmol/l) 5.5 (0.9) 5.5 (0.9) 0.172 
  Creatinin  (µmol/l) 81 (26.0) 78 (23.0) 0.019 
Comorbidity    
  Coronary disease 25 (6.2%) 56 (3.2%) 0.005 
  Heart failure 21 (5.2%) 37 (2.1%) 0.001 
  Hypertension 306 (76.1%) 1274 (73.2%) 0.233 
  Stroke 30 (7.5%) 74 (4.3%) 0.007 
  Diabetes 25 (6.2%) 122 (7.0%) 0.571 
  Osteoporosis 61 (15.2%) 190 (10.9%) 0.017 
  Cancer 58 (14.4%) 242 (13.9%) 0.787 
  Anemia 34 (8.5%) 109 (6.4%) 0.117 
  Kidney disease 137 (34.3%) 469 (27.1%) 0.004 
Comorbidity count    
  0 46 (11.6%) 264 (15.5%)  
  1 138 (34.8%) 704 (41.3%)   
  ≥2 213 (53.7%) 736 (43.2%)       0.001 
Categorical variables are expressed as numbers (percentages). Values of continuous variables are expressed as 
median (interquartile range (IQR)). Comorbidity count determined in participants without missing 
comorbidities (n=2101; coronary disease was missing in 4 participants, heart failure in 11, anemia in 28 and 
kidney disease in 12 participants). 
Abbreviations: BMI = Body Mass Index, WBC = White Blood Cells, COPD = Chronic Obstructive Pulmonary 
Disease 
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COPD and frailty 
Of the 2142 subjects included in the analyses, 402 subjects had an obstructive lung function 
and were categorized according to the modified Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) classification of airflow limitation into 200 (49.8%) mild, 174 (43.3%) 
moderate and 28 (7.0%) severe COPD.24 100 subjects were frail including 41 of the 402 
(10.2%) subjects with COPD compared to 59 of the 1740 (3.4%) subjects without COPD. 
Figure 2 represents the prevalence of frailty according to the COPD status and severity of 
airflow limitation. The prevalence of frailty shows to be highly associated with the severity of 
COPD according to the degree of airflow limitation (GOLD 2007). The prevalence of 
intermediate frailty was inversely associated with the severity of airflow limitation, while the 
prevalence of subjects without any of the frailty criteria did not change substantially over 
the COPD stages. 
 
   
Figure 2: Prevalence of frailty according to severity of airflow limitation.  
Abbreviations: CI = Confidence Interval, COPD = Chronic Obstructive Pulmonary Disease. 
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Table 2: COPD and the risk of frailty. 
 
 
Model 1 (n=2142) Model 2 (n=2098) 
OR 95% CI P-value OR 95% CI P-value 
COPD (n=402) 3.1 2.01-4.83 <0.001 2.4 1.52-3.86 <0.001 
COPD, mild (n=200) 1.6 0.78-3.09 0.209 1.4 0.70-2.84 0.333 
COPD, moderate (n=174) 4.0 2.28-6.86 <0.001 2.9 1.57-5.21 0.001 
COPD, severe (n=28) 14.1 5.56-35.77 <0.001 10.0 3.84-26.30 <0.001 
COPD, exacerbations <2 (n=375) 3.0 1.90-4.69 <0.001 2.3 1.41-3.71 0.001 
COPD, exacerbations ≥2 (n=27) 5.1 1.62-16.23 0.005 4.4 1.41-14.04 0.011 
COPD, group A (n=199) 1.8 0.91-3.47 0.090 1.5 0.74-3.00 0.264 
COPD, group B (n=152) 3.9 2.20-6.86 <0.001 2.9 1.58-5.34 0.001 
COPD, group C (n=17) 1.6 0.19-12.95 0.668 1.4 0.17-11.20 0.767 
COPD, group D (n=32) 11.1 4.54-27.29 <0.001 8.3 3.25-20.96 <0.001 
Model 1: age and sex adjusted. 
Model 2: adjusted for age, sex, pack years and comorbidity count. 
COPD was defined as FEV1/FVC < 70% and categorized according to the modified Global Initiative for Chronic 
Obstructive Lung Disease (GOLD) classification of airflow limitation 200724 into mild COPD (GOLD1; 
FEV1≥80%pred), moderate COPD (GOLD2; 50%≤FEV1<80%pred) & severe COPD (GOLD3; FEV1<50%pred) and 
according to the updated GOLD group categorization 20131 A (low risk, less symptoms), B (low risk, more 
symptoms), C (high risk, less symptoms) and D (high risk, more symptoms). 
Abbreviations: OR= Odds Ratio; CI= Confidence Interval; COPD= Chronic Obstructive Pulmonary Disease 
 
 
Table 2 demonstrates that the prevalence of frailty was significantly increased in subjects 
with COPD, even after adjustment for age, sex, pack years of smoking and the comorbidity 
count (OR 2.4, 95%CI 1.52-3.86, p<0.001). When classified according to severity of airflow 
limitation, severe COPD subjects had a tenfold increased risk of frailty compared to subjects 
with a normal lung function. Subjects with mild COPD were not significantly more frequently 
frail. However, they were more frequently pre-frail, defined as having one or two frailty 
characteristics (p=0.048, adjusted for age and sex). Since exacerbations and respiratory 
symptoms contribute to the morbidity and mortality in COPD, we categorized subjects with 
COPD according to the updated GOLD group categorization into 199 (49.8%) group A, 152 
(38.0%) group B, 17 (4.3%) group C and 32 (8.0%) group D (GOLD 2011).1 When classified 
according to the updated GOLD group categorization, the odds ratio for frailty was highest in 
COPD subjects belonging to GOLD group D. The frailty prevalence was not significantly 
higher for subjects belonging to GOLD group A and C, compared to subjects without COPD. 
Finally, frequent COPD exacerbators showed a 4.4 fold increased risk to be frail compared to 
subjects without COPD (OR 4.4, 95%CI 1.41-14.04, p<0.011; Table 2). 
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COPD, comorbidities, drug-use and frailty 
We performed a stepwise regression analysis with backward elimination including age, sex, 
smoking status, pack years of cigarette smoking, BMI, COPD, current use of diuretics, beta-
blockers, calcium channel blockers, drugs acting on the renin-angiotensin system, drugs for 
obstructive airway diseases and current and cumulative use of oral corticosteroids, and all 
lab values and individual comorbidities of Table 1. This resulted in a final model which is 
represented in Table 3. Importantly, COPD remained significantly associated with frailty, 
independent of age, sex, smoking pack years, cholesterol and hematocrit levels, stroke, 
osteoporosis, current beta-blocker and calcium channel blocker use, and cumulative use of 
corticosteroids (OR 2.2, 95% CI 1.34-3.54, p=0.002, Table 3). 
 
Table 3: Final step of a backward regression model determining the most informative factors 
for frailty. 
 OR 95% CI P-value 
COPD 2.2 1.34-3.54 0.002 
Age 1.9 1.14-3.21 0.014 
Female sex 1.1 1.11-1.19 <0.001 
Cholesterol (mmol/l) 0.7 0.59-0.93 0.011 
Hemoglobin (mmol/l) 0.7 0.52-0.96 0.025 
Pack years 1.0 1.00-1.02 0.011 
Stroke 3.0 1.54-5.94 0.001 
Osteoporosis 1.9 1.10-3.22 0.021 
Beta-blockers  0.5 0.28-0.84 0.010 
Calcium channel blockers 1.9 1.02-3.53 0.044 
Cumulative oral corticosteroids 1.0 1.01-1.06 0.008 
Final step of a stepwise regression with backward elimination including age, sex, smoking status, pack years 
of cigarette smoking, body mass index, COPD, current use of diuretics, beta-blockers, calcium channel 
blockers, drugs acting on the renin-angiotensin system, drugs for obstructive airway diseases and current and 
cumulative use of oral corticosteroids, hemoglobin (mmol/l), white blood cell count (count/mm3), cholesterol 
(mmol/l), glucose (mmol/l), creatinin (µmol/l), coronary disease, heart failure, hypertension, stroke, diabetes, 
osteoporosis, cancer, anemia and kidney disease. 
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DISCUSSION 
This is the first general population study showing that subjects with COPD have a more than 
twofold increased risk to develop frailty, independent of age, sex, smoking, systemic 
corticosteroid use and comorbidities. We demonstrated that the association was stronger in 
COPD subjects with severe airflow limitation and moreover with frequent exacerbations and 
more symptoms (GOLD group D). The results further suggest that with increasing COPD 
severity of airflow limitation more intermediate frail elderly become frail, while the 
prevalence of subjects without any of the frailty criteria does not change substantially. 
 
Our results demonstrating that COPD is independently associated with frailty are in line with 
previous suggestions of an association between frailty and respiratory impairment.410, 411 Vaz 
Fragoso et al. have demonstrated that airflow limitation is associated with frailty, 
independent of age, gender, smoking history, height, BMI, health status and several chronic 
conditions.411 In this cross-sectional and longitudinal cohort study, the researchers stated 
that the association between airflow limitation and frailty is likely due to COPD although 
subjects suggestive of a restrictive syndrome were also included. In addition, this study did 
not take into account corticosteroid use which has been associated with significant 
morbidity, including osteoporosis, falls, fractures, hyperglycemia, hypertension and muscle 
wasting, and mortality.412-414 These side effects of systemic corticosteroids are all clinical 
characteristics related to frailty. Our study is the first to demonstrate that the use of 
corticosteroids, frequently prescribed in COPD, does not explain the association of COPD and 
frailty. Park et al. also have argued that frailty is prevalent in people with COPD.410 In line 
with our results, those COPD subjects with shortness of breath were more likely to be frail. 
However, unlike the assessment of physical frailty criteria in our study, the used frailty index 
was primarily based on survey responses.410 Furthermore, in this study an odds ratio of 
COPD and frailty has not been estimated. In our study, not only we have demonstrated a 
significant association of frailty and COPD, we also have shown that this association was 
stronger with increasing COPD severity. The percentage of prevalent frailty increased from 
mild, over moderate to severe COPD. However, the percentage of non-frail subjects did not 
differ significantly over the different groups. Therefore, it seems that intermediate frailty 
converts into frailty with increasing COPD severity. Fried et al. have found that intermediate 
frail elderly are at an increased risk of becoming frail.38 Possibly, COPD places intermediate 
frail elderly at an even more increased risk of frailty. This could result in an aggravation of 
intermediate frailty towards frailty with increasing COPD severity. Elderly people without any 
of the frailty characteristics might be less susceptible to the negative impact of increasing 
COPD severity, because of sufficient physiologic reserves and thus a preserved resilience.37 
 
The regulatory pathway responsible for the association between COPD and frailty has not 
yet been elucidated, but might involve impaired innate immune defenses.13 Both frailty and 
COPD are furthermore associated with systemic inflammation as evidenced by increased 
levels of inflammatory markers, such as white blood cell (WBC) count, high-sensitivity C-
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reactive protein (hsCRP), interleukin 6 (IL6) and tumor necrosis factor-α (TNF-α).34, 37, 45-51, 415 
IL6 in particular has been associated with anemia, decreased lean body mass and sarcopenia 
and is inversely correlated with circulating hormones like insulin-like growth factor-1 (IGF-I) 
and dehydroepiandrosterone sulfate (DHEA-S) in frail elderly.47, 52, 53 Possibly, the subset of 
elderly subjects with COPD that have a persistent inflammation are particularly prone to 
develop frailty.34  
 
The strengths of this study are the high quality and detail of medical information, the 
objective measurement of comorbidities and frailty, the general population based setting 
and the large number of elderly subjects that participated in the Rotterdam Study. Possible 
limitations include the cross-sectional design implying that we cannot infer causal 
mechanisms between COPD and frailty. However, the association is biologically plausible and 
the risk of frailty increased according to the severity of COPD. The identification of frail COPD 
patients could be of importance to identify those COPD subjects at high risk of mortality. 
Especially in COPD subjects with mild airflow limitation, preventive measures might be 
required to prohibit them of becoming frail, a state wherein adverse health events are 
inevitable. 
 
In conclusion, our results suggest that COPD is associated with frailty independent of age, 
sex, smoking and comorbidities. Potentially, a more holistic approach is required to improve 
life of patients with COPD. 
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 ABSTRACT 
 
Background 
Gait disturbances are a potential systemic manifestation of chronic obstructive 
pulmonary disease (COPD), which may lead to disability and falls in patients with COPD. 
Although walking endurance tests are extensively performed in patients with COPD, 
studies assessing the gait pattern including gait kinematics, are sparse. 
 
Objectives 
To investigate associations of COPD and lung function parameters with various gait 
domains and to explore a potential link with falling. 
 
Methods 
Cross-sectional analysis within the Rotterdam Study, a prospective population-based 
cohort study in persons aged ≥ 55 years. Spirometry was used to assess lung function and 
confirm the diagnosis of COPD. Gait was measured using an electronic walkway and 
summarized into seven gait domains: Rhythm, Phases, Pace, Base of Support, Tandem, 
Turning, and Variability. 
 
Results  
Persons with COPD (n = 196) exhibited worse Rhythm (z-score -0.21, 95%CI: -0.36; -0.06) 
compared to persons with normal lung function (n = 898) independent of age, sex, 
height, primary education, smoking and use of analgesics. This effect was most 
pronounced in COPD persons with dyspnea and severe airflow limitation or frequent 
exacerbations (GOLD D, -0.83 SD, 95%CI: -1.25; -0.41). Similarly, all lung function 
measurements except FVC associated with Rhythm. Additionally, FEV1 associated with 
Pace, FVC with Pace and Phases, FEV1/FVC with Phases, and DLCOc with Pace and 
Turning. Fallers with COPD had significantly worse Rhythm compared to non-fallers with 
COPD, fallers without COPD, and non-fallers without COPD. 
 
Conclusions 
This study demonstrates that people with COPD have worse Rhythm, especially fallers 
with COPD. Additionally, impaired lung function parameters and frequent exacerbations 
associated with worse gait. These results suggest that COPD may affect gait quality in 
addition to walking endurance. 
 
 
 
 
 
 
 
 
 
 
 
 
  
Part IV: COPD and frailty 141 
14. Gait patterns in COPD 
INTRODUCTION  
Worldwide, COPD is a leading cause of morbidity and mortality.1 COPD is primarily 
characterized by persistent airflow limitation that is associated with an abnormal 
inflammatory response of the lungs to noxious particles or gases.13 However, its systemic 
effects also have an important impact on symptoms and prognosis.1 Even in COPD patients 
with mild disease severity, cardiovascular comorbidities and muscle weakness precede the 
development of functional limitations.178 Since COPD also affects function and mobility, 
persons with COPD have an increased risk of falling.177, 178, 359, 416-418 Falling is a major health 
concern, representing one of the main causes of pain, disability and death in the elderly.417, 
419 Even without injuries, a fall can negatively impact the quality of life of an individual 
through fear of falling, which often inhibits performing activities.420   
 
Poor gait is one of the main risk factors of falls and an important indicator of general 
health.421-423 Gait is affected by various organ systems, such as the central nervous system, 
cardiovascular system, and musculoskeletal system, and poor gait is a strong risk factor of 
death.424-428 COPD may affect gait through any of these systems by inducing hypoxia or 
systemic inflammation. 
 
Gait is a complex concept that can be assessed using many parameters, which can be 
summarized into seven gait domains.427 As of yet, COPD has mostly been associated with a 
shorter walking distance. Associations of COPD and lung function parameters with specific 
gait domains may give an indication of the pathways underlying their associations with gait. 
In turn, this knowledge may aid in identifying better intervention strategies to prevent future 
falling in patients with COPD.  
 
The aim of this study was to investigate the associations of COPD and lung function 
parameters with various gait domains, in a community-dwelling population. Moreover, we 
evaluated the influence of COPD severity by airflow limitation, symptoms and/or frequent 
exacerbations. Additionally, we explored a potential link between gait differences in COPD 
and falling. 
 
METHODS  
Study design  
The present study is embedded within the Rotterdam Study (RS), a population based cohort 
study aimed at assessing the occurrence and risk factors of chronic diseases in the elderly.108 
The study was initiated in 1990 (RS-I), when all inhabitants aged ≥55 of the suburb 
Ommoord, in Rotterdam, were invited to participate. This study was extended in 2000 (RS-II) 
and another time in 2006 (RS-III), this last time inviting all inhabitants aged ≥45. At baseline 
and every 3 to 4 years of follow-up participants undergo a home interview and medical 
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examinations at the research centre, including spirometry. From March 2009 onwards, gait 
assessment has been implemented in the core protocol.108 The home interview included 
standardized questionnaires on smoking including cumulative smoking history and history of 
falls in the past 12 months. The present study comprises all participants from the first two 
cohorts (RS-I and RS-II) who completed gait assessment and spirometry successfully until 
December 2011. The Rotterdam Study has been approved by the medical ethics committee 
according to the Population Study Act Rotterdam Study, executed by the Ministry of Health, 
Welfare and Sports of the Netherlands. A written informed consent was obtained from all 
participants.  
 
Assessment of lung function parameters and COPD 
Spirometry and diffusing capacity were performed using a Master Screen® PFT Pro 
(CareFusion, San Diego, CA) by trained paramedical personnel according to the ATS/ERS 
guidelines.22, 23 The diagnosis of COPD was based on an obstructive spirometry examination 
according to the modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) 
criteria [proportion of the forced vital capacity exhaled in the first second (FEV1/FVC) < 70%] 
and classified into mild and moderate/severe airflow limitation by forced expiratory volume 
in one second (FEV1)% predicted of ≥ 80%, <80% respectively.24, 232 Furthermore, 
participants with COPD were also classified according to the updated GOLD group 
categorization into group A (low risk, less symptoms), B (low risk, more symptoms), C (high 
risk, less symptoms) and D (high risk, more symptoms).1 Exacerbations were counted as the 
total number of moderate and severe exacerbations in the year 2010. Frequent exacerbators 
were defined as COPD persons having at least two moderate or severe exacerbations. 
 
Assessment of gait 
Gait was assessed with a 5.79 m long electronic walkway with 1.27 cm wide pressure sensors 
(4.88 m active area; GAITRite Platinum; CIR systems Inc., Sparta, New Jersey USA).427 The 
walkway checked for activation of the pressure sensors at 120Hz. The standardized gait 
protocol includes three different walking conditions (Figure 1): normal walk, turn and 
tandem walk. In normal walk, participants were asked to walk at their usual pace across the 
walkway, until they were of the walkway. The normal walk was performed four times in both 
directions (eight recordings). In turn, participants were asked to walk at their usual pace 
across the walkway, turn halfway and return to their starting position (one recording). In 
tandem walk, participants were asked to walk tandem (heel-to-toe) over a line visible on the 
walkway until they were off the walkway (one recording). The first recording of the normal 
walks was considered a practice walk and not included in the analyses. 
All gait parameters from the normal walk were automatically quantified by the walkway 
software. Parameters were quantified for both steps and strides, e.g. step length is the 
distance between two opposite feet on the line of progression, while stride length is the 
distance between two feet of the same side on the line of progression. Variability measures 
were quantified as standard deviations of the gait parameters among steps or strides. 
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Turning time was calculated from the walkway generated data as the time between foot off 
of the first foot and first contact of the last foot (Figure 1). Turning step count was calculated 
as the automatically quantified number of steps in the turn minus one. Errors in tandem 
walking were calculated as the distance of sidesteps from the line and the surface of these 
sidesteps, with aid of the automatically generated surface and distance parameters from the 
walkway software. Additionally, we scored the number of double steps, i.e. two consecutive 
steps with the same foot on the line, as errors in tandem walking. 
As previously described, principal components analysis was used to summarize 30 gait 
parameters, including 25 from normal walking, 2 from turn and 3 from tandem walking, into 
fewer independent gait domains, while capturing the largest amount of variance. Each gait 
domain had to explain at least as much variance as a single gait parameter. Varimax rotation 
was used to ensure that the gait domains were mutually independent. We found seven 
independent gait domain: Rhythm, Variability, Phases, Pace, Tandem, Turning and Base of 
Support.427 Among others, Rhythm reflects cadence and stride time; Variability reflects stride 
length and time variability; Phases reflects double support time and double support as a 
percentage of the gait cycle; Pace reflects stride length and velocity; Tandem reflects errors 
in tandem walking; Turning reflects the number of turning steps and turning time; and Base 
of Support reflects stride width and its variability. Finally, Global Gait was calculated by 
summing all gait domains, dividing by the number of gait domains, and subsequently 
calculating a new z score.425 To facilitate interpretation of our findings, we additionally 
included the two most commonly assessed gait parameters, velocity and cadence, and the 
highest constituting gait parameters of the three domains strongest associated with COPD 
and lung function: single support time for Rhythm, stride length for Pace, and single support 
percentage for Phases. Single support time reflects the absolute time (in seconds) that a 
person supports on one leg during one stride, while single support percentage reflects the 
relative time (in %) that a person supports on one leg during one stride. For interpretation, 
lower velocity, cadence, stride length and single support percentage is considered worse 
gait, while lower single support time is considered better. 
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Figure 1: The three walking conditions, including the five gait domains of normal walking. 
The gait domains of normal walking are visualized using constituting gait parameters, which 
are mentioned in parenthesis. For turn, only the feet used in the calculation of turning time 
and turning step count are numbered. Turning time was calculated as the time between foot 
off of foot 1 until first contact of foot 7. Turning step count was calculated as the number of 
steps in the turn minus one. In this figure, turning step count would be five. 
 
Statistical analyses  
Differences between persons with and without COPD were studied using Mann-Whitney U 
test for continuous variables and Chi-Square test for categorical variables. Univariate 
ANCOVAs and linear regression analyses were used to investigate associations of COPD and 
lung function respectively, with the gait domains. Age, sex, height, weight, primary 
education, MMSE, pack years and use of analgesics (N02) within 90 days preceding gait 
assessment were considered as potential confounders and models were adjusted for those 
showing trends of an association with both COPD and gait (p<0.10). Models including 
tandem walk were additionally adjusted for step count and mean step length. We repeated 
these analyses to investigate associations of lung function and COPD with velocity, cadence, 
stride length, single support time and single support percentage. For gait domains that 
associated with COPD, we further investigated an association with falls by univariate 
ANCOVAs. Since cognition has been shown to be very strongly associated with gait, we 
performed a sensitivity analysis repeating all analyses additionally adjusted for MMSE. In this 
way we could whether any of our associations were the result of residual confounding by 
cognition. Statistical analyses were performed using SPSS, version 20.0 for Windows (IBM, 
North Castle, NY).  
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RESULTS  
Between March 2009 and December 2011, 1791 participants were invited for gait 
assessment. Of these, 199 participants did not perform all walking conditions for the 
following reasons: 152 for physical inability, 36 for technical reasons, and 11 for refusal. Of 
remaining 1592 participants, 182 had to be excluded for technical reasons, 26 for completing 
less than 16 steps in the normal walks, lowering validity of the measurements429, 7 for not 
following instructions, and 2 for using walking aids. Of the 1375 participants with complete 
and valid gait data, 1247 had interpretable spirometry data available. Of these, participants 
with a restrictive spirometry (n=46) or asthma (n=107) were excluded. Baseline 
characteristics of the study population (n=1094) are presented in Table 1. Among 
participants, 196 (17.9%) persons had COPD (96 mild COPD and 100 moderate to severe 
COPD). COPD persons were slightly older, less often female, smoke(d) more frequently and 
presented with worse lung function parameters. 
We found COPD to associate with lower Rhythm (-0.21 SD [95%CI: -0.36; -0.06], Table 2) 
independent of age, sex, height, primary education, pack-years of cigarette smoking and use 
of analgesics. Regarding the lung function parameters, higher FEV1 associated significantly 
with higher Global Gait, Rhythm and Pace; higher FEV1/FVC with higher Rhythm but lower 
Phases.(Table 2) Additionally, higher FVC associated significantly with higher Global Gait, 
Phases and Pace; higher diffusing capacity DLCO,c with higher Global Gait, Rhythm and Pace 
but lower Turning; and higher DLCO,c/Va with higher Rhythm.(Table 2) 
Regarding the influence of disease severity, COPD persons with moderate/severe airflow 
limitation significantly related to lower Rhythm compared to persons without COPD.(Table 
3) Both COPD with and without frequent exacerbations associated with lower Rhythm, with 
the effect size for COPD with frequent exacerbations being four times larger than for COPD 
without frequent exacerbations (-0.65 SD [95%CI: -1.04; -0.27] compared to -0.16 SD [95%CI: 
-0.31; 0.00] respectively, Table 3).  
Figure 2 represents the gradual decrease of the age and sex-adjusted Z-scores of walking 
Rhythm over the GOLD 2011 categories. GOLD group C and D were significantly related to 
lower Rhythm and GOLD group D related moreover to lower Global Gait score and Pace 
compared to persons without COPD.(Table 3) In contrast, GOLD group A associated with 
higher Global Gait and Pace.  
234 (21.4%) participants reported that they had fallen in the past 12 months, including 195 
(21.7%) subjects without COPD versus 39 (19.9%) subjects with COPD (pdifference=0.564). 
Figure 3 shows Rhythm to be lowest in COPD persons who fell in the previous year. Fallers 
with COPD had significantly lower Rhythm than fallers without COPD (p=0.004), non-fallers 
with COPD (p=0.022), and non-fallers without COPD (p<0.001), after adjustment for age and 
sex. These differences remained significant after additional adjustment for height, primary 
education, pack-years of cigarette smoking and use of analgesics. 
We found a very similar pattern of associations for the original gait parameters as for the 
gait domains. COPD was associated with a lower cadence and longer single support time. 
GOLD group A associated with higher velocity, stride length and single support percentage. 
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GOLD groups C and D associated with lower cadence and longer single support time and 
group D additionally with lower velocity. With regard to lung functions, we found higher 
FEV1 to associate with higher velocity and cadence, shorter single support time and larger 
stride length; higher FEV1/FVC to associate with shorter single support time but also shorter 
single support percentage; higher DLCO,c with higher velocity and cadence, shorter single 
support time and larger stride length; and higher DLCO,c/Va to associate with higher cadence 
and shorter single support time. When additionally adjusting for MMSE, our associations 
hardly changed. Only the association of COPD without frequent exacerbations became 
borderline non-significant (p=0.055). 
 
Table 1: Baseline characteristics of the study population. 
Characteristic No COPD (n = 898) COPD (n = 196) p-valuea 
 Age [years] 74.2 (5.2) 75.5 (5.5) 0.003 
 Sex [females] 483 (53.8) 76 (38.8) <0.001 
 Height [cm] 167.3 (8.9) 170.5 (8.9) <0.001 
 Weight [kg] 76.2 (12.7) 80.8 (18.7) 0.877 
 Body Mass Index [kg/m²] 27.2 (3.7) 26.6 (3.7) 0.049 
 Primary education [n] 89 (10.1%) 33 (17.1%) 0.013 
 MMSE-score [points] 27.9 (1.8) 27.8 (1.9) 0.957 
 Past smoker [n] 508 (56.6%) 125 (63.8%) <0.001 
 Current smoker [n] 67 (7.5%) 35 (17.9%) <0.001 
 Pack-years [pack-years] 12.6 (18.3) 25.2 (25.9) <0.001 
 Analgesics [n] 37 (4.1%) 14 (7.1%) 0.051 
 Velocity [cm/s] 118.2 (18.3) 115.1 (19.1) 0.122 
 FEV1 [%] 110.9 (16.3) 80.8 (18.7) <0.001 
 FVC [%] 111.9 (16.7) 99.2 (20.9) <0.001 
 FEV1/FVC [%] 78.6 (4.7) 63.4 (6.0) <0.001 
 DL CO,c [%]b 97.5 (15.3) 89.1 (18.5) <0.001 
 DL CO,c /Va [%]b 111.6 (17.2) 105.3 (21.1) <0.001 
Categorical variables are expressed as numbers (percentage). Values of continuous variables are expressed as 
mean (standard deviation). a p-values for differences between participants with COPD and without COPD, 
adjusted for age and sex (if applicable). b Total n = 942. 
Abbreviations: COPD=Chronic Obstructive Pulmonary Disease; DLCO,c = diffusing capacity of the lungs measured 
using carbon monoxide and corrected for the hemoglobin concentration, FEV1= forced expiratory volume in 
one second, FEV1/FVC= proportion of the forced vital capacity exhaled in the first second, MMSE = mini–mental 
state examination, Va= alveolar volume. 
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Table 2: Associations between COPD, lung function and the gait domains, adjusted for 
potential confounders. 
 COPD FEV1 (/10%) FEV1/FVC (/10%) 
Global gait 0.02 (-0.14; 0.17) 0.05 (0.03; 0.08) -0.01 (-0.09; 0.07) 
Rhythm -0.21 (-0.36; -0.06) 0.04 (0.01; 0.07) 0.11 (0.04; 0.19) 
Variability 0.11 (-0.05; 0.27) 0.00 (-0.03; 0.03) -0.04 (-0.13; 0.04) 
Phases 0.12 (-0.03; 0.28) 0.01 (-0.02; 0.04) -0.10 (-0.18; -0.02) 
Pace -0.05 (-0.19; 0.08) 0.06 (0.04; 0.09) 0.02 (-0.04; 0.09) 
Tandema 0.00 (-0.16; 0.15) 0.03 (0.00; 0.06) 0.05 (-0.03; 0.13) 
Turning 0.03 (-0.13; 0.20) 0.00 (-0.03; 0.03) -0.01 (-0.10; 0.07) 
Base of Support 0.04 (-0.12; 0.20) -0.01 (-0.04; 0.03) -0.05 (-0.13; 0.04) 
 FVC (/10%) DL CO,c (/10%) DL CO,c /Va (/10%) 
Global gait 0.08 (0.04; 0.11) 0.05 (0.01; 0.08) 0.02 (-0.02; 0.05) 
Rhythm 0.03 (-0.01; 0.06) 0.06 (0.03; 0.10) 0.06 (0.03; 0.10) 
Variability 0.01 (-0.02; 0.05) 0.01 (-0.03; 0.05) 0.02 (-0.02; 0.05) 
Phases 0.04 (0.00; 0.07) 0.00 (-0.04; 0.04) -0.03 (-0.07; 0.00) 
Pace 0.08 (0.05; 0.11) 0.07 (0.03; 0.10) 0.03 (0.00; 0.06) 
Tandema 0.03 (-0.01; 0.06) 0.00 (-0.04; 0.04) -0.01 (-0.04; 0.03) 
Turning 0.01 (-0.03; 0.05) -0.05 (-0.09; -0.01) -0.03 (-0.07; 0.00) 
Base of Support 0.00 (-0.03; 0.04) 0.02 (-0.02; 0.06) 0.01 (-0.03; 0.05) 
Values represent differences in z-scores of gait (95% Confidence Interval). Values in bold survived thresholds of 
nominal significance (p < 0.05). A lower value of gait represents worse gait. All analyses were adjusted for age, 
sex, height, primary education, pack-years and use of analgesics. 
a Additionally adjusted for the step count and step size within the tandem walk. 
Abbreviations: COPD= Chronic Obstructive Pulmonary Disease; FEV1= forced expiratory volume in one second; 
FEV1/FVC = proportion of the forced vital capacity (FVC) exhaled in the first second; DLCO,c = diffusing capacity of 
the lungs measured using carbon monoxide and corrected for the hemoglobin concentration, Va= alveolar 
volume. 
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Table 3: Stratified analyses of the associations between COPD and the gait domains, 
adjusted for potential confounders. 
 
 Mild COPD Moderate/severe 
COPD 
Infrequent 
exacerbator 
Frequent 
exacerbator 
Global gait 0.14 (-0.06; 0.34) -0.11 (-0.32; 0.09) 0.05 (-0.11; 0.21) -0.23 (-0.63; 0.17) 
Rhythm -0.16 (-0.35; 0.04) -0.27 (-0.46; -0.07) -0.16 (-0.31; 0.00) -0.65 (-1.04; -0.27) 
Variability 0.06 (-0.15; 0.27) 0.17 (-0.04; 0.39) 0.09 (-0.07; 0.26) 0.26 (-0.16; 0.68) 
Phases 0.06 (-0.14; 0.27) 0.18 (-0.03; 0.39) 0.12 (-0.04; 0.28) 0.13 (-0.28; 0.54) 
Pace 0.06 (-0.11; 0.23) -0.17 (-0.35; 0.00) -0.03 (-0.16; 0.11) -0.30 (-0.65; 0.05) 
Tandema 0.16 (-0.04; 0.37) -0.18 (-0.39; 0.03) -0.02 (-0.18; 0.15) 0.10 (-0.32; 0.51) 
Turning 0.20 (-0.01; 0.42) -0.14 (-0.36; 0.07) 0.04 (-0.13; 0.21) -0.04 (-0.47; 0.39) 
Base of Support -0.04 (-0.25; 0.17) 0.12 (-0.09; 0.34) 0.05 (-0.11; 0.22) -0.07 (-0.49; 0.36) 
 COPD A COPD B COPD C COPD D 
Global gait 0.26 (0.05; 0.46) -0.19 (-0.42; 0.04) 0.02 (-0.56; 0.61) -0.48 (-0.92; -0.05) 
Rhythm -0.06 (-0.26; 0.13) -0.21 (-0.43; 0.01) -0.73 (-1.29; -0.17) -0.83 (-1.25; -0.41) 
Variability 0.11 (-0.11; 0.32) 0.08 (-0.17; 0.32) 0.32 (-0.30; 0.93) 0.15 (-0.31; 0.61) 
Phases 0.30 (0.09; 0.51) -0.10 (-0.33; 0.14) 0.33 (-0.26; 0.93) -0.08 (-0.53; 0.37) 
Pace 0.12 (-0.06; 0.29) -0.18 (-0.38; 0.02) -0.24 (-0.75; 0.27) -0.40 (-0.78; -0.02) 
Tandema 0.02 (-0.19; 0.24) -0.07 (-0.31; 0.17) 0.17 (-0.44; 0.78) 0.04 (-0.41; 0.50) 
Turning 0.08 (-0.14; 0.30) -0.01 (-0.26; 0.24) -0.01 (-0.64; 0.62) -0.01 (-0.48; 0.47) 
Base of Support 0.11 (-0.11; 0.32) -0.04 (-0.28; 0.20) 0.26 (-0.36; 0.88) -0.13 (-0.59; 0.34) 
 
Values represent differences in z-scores of gait (95% Confidence Interval). A lower value of gait represents 
worse gait. Values in bold survived thresholds of nominal significance (p < 0.05). All analyses were adjusted for 
age, sex, height, primary education, pack-years, and use of analgesics. a Additionally adjusted for the step count 
and step size within the tandem walk. COPD was defined as FEV1/FVC < 70% and categorized according to the 
modified Global Initiative for Chronic Obstructive Lung Disease (GOLD) classification of airflow limitation 2007 
into mild COPD (GOLD1; FEV1≥80%pred) or moderate/severe COPD (GOLD2&3; FEV1<80%pred) and according 
to the updated GOLD group categorization 2013. A (low risk, less symptoms), B (low risk, more symptoms), C 
(high risk, less symptoms) and D (high risk, more symptoms). Exacerbations were counted as the total number 
of moderate and severe exacerbations in the year 2010. Frequent exacerbators were defined as COPD persons 
having at least two moderate or severe exacerbations. 
Abbreviation: COPD= Chronic Obstructive Pulmonary Disease 
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Figure 2: Means of walking Rhythm across the COPD GOLD 2011 categories, adjusted for age 
and sex. Error bars represent the 95% confidence interval.  
* p < 0.05 ; ** p < 0.005; ***p < 0.001 by ANCOVA 
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Figure 3: Means of walking Rhythm stratified for COPD and a history of falls, adjusted for age 
and sex. Error bars represent the 95% confidence interval.  
* p < 0.05 ; ** p < 0.005; ***p < 0.001 by ANCOVA 
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DISCUSSION  
In this large population based cohort study, we demonstrated that COPD and continuous 
lung function parameters associated with gait. We found COPD to be specifically associated 
with taking slower steps (lower Rhythm). Moreover, a clinical association between Rhythm 
and falls according to the COPD status, was observed. Additionally, we found better lung 
function in all parameters to associate with better gait, especially in Rhythm and Pace. 
 
We are the first study to comprehensively investigate the associations of COPD and lung 
function parameters with the gait pattern. A lower walking distance during a six-minute walk 
or shuttle walk test, has been extensively reported in people with COPD; however, literature 
on gait velocity and other gait deficits is scarce.418 Our results show that COPD is especially 
related with taking slower steps (lower Rhythm). This indicates that any slowing in gait 
velocity is mainly driven by a lower cadence instead of taking smaller steps. This notion was 
supported by the associations found with the original gait parameters. A possible 
explanation for this decrease in cadence may be an adaption mechanism to cope with 
impaired walking endurance due to lack of oxygen supply. Taking slower steps may decrease 
oxygen need of the leg muscles and thus allow for long distance walking in people with 
impaired lung function. The lower Rhythm might further result from systemic effects of 
COPD on the brain, cardiovascular system, muscle strength or bone mineralization.141, 232, 418, 
430-432 Beauchamp et al. found that gait deficits in patients with COPD were similar to 
patients with an elevated fall risk or neuromuscular disease.359 The increased risk of falling in 
patients with COPD is thought to be caused by an inability to respond quickly in 
circumstances of instability.359 Our finding of an especially low Rhythm in fallers with COPD 
may reflect this inability, because people who take steps slowly may also be slower at 
reacting to imbalances. However, further research is needed to determine whether this 
association of low Rhythm with a history of falling in people with COPD is also reflected in 
future falling. 
 
The effect of COPD on Rhythm was especially strong in more severe COPD, which is in line 
with a recent study by Yentes et al.433 Similarly, we found the severest COPD GOLD category 
to associate with worse Global Gait and Pace. In contrast, GOLD A was related to better 
Global Gait and Phases. These positive associations may be the result of a healthy selection 
effect, i.e. GOLD A represents the most healthy people with COPD who may have better gait 
than the general population. 
 
Our study also demonstrates that continuous lung function parameters associate with gait. 
Less airflow limitation (i.e. higher FEV1) was associated with better Global Gait, Rhythm, and 
Pace (larger steps). Less airflow obstruction (FEV1/FVC) associated with better Rhythm, but 
worse Phases (more double support). The associations of higher FVC and lower FEV1/FVC 
with better Phases may indicate that Phases is more related to restrictive lung disorders. A 
preserved diffusing capacity DLCO,c associated with better Global Gait, Rhythm and Pace, but 
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worse Turning (longer turning time). The latter result suggests that when the lungs transfer 
less oxygen to the blood and carbon dioxide from the blood, persons have a lower cadence, 
take smaller steps and more turning steps and time. When dividing the DLCO,c by the alveolar 
volume, it only remained significantly associated with Rhythm. We found very similar 
associations of lung function with the original gait parameters, supporting our suggestions. 
 
The main strength of our study is that we for the first time investigated associations of 
different gait domains, including different walking conditions, with COPD and lung function 
in a community-dwelling population. Furthermore, we investigated the influence of disease 
severity – taking into account exacerbations and the updated GOLD categories besides the 
severity of airflow limitation- on the association of COPD with the gait domains and explored 
associations of the related gait domain with falling. To cope with confounding, all analyses in 
our observational study were adjusted for potential confounders that showed a trend of an 
association with both COPD and gait.416, 427, 434 
 
A first potential limitation of this study is that persons with severe COPD and very poor lung 
function might be less likely to come to the research centre for gait assessment. However, if 
anything, this selective refusal of participation would have underestimated the strength of 
association of COPD and worse lung function with gait disturbances. Second, given the cross-
sectional analysis and the retrospective interrogation of falls, we cannot infer causality. 
Consequently, the worse Rhythm in COPD patients may lead to more falls, or, falls in COPD 
patients may aggravate anxiety and unsecured gait leading to worse Rhythm.416  
 
In conclusion, COPD associates with worse gait, especially with taking slower steps, in a 
community-dwelling population. Additionally, less airflow limitation, more forced vital 
capacity, and better oxygen diffusion capacity associate with better gait, as especially 
reflected by quicker and larger steps. Further research should investigate the underlying 
mechanisms of these associations, to enable development of proper intervention strategies 
to prevent falling in patients with COPD. 
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PART V: GENERAL DISCUSSION 
COPD is a common and progressive chronic pulmonary inflammatory disease affecting 
millions of people worldwide. In addition to the degree of airflow limitation, the presence of 
symptoms, exacerbations and comorbidities has been increasingly recognized to have a large 
impact on the severity of COPD. Since comorbidities have a profound influence on the 
morbidity and mortality in patients with COPD, the identification of (early predictors of) 
comorbidities is crucial in the management of patients with COPD. Therefore, the main 
objective of this thesis was to identify and explore (novel) co-morbid conditions and 
systemic effects of COPD within the Rotterdam Study, a large population-based cohort 
study. In this general discussion, I will first summarize and discuss the most important 
findings. Second, I will highlight some of the methodological issues regarding our studies. 
Finally, I will conclude with potential implications of my research and some suggestions for 
future research. 
 
MAIN FINDINGS 
Systemic inflammation in COPD 
The knowledge on COPD has evolved from a specific lung disease characterized by poorly 
reversible airflow limitation towards a multicomponent disease characterized by airflow 
limitation associated with an abnormal inflammatory response of the lungs, exacerbations 
and extrapulmonary effects that further impact the disease severity and prognosis.1 A 
mosaic of processes contribute to the pathogenesis of COPD including variable gene 
expression, abnormal immune responses, influence of hormones and damaging effects of 
environmental factors.435 During my PhD, I collaborated on several genome wide association 
studies to further elucidate the genetic susceptibility.436-438 COPD research has largely 
focused on the damaging smoking effects as disease initiator. However, little is known on 
the underlying predisposing conditions explaining why COPD develops in only 20% of 
smokers and how it develops in never smokers, why the inflammation persists in COPD after 
smoking cessation and how COPD leads to comorbidities independent of smoking. The role 
of innate and adaptive immunity in these predisposing conditions is intriguing. Next to local 
airway inflammation, COPD is also associated with systemic inflammation and both correlate 
with each other, at least when measured during an exacerbation.166 Relating to the 
unanswered questions regarding the predisposing conditions in COPD and the potential role 
of systemic inflammation herein, the aim in chapter 5 was to investigate whether increased 
levels of systemic inflammatory markers (i.e. plasma levels of IL6) were causally related with 
the risk of developing COPD. Together with previous findings on hsCRP, our results do 
suggest that systemic inflammation is associated with COPD, but is not causally driving the 
pathogenesis of COPD.61  
 
The systemic inflammation in COPD might be explained by a direct spill-over of pulmonary 
inflammation or by pathophysiologic changes due to COPD, including processes of increased 
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oxidative stress, hypoxia and hyperinflation. In addition, physical inactivity, obesity and 
comorbidities of COPD might contribute to systemic inflammation. Furthermore, the bone 
marrow as production site of inflammatory cells might be involved in the initiation or 
aggravation of systemic inflammation too.266, 439 Regarding the bones, we demonstrated 
within the Rotterdam Study that low bone mineral density is associated with COPD 
mortality.432 
 
Interestingly, elevated levels of systemic inflammatory markers are associated with an 
increased risk of future exacerbations and major comorbidities in subjects with COPD.440, 441 
Although the specific causal role of systemic inflammation herein requires further research, 
elevated levels of systemic inflammatory markers can have a clinically prognostic value. For 
example in chapter 6, we demonstrated that the cumulative survival of COPD patients with 
higher levels of a systemic inflammatory marker (i.e. serum hsCRP), was worse than for 
those COPD patients without an elevated hsCRP at baseline. Furthermore, we demonstrated 
in the same chapter that statin use was associated with a reduced mortality, particularly in 
COPD subjects having increased systemic inflammation at baseline. In addition to their lipid-
lowering effects, statins also possess pleiotropic anti-inflammatory and immunomodulating 
properties, reducing levels of inflammatory markers such as CRP and IL6.104, 107 Finally, in 
chapter 7, we observed that the risk of COPD frequent exacerbators on sudden cardiac 
death was modified by higher levels of systemic inflammation (i.e. serum hsCRP) at baseline. 
From part II of this thesis, we might thus conclude that increased levels of systemic 
inflammatory markers are present in a subgroup of subjects with COPD and may have a 
clinical prognostic value by identifying COPD subjects with an increased mortality risk. 
Overall, systemic inflammation is likely to be one mechanism underlying the development of 
cardiovascular comorbidities in COPD and frequent exacerbations might aggravate this 
inflammatory pathway. 
 
Angiopathy in COPD 
Angiopathy can be divided into two types, namely macro- and microangiopathy affecting 
large and small blood vessels, respectively. Because COPD has been associated with vascular 
dysfunction, we explored both angiopathies in chapters 9 and 10 respectively.  
 
Regarding macroangiopahty, we investigated the presence of increased carotid intima-media 
wall thickness (IMT) on ultrasonography as well as the plaque content on Magnetic 
Resonance Imaging (MRI). Both measurements provide valuable information and may reflect 
different underlying mechanisms. The carotid IMT is an indicator of subclinical generalized 
atherosclerosis and a strong predictor of stroke as well of coronary heart disease and left 
ventricular hypertrophy.442-445  We demonstrated in chapter 9 that COPD subjects have a 
twofold increased risk of carotid artery wall thickening compared to controls with a normal 
lung function. Moreover, an increased carotid IMT was more prevalent in COPD subjects 
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with a higher degree of airflow limitation, clinical symptoms of dyspnea or chronic 
bronchitis. 
 
The composition of the atherosclerotic plaque can be differentiated into vulnerable plaques 
versus more stable calcified plaques. Especially plaques with a lipid core are along with a thin 
fibrous cap more prone to rupture.334 The MRI data from subjects with increased carotid IMT 
in our study, showed that plaques are more lipid-rich in COPD subjects compared to control 
subjects, and that lipid core plaques are also more prevalent in COPD subjects suffering from 
dyspnea. In contrast, effects on lipid core plaques were not as strongly modified by the 
degree of airflow limitation or chronic bronchitis as they were on an increased carotid IMT. 
Interestingly, COPD patients with increased systemic inflammation are more characterized 
by obesity, dyspnea and cardiovascular disease than by the presence of chronic bronchitis or 
increased airflow limitation.34 Although numbers were lower in the MRI than ultrasound part 
of our study, we hypothesize from this observation that the systemic inflammation might 
play a bigger or more direct role in making plaques vulnerable than in initiating plaques. 
Mechanisms on how systemic inflammation might lead to vulnerable plaques are in detail 
discussed in an editorial by Sin and MacNee and presented in Part I, Figure 4 of this thesis.266 
 
Regarding microangiopathy, we investigated the prevalence and incidence of cerebral 
microbleeds which are small areas of hypointensity on MRI. Cerebral microbleeds are 
markers of cerebral small vessel disease and thus indicative of specific underlying 
microscopic pathological changes in cerebral small vessels.202 The findings from chapter 10 
indicate that the prevalence of cerebral microbleeds is higher in subjects with COPD 
compared to subjects with a normal lung function, even after adjustment for potential 
confounders such as smoking. Furthermore, we investigated the location of these cerebral 
microbleeds since the location appears to reveal the underlying disease mechanism. In 
particular, microbleeds in deep or infratentorial locations are suggestive of hypertensive or 
arteriolosclerotic microangiopathy, whereas those occurring in strictly lobar brain sites are 
indicative of cerebral amyloid angiopathy.202, 204 We observed that cerebral microbleeds 
within subjects with COPD occurred more frequently in deep or infratentorial locations. In 
contrast, COPD was not significantly associated with microbleeds occurring in strictly lobar 
brain sites. This preferential location suggests that cerebral microbleeds in patients with 
COPD occur by arteriolosclerosis on the basis of hypertensive vasculopathy and 
lipohyalinosis.  
 
It is important here to differentiate arteriolosclerosis used in chapter 10 from atherosclerosis 
used in chapter 9. The term “arteriolosclerosis” refers to microangiopathy caused by 
stiffening of small arteries and arterioles. This loss of compliance can be caused by increased 
protein deposition in the vessel wall, seen in hypertension or diabetes. Arteriolosclerosis is 
pathophysiologically different from atherosclerosis. Atherosclerosis is a process of fat 
depositing which over time leads to stiffening of the wall of large/middle arteries. To further 
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explore causality between COPD and deep or infratentorial microbleeds, we performed 
longitudinal analyses in participants who had two MRI brain scans and no cerebral 
microbleed at the time of the first MRI scan. Herein, we confirmed that COPD was 
significantly associated with an increased risk of developing deep or infratentorial 
microbleeds in the subsequent three years. Although the association between COPD 
subjects and deep or infratentorial microbleeds seemed to be more modified by an 
increased IMT than additionally by the presence of a lipid core, the association did not 
disappear after adding carotid artery wall thickening to the model. This suggests that 
although macro- and microangiopathy in COPD may share common risk factors, treating 
generalized atherosclerosis may not entirely prevent arteriolosclerosis in patients with 
COPD.  
 
Comorbidities in COPD 
Although COPD is a chronic disease of the lungs which eventually can lead to death from 
respiratory failure, the majority of COPD patients suffers and dies from comorbidities before 
they reach end stage lung diseas. In chapter 6, we observed that most COPD participants 
died due to cardiovascular causes. The protective effect of statins on the all cause mortality 
in COPD observed in this chapter, might therefore represent effects on the cardiovascular 
comorbidities. However, our results also suggest that statin use affected respiratory 
mortality, potentially by downregulating the expression of CCL2, CXCL8 and the matrix 
metalloproteinases (MMPs) involved in COPD matrix remodelling, such as MMP2, MMP9 
and MMP12.114-117 In chapter 7, we demonstrated that COPD is an independent risk factor 
for sudden cardiac death in the general population. These observations are in line with the 
previous observed increased cardiovascular morbidity and mortality risk, and with results 
from studies in specific patient populations at high risk of sudden cardiac death.131, 132, 135-138, 
154-156  
 
Since both carotid artery plaques and cerebral microbleeds are associated with 
cerebrovascular morbidity, we dedicated chapter 8 to a poorly explored field of research, 
namely that of interactions between the lung and the brain in the elderly. Although 
neurological disorders have a profound impact on wellbeing and functional capacity, their 
assessment in patients with COPD is not common practice. However, several central nervous 
system disorders have been described in relation to COPD. Since current techniques make it 
possible to even visualize early markers of central nervous system disorders, future research 
might bridge the current knowledge gaps regarding the potential underlying mechanisms.   
 
Carotid artery plaques and cerebral microbleeds are associated with ischemic and 
hemorrhagic stroke respectively.446 Consequential to our results and mechanistic insights 
from chapters 9 and 10, we explored an association between COPD and stroke subtypes in 
chapter 11. Herein, we showed that subjects with COPD have an increased risk of stroke 
during follow-up. We found age and sex independent associations with both ischemic and 
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hemorrhagic stroke. Smoking had again an important influence and the relationship 
between COPD and stroke was not independent of the effects of smoking. Interestingly, the 
association between COPD and incident hemorrhagic stroke was still borderline significant 
after adjusting for smoking and we found for ischemic stroke larger associations in persons 
with cortical stroke or strokes due to large artery atherosclerosis. Overall, we conclude from 
this part that (I) COPD is associated with both subclinical macro- and microvascular disease 
in the cerebral circulation, and (II) that smoking amplifies risks and is most likely crucial in 
developing clinical events as stroke. 
 
Cachexia and skeletal muscle weakness are two other important comorbidities in COPD.265, 
447 This has driven us to further explore frailty in patients with COPD. Because of a global 
interest in healthy aging, the prevention of frailty among elderly gets increasing attention. 
Since frailty was not yet explored within the Rotterdam Study, we identified physically frail 
subjects and estimated their prevalence in chapter 12 of this thesis. The observed frailty 
prevalence (5.8%) was in line with literature increasing the generalizability of the Fried frailty 
criteria.38 Furthermore, frail elderly were more likely to be older and female, to have worse 
quality of life, more falls and hospitalizations and an increased risk of dying within three 
years. Frail subjects had also more comorbidities including COPD.  
 
Intriguingly, both frailty and COPD are associated with decline in function across multiple 
systems that in composite contribute to geriatric syndromes, including osteoporosis, 
cognitive decline, anemia, immune deficiency, weight loss and muscle dysfunction. In line 
with studies suggesting an association between frailty and respiratory impairment, we 
demonstrated that COPD was significantly associated with frailty in chapter 13.410, 411 Since 
osteoporosis and muscle wasting are also known side effects of systemic corticosteroids and 
since corticosteroids are frequently prescribed in COPD, we added oral corticosteroid use 
together with other potential confounders to our models. COPD remained significantly 
associated with frailty, even after adjusting for age, sex, smoking, dyslipidemia, anemia, 
stroke, osteoporosis, antihypertensive use, and cumulative use of systemic corticosteroids. 
These results suggest that COPD is linked with frailty beyond common comorbidities or the 
use of systemic corticosteroids. Systemic inflammation may underlie this association since 
both frailty and COPD subjects present with increased levels of inflammatory markers, such 
as white blood cell count, hsCRP, IL6 and tumor necrosis factor-α.34, 37, 45-51, 415 In turn, 
inflammation and oxidative stress have synergistic effects on muscle breakdown.265 
Importantly, the results suggest that with increasing degree of airflow limitation more 
intermediate frail elderly become frail, while the prevalence of COPD subjects without any of 
the frailty criteria did not change substantially across the stages. This might imply that 
prevention of frailty should focus on mild-to-moderate COPD subjects.  
 
In chapter 14, we explored whether devastating effects of COPD on the cardiovascular 
system, central nervous system, and musculoskeletal system observed in previous chapters 
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might have an impact on the gait pattern. COPD appeared to be specifically associated with 
taking slower steps (lower Rhythm) and an association between gait Rhythm and falls 
according to the COPD status was observed. However, the cross-sectional analysis and the 
retrospective interrogation of falls did not allow us to conclude whether the worse Rhythm 
in COPD patients leads to more falls, or conversely, whether falls in COPD patients aggravate 
anxiety and unsecured gait leading to worse walking Rhythm.416 Additionally, we found 
better lung function in all parameters to associate with better gait, especially with Rhythm 
and pace. From this part, we might conclude that interactions between the lung and the 
brain, cardiovascular, and musculoskeletal system might result in observable deficits in 
physical functioning. 
 
METHODOLOGICAL CONSIDERATIONS 
Study setting and design  
All studies described in this thesis were embedded within the Rotterdam Study (RS), a large 
prospective population-based cohort study aimed at assessing the occurrence of, and risk 
factors for chronic diseases in the elderly.20 The Rotterdam Study (RS) has multiple strengths 
including the large number of participants and continued prospective follow-up, making this 
study very well suited to investigate most of our COPD research questions. All inhabitants of 
one district of Rotterdam (Ommoord) were invited to the original cohort in 1990 and the 
response rate was high (78%).20, 21 The sole inclusion criteria was the age, i.e. 55 years or 
older for RS-I and RS-II, 45 years or older for RS-III. Participants were recruited irrespective of 
their disease status and the majority of elderly chronic diseases were diagnosed during 
follow-up. Selection bias was thus avoided as much as possible. 
Assessment of COPD 
Previously, 928 (11.6%) subjects with COPD were identified in RS-I. Chapter 5 and 6 describe 
studies based on these COPD patients. During my PhD, I further identified incident COPD 
cases in RS-I and all prevalent and incident cases within RS-II and RS-III. Until January 1st 
2011, 1615 (10.8%) subjects with COPD and without asthma or asthma-COPD Overlap 
Syndrome (ACOS) were identified within the three cohorts of the RS. Chapters 7 and 11 
include all identified COPD cases. Controls were subjects without COPD or asthma or ACOS 
during follow-up. The diagnosis of 883 subjects was based on an obstructive lung function 
measurement at the research centre, 487 (55.2%) participants of them had moderate to 
severe airflow limitation and 396 (44.8%) participants had mild airflow limitation. The 
manuscripts investigating the association between COPD and angiopathy, frailty and gait 
included only subjects who recently performed an interpretable spirometry at the research 
centre (chapters 9,10,13,14). Subjects with an obstructive lung function measurement were 
cases, subjects with a normal lung function were controls. Subjects with a restrictive lung 
function measurement, asthma or ACOS were excluded. 
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The diagnosis of the remaining 447 and 285 subjects was based on a validated diagnosis by 
the pulmonologist or general practitioner (GP) respectively based on the combination of 
clinical history, physical examination, and spirometry. We evaluated whether the exclusion 
of COPD patients diagnosed by GP affected our results substantially in chapter 6, but it did 
not. Pharmacy dispensing data, questionnaires on respiratory symptoms, hospital discharge 
letters and mortality reports were used next to lung function tests for continued case-
finding. During my PhD, I also identified frequent COPD exacerbators by validating moderate 
exacerbations, i.e. exacerbations of COPD treated with antibiotics and/or systemic 
corticosteroids, and severe exacerbations, i.e. hospitalizations due to exacerbations of COPD 
during the complete follow-up.  
Since the spirometry at the research centre was only introduced in the study protocol since 
the fourth cross-sectional round of RSI, we might have missed some subjects with clinically 
silent but spirometrically identifiable COPD in the beginning, underestimating the incidence 
of COPD in RS-I in the nineties. Other limitations might be that reversibility tests were not 
conducted (although we identified and excluded all asthma subjects from our analyses) and 
that the simple, generally recommended fixed ratio was used to diagnose COPD instead of 
the lower limit of normal (LLN). Although the fixed ratio might overestimate COPD in healthy 
elderly, subjects identified with the fixed cut-off but not with LLN do have poorer 
prognosis.448, 449  
Assessment of comorbidities 
All participants are very meticulous monitored for the onset of diseases and carefully 
examined at the research centre with non-invasive state of the art techniques.20 This thesis 
was accomplished through the fruitful cooperation with doctors and researchers from 
different disciplines and departments, who are all experts in their field. The specific 
assessment of the relevant comorbidities are discussed in detail in the respective chapters. 
The prospective independent data collection has the advantage that our research 
hypotheses did not impact data collection, preventing information bias. A downside might 
be that one is restricted to the questionnaires, examinations and collections which were part 
of the study protocol in the past. However, some tests are too invasive or time-consuming 
and investigating everything would be impossible for the participants or budget holders, and 
might limit the researcher’s creativity in finding answers. 
 
Bias and confounding 
Despite our best efforts to minimize biases through high response rates, independent 
prospective data collection and adjustment for known confounders, the validity of our 
studies may still to some extent have been affected by selection bias, information bias and 
confounding. Details are given in the respective chapters, however, I like to present here a 
general discussion regarding bias and confounding with respect to my thesis.   
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First, some selection might have occurred by those participants who declined the invitation 
to participate to the Rotterdam study for unknown reasons. Since most of COPD onset 
occurred during follow-up and COPD incidence rates within the Rotterdam Study are in line 
with general figures, it is unlikely that reasons were related to COPD. 
Second, some information might have been missed on our investigated exposures and 
outcomes. However, information on dispensed prescriptions for medication exposure is 
gathered prospectively and automatically, and COPD and the described comorbidities were 
very meticulous assessed. Differential misclassification of the outcome was reduced as the 
outcomes under analyses were collected independently of the exposure of interest, mostly 
COPD. However, we have to acknowledge that few deaths occurred under extensive 
monitoring or were autopsied, that radiation exposure has been limited and contrast 
material has not been administered, that sometimes participation to tests at the research 
centre or questionnaires was refused and that all tests are limited by their sensitivity and 
specificity. Because non-differential misclassification or misclassification by underestimation 
are generally thought to underestimate true effects, associations with COPD may be rather 
higher than we have found. 
 
Third, some unknown or unmeasured confounders might have attenuated our associations. 
Potential confounding is inherent to observational study designs and COPD and the 
described comorbidities frequently share major risk factors as old age and smoking history. 
COPD is moreover a very heterogeneous disease associated with accelerated aging and 
multiple comorbid conditions. Although we carefully evaluated the influence of potential 
confounders and appropriately adjusted models, residual confounding might have been 
present. 
 
Causal inference 
Some studies in this thesis were limited to a cross-sectional design which makes it difficult to 
judge the sequence of cause and effect. Therefore, we cannot infer causal mechanisms 
between COPD and carotid artery plaques, nor between COPD and frailty and gait 
respectively. There might exist a phenotype more sensitive to smoking, simultaneously 
developing cardiovascular, cerebral, musculoskeletal and pulmonary abnormalities. 
Although longitudinal studies are necessary to further explore the temporal sequence of 
association, we did observe some biological gradient since the associations were stronger 
along with the COPD severity and we presented several potential biological mechanisms in 
the concerning chapters.450 Furthermore, to control for reverse causation and unmeasured 
confounding in the association between interleukin 6 and COPD, we used the Mendelian 
randomization method, described in chapter 5. Herein, we use genetic variation in the IL6 
gene as an instrument for strengthening causal inference between IL6 and COPD. 
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POTENTIAL IMPLICATIONS AND FUTURE DIRECTIONS 
The general aim was to increase our knowledge on comorbidities and systemic effects in 
COPD, a common disease in the elderly associated with a high burden on healthcare costs, 
morbidity and mortality. To achieve healthy aging and to keep costs of our aging population 
affordable, we have to find ways to reverse or optimally prevent vulnerability in elderly. Our 
results on COPD, cardio- and cerebrovascular comorbidities, angiopathy and frailty might aid 
herein by identifying vulnerable elderly. Moreover, the results of this thesis might enhance 
further research into the underlying mechanisms to find new targets for preventive 
strategies or more effective management of chronic diseased people. Despite the enormous 
global impact of COPD, no current drug therapies have shown conclusively to prevent 
disease progression or reduce mortality. The results from this thesis might help to shift the 
sole focus on lung function decline towards a more multidisciplinary approach to tackle 
general decline. Especially in the early stages of the disease where COPD is still a silent killer 
through its comorbidities. 
 
First, more research is needed into the origin of the systemic inflammation in COPD since it 
even persists in ex-smokers, and into the differentiation of highly prognostic inflammatory 
markers and causal makers of the disease. Furthermore, it is of particular interest whether 
systemic inflammation influences the innate defenses of the lungs against microbial 
pathogens, or whether it reflects impaired lung defense and consequent immune-
inflammatory dysregulation.451  However, since a recent study showed that elevated levels 
of systemic inflammatory markers are only present in a subset of COPD patients and 
sometimes merely intermittent, it remains generally questionable whether the number or 
severity of acute flares of inflammation is not even more important than the persistence of a 
low grade inflammation.34  
 
Second, more research is needed into the mechanisms underlying the comorbidities in 
COPD. Regarding the association of COPD with macro- and microangiophaty, it would be of 
particular interest to further unravel genetic susceptibility or systemic inflammatory 
markers. Regarding the genetic susceptibility, the receptor for Advanced Glycation End 
products (RAGE) has been associated with atherosclerosis and arteriolosclerosis in diabetic 
patients.452-454 Furthermore, genetic variation in the gene of this receptor has been shown to 
be associated with pulmonary function.11 Since both COPD and lipohyalinosis are associated 
with advanced glycation end products, I like to further explore whether there is a potential 
genetic susceptibility underlying cerebral microangiopathy in COPD. Regarding the systemic 
inflammatory markers, this requires longitudinal follow-up and potentially multiple CRP 
measurements. Since for example in patients with rheumatoid arthritis, the magnitude and 
chronicity of the inflammatory response over time (and not the cross-sectional CRP 
measurement at the time of the ultrasound study) was associated with the carotid IMT.455  
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Third, we like to further investigate the vascular status of patients with COPD and explore 
whether the (systemic) atherosclerosis is associated with cognitive impairment. Since we 
now have identified frail subjects, we will evaluate prospectively the direction of the 
association with COPD.  In addition, we like to explore whether certain phenotypes of COPD- 
for example the frequent exacerbator or chronic bronchitis phenotype- are more prone to 
develop frailty. Longitudinal follow-up is also required in our gait research. Both gait 
disturbances and COPD have independently been linked to cerebral small-vessel disease, 
however, little is known about underlying mechanisms.200, 416, 456 In this thesis, we 
demonstrated that COPD persons have an increased risk of developing cerebral microbleeds 
in deep or infratentorial locations.141 Since the deep and infratentorial regions harbour 
structures crucial to gait regulation, such as the cerebellum (coordination, adaptation), the 
basal ganglia (initiation, automatisation), brainstem (integration) and the thalamus, cerebral 
microbleeds in these regions might contribute to gait disturbances in persons with 
COPD.457,458  
To tailor current and future treatment strategies, there is also a need for better 
characterization of the COPD heterogeneity. An example where we could meet herein might 
be the overlap with asthma. Since we also identified elderly with asthma or asthma-COPD 
Overlap Syndrome (ACOS), many opportunities are left to answer research questions about 
these underinvestigated phenotypes. We further aim to conduct more research into gender 
differences in patients with COPD. It would be of particular interest to know whether woman 
are more (or less) susceptible to smoking,  acute exacerbations, early onset of the disease or 
with regard to this thesis, to certain comorbidities.  
Lastly, the way from bench to bedside might be shortest for our research regarding statins. 
Randomized clinical trials (RCTs) are performed to confirm the protective effects of statin 
use we and others have seen in COPD observational studies.101, 103, 140, 459 The large ‘real-life’ 
effect sizes of statins seem sometimes improbable and warrant further study. The great 
advantage of RCTs is that the exposure is randomly assigned and the design is very well 
suited to evaluate efficacy of a treatment. However, the first RCT recently published 
regarding statins in COPD demonstrated that simvastatin did not affect exacerbation rates or 
mortality.459 Besides potential confounding in our study as discussed previously, three other 
factors might explain the discordant mortality results and generally reflect the major 
differences between RCTs and observational studies. First, the STATCOPE study results may 
not hold for COPD patients with mild airflow limitation or cardiovascular comorbidities. 
Although the majority of COPD patients has comorbidities, many have mild airflow limitation 
and a substantial amount did not smoke or had less than twenty packyears, they are all 
consistently excluded from clinical trials. These exclusions impede generalizability of the 
results and increase off-label use. Second, the protective effect of statins on mortality was 
especially observed in our study after prolonged treatment, while the mean follow-up of the 
STATCOPE study was less than two years since the study terminated early for futility on the 
primary endpoint.140, 459 Because long-term follow-up is very expensive and hard endpoints 
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are also harder to measure, many RCTs in COPD focus on surrogate endpoints as lung 
function and lung function-associated parameters. Third, since we observed in our study that 
the protective effect of statins on mortality in subjects with COPD was modified by the 
degree of systemic inflammation at baseline, an enrichment design enrolling COPD patients 
with systemic inflammation or stratification by measured systemic biomarkers of 
inflammation would be of interest. Management of the COPD patient would optimally 
integrate the treatment of comorbidities. However, prevention of the systemic effects would 
be even better and it is very tempting to find solutions in minimizing the systemic 
inflammation. In addition to smoking cessation, increasing physical activity and treating 
impaired immunity might be effective preventive strategies too. Another prevention could 
consist of screening all COPD patients for the presence of concomitant atherosclerosis and 
patients with ischemic heart disease for the presence of airflow limitation.30  
In conclusion, COPD and its potential role in other diseases clearly demonstrates that COPD 
is a very heterogenous disease deserving a multidisciplinary approach and much more 
scientific investigation. I hope that the results and suggestions in this thesis give oxygen to 
novel ideas for research and may be translated one day into making patients with COPD 
breathe better and live longer. 
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PART VI: SUMMARY 
COPD is a common respiratory disease among elderly which is characterized by a progressive 
airflow limitation. In addition to the chronic inflammatory response in the lungs, systemic 
effects and comorbidities are frequently present and determine the prognosis in patients 
with COPD. A first step towards a better prevention and treatment of comorbidities in COPD 
is the identification of those COPD subjects in the general population at high risk of co-
morbid conditions. The main objective of this thesis was therefore to identify and explore 
(novel) comorbid conditions and systemic effects of COPD within the Rotterdam Study, a 
large population-based cohort study. 
 
Part II of this thesis focuses on the systemic inflammation and cardiovascular mortality in 
subjects with COPD. The systemic inflammation is potentially involved in the underlying 
mechanisms leading to COPD comorbidities. First, we investigated the role of interleukin 6 
(IL6) and high sensitivity C-reactive protein (hsCRP). In chapter 5, we demonstrated that 
increased IL6 plasma levels at baseline were associated with the risk of developing COPD 
during follow-up. In contrast, our study could not find strong evidence for an association 
between common variation in the IL6 gene and the risk of developing COPD. Our findings 
suggest that IL6, next to hsCRP, is a marker of systemic inflammation in patients with COPD, 
but is not causally driving the pathogenesis of the pulmonary dysfunction in COPD (maker of 
disease). However, further research is needed to study their specific role in the development 
of COPD comorbidities and the subsequent mortality. The results of chapter 6 already 
suggest a potential role of systemic inflammation in the all cause mortality of patients with 
COPD. COPD subjects with an increased level of systemic inflammation at baseline had 
worse survival. Statins were associated with a reduced mortality, particularly in COPD 
subjects having increased serum levels of hsCRP at baseline. Although the protective effect 
of statins in COPD patients could represent solely an indirect effect on the cardiovascular 
comorbidities associated with COPD, our results also suggest an effect on respiratory 
mortality by statin use compared to never use. The results further imply that in COPD 
elderly, CRP levels rather than total cholesterol levels, might guide the clinician in the 
decision to start statin therapy. In this study, we also observed that most COPD cases died 
due to cardiovascular causes. Therefore, we focused on the cardiovascular mortality in 
chapter 7. Taking advantage of the enormous person-years of follow-up within the 
Rotterdam Study, we reported that COPD is an independent risk factor for sudden cardiac 
death in the general population. The risk especially increased five years after the diagnosis of 
COPD in frequent exacerbators having increased serum levels of hsCRP at baseline. This 
study might provide directions for better targeted actions in the general population for the 
prevention of sudden cardiac death. 
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Part III is dedicated to angiopathy and cerebrovascular comorbidities in COPD. Chapter 8 
presents a general overview of the current literature regarding the interplay between the 
lung and the brain in an aging population. Because COPD has been associated with vascular 
dysfunction, we investigated in the subsequent chapters the effects of COPD on the large 
and small blood vessels supplying the brain of oxygen and nutrients. In chapter 9, we 
demonstrated that COPD is associated with an increased risk of carotid artery wall 
thickening on ultrasonography compared to controls with a normal lung function. 
Importantly, vulnerable lipid core plaques on magnetic resonance imaging (MRI) were more 
frequent in COPD cases than in control subjects. Since persons with vulnerable carotid artery 
plaques are at risk for ischemic stroke through disruption of the plaque surface and 
thromboembolism, these observations offer new insights into the epidemiologic link 
between COPD and ischemic stroke. In chapter 10, we describe that COPD is associated with 
a higher prevalence of cerebral microbleeds, a marker of cerebral small-vessel disease 
determined by MRI. These findings tend to be driven by a greater occurrence of microbleeds 
in deep or infratentorial locations in subjects with COPD. In contrast, COPD was not 
significantly associated with microbleeds occurring in strictly lobar brain sites. The 
preferential location gives more insight into the potential underlying mechanism because 
microbleeds in deep or infratentorial locations are thought to occur by arteriolosclerosis on 
the basis of hypertensive vasculopathy and lipohyalinosis. Moreover, in this study, we were 
able to follow-up subjects without a cerebral microbleed at baseline and demonstrated that 
COPD is an independent risk factor to develop deep or infratentorial cerebral microbleeds 
during follow-up. After measuring brain angiopathy in chapters 9 and 10, we explored in 
chapter 11 whether subjects with COPD have an increased risk of stroke during follow-up. 
We observed that COPD was associated with both the development of ischemic and 
hemorrhagic stroke. However, these findings tend to be driven by the shared etiology of 
smoking. 
Part IV elaborates on another common syndrome in the elderly, frailty. In chapter 12, we 
estimated that the prevalence of physically frail elderly in the Rotterdam Study is 5.8%. 
Furthermore, we found that frail elderly were more likely to be older and female, to have an 
impaired quality of life and to have fallen or to have been hospitalized. Moreover, frail 
elderly had a significantly increased risk of dying within three years compared to the non-
frail elderly, even when adjusted for age, sex and comorbidities. Chapter 13 elaborates on 
the interrelationship between COPD and frailty. In this study, we evaluated the added value 
of the identification of the frail COPD phenotype. We were particularly interested in whether 
clinicians should mainly treat the individual comorbidities in patients with COPD or that a 
more holistic approach towards the most vulnerable COPD patients is necessary. In chapter 
14, we further investigated the disability in subjects with COPD by exploring the impact of 
COPD on their gait pattern. In this study, we demonstrated that COPD was specifically 
associated with taking slower steps (lower Rhythm). We also observed that the Rhythm was 
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worst in COPD persons with dyspnea, severe airflow limitation and frequent exacerbations 
(GOLD category D) and moreover, in COPD fallers.  
 
Part V finally, gives a general interpretation of the most important results and places the 
findings into perspective. In addition, I highlighted some of the methodological issues 
regarding our studies and discussed some implications and suggestions for the future. 
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SAMENVATTING 
COPD is een veel voorkomende respiratoire ziekte bij ouderen die wordt gekenmerkt door 
een progressieve luchtwegobstructie. Naast de chronische ontstekingsreactie in de longen, 
zijn systemische effecten en comorbiditeiten vaak aanwezig en bepalen ze in belangrijke 
mate mee de prognose van patiënten met COPD. Een eerste stap naar een betere preventie 
en behandeling van comorbiditeiten bij COPD is de identificatie ervan in de algemene 
bevolking. Het belangrijkste doel van dit proefschrift was dan ook (nieuwe) comorbiditeiten 
en systemische effecten van COPD te onderzoeken in de Rotterdam Study, een grote cohort 
studie bij de algemene bevolking. 
 
Deel II van dit proefschrift richtte zich op de systemische inflammatie en cardiovasculaire 
mortaliteit bij patiënten met COPD. De systemische ontsteking is namelijk mogelijks 
betrokken in de onderliggende mechanismen die leiden tot comorbiditeiten bij COPD. 
Vooreerst hebben we de rol van interleukine-6 (IL6) en hoog sensitief C-reactief proteïne 
(hsCRP) onderzocht. In hoofdstuk 5 hebben we aangetoond dat verhoogde IL6 plasma 
spiegels bij aanvang van de studie geassocieerd waren met het risico op het ontwikkelen van 
COPD tijdens de follow-up. Daarentegen kon onze studie geen sterk bewijs aanleveren dat 
veel voorkomende variatie in het IL6-gen geassocieerd zou zijn met het risico op COPD. Onze 
bevindingen suggereren dus eerder dat IL6, naast hsCRP, een merker is van systemische 
inflammatie bij COPD-patiënten, maar niet causaal betrokken is bij de pulmonale 
pathogenese van COPD (maker van de ziekte). Er is echter verder onderzoek nodig om de 
specifieke rol van deze twee markers in de ontwikkeling van COPD comorbiditeiten en de 
daaropvolgende mortaliteit te bestuderen. De resultaten van hoofdstuk 6 suggereren alvast 
een mogelijke rol van systemische ontsteking in de mortaliteit bij patiënten met COPD. 
COPD-patiënten met een verhoogd niveau van systemische ontsteking bij aanvang van de 
studie, hadden namelijk een slechtere overleving. Statines waren bovendien geassocieerd 
met een verminderde mortaliteit, vooral bij COPD patiënten met verhoogde serumspiegels 
van hsCRP bij aanvang van de studie. Hoewel het beschermend effect van statines bij COPD 
patiënten mogelijks volledig te wijten is aan een indirect effect op de cardiovasculaire 
comorbiditeiten, suggereren onze resultaten ook een effect op de respiratoire mortaliteit. 
Mogelijks is de aanwezigheid van systeeminflammatie dus een betere indicatie dan een 
verhoogd cholesterol om statines op te starten bij ouderen met COPD. In deze studie konden 
we ook vaststellen dat de meeste personen met COPD overlijden ten gevolge van 
cardiovasculaire oorzaken. Daarom hebben we ons gericht op de cardiovasculaire mortaliteit 
in hoofdstuk 7. Gebruikmakend van het enorme aantal persoonsjaren aan follow-up binnen 
de Rotterdam Study, hebben we een verband aangetoond tussen COPD en plotse hartdood 
in de algemene bevolking. De relatie was vooral sterker vijf jaar na de COPD diagnose en in 
COPD personen die frequent exacerbaties ondergingen én bij aanvang van de studie 
verhoogde serumspiegels van hsCRP hadden. Dit onderzoek zou mede een betere preventie 
van plotse hartdood kunnen bewerkstelligen. 
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Deel III is volledig gewijd aan angiopathie en cerebrovasculaire comorbiditeiten bij COPD. 
Hoofdstuk 8 geeft hierbij een algemeen overzicht van de huidige literatuur omtrent de 
interacties tussen de longen en de hersenen bij ouderen. Omdat de literatuur suggereert dat 
COPD onder andere geassocieerd is met subklinische hersenschade, onderzochten we in de 
daaropvolgende hoofdstukken de effecten van COPD op de grote en kleine bloedvaten die 
de hersenen van zuurstof en voedingsstoffen voorzien. In hoofdstuk 9 hebben we 
aangetoond dat COPD geassocieerd is met een verhoogd risico op halsslagader 
wandverdikking op echografie in vergelijking met personen met een normale longfunctie. 
Belangrijk hierbij is dat kwetsbare plaques met een lipide kern op magnetische resonantie 
beeldvorming (MRI) vaker voorkwamen bij personen met COPD dan bij controle personen. 
Gezien kwetsbare plaques ter hoogte van de halsslagader een risico vormen op ischemische 
beroerte door het ontstaan van trombo-embolie aan de plaque-oppervlakte, bieden deze 
observaties nieuwe inzichten in de relatie tussen COPD en ischemische beroerte. In 
hoofdstuk 10, beschrijven we dat COPD geassocieerd is met een hogere prevalentie van 
cerebrale microbloedingen, een MRI-merker voor cerebrale kleine vaatziekte. Deze 
bevindingen blijken vooral gedreven door een grotere aanwezigheid van microbloedingen in 
diep of infratentoriële hersengebieden in personen met COPD. Daarentegen was COPD niet 
significant geassocieerd met microbloedingen die zich strikt lobair in de hersenen bevinden. 
De preferentiële locatie geeft meer inzicht in de mogelijks onderliggende mechanismen 
omdat microbloedingen in diep of infratentoriële locaties zouden ontstaan door 
arteriolosclerose op basis van hypertensieve vasculopathie en lipohyalinosis. Bovendien 
konden we in deze studie nagaan of deelnemers zonder microbloedingen bij aanvang van de 
studie, microbloedingen ontwikkelden tijdens follow-up. Hierbij hebben we aangetoond dat 
COPD wel degelijk een onafhankelijke risicofactor blijkt te zijn om diep of infratentoriële 
cerebrale microbloedingen te ontwikkelen.  
Na het meten van de bloedvataantasting in hoofdstukken 9 en 10, onderzochten we in 
hoofdstuk 11 of deelnemers met COPD een verhoogd risico hadden op een beroerte tijdens 
follow-up. We vonden dat COPD geassocieerd is met zowel de ontwikkeling van ischemische 
als hemorragische beroerte. Echter, deze bevindingen waren in belangrijke mate gedreven 
door de gemeenschappelijke etiologie van roken. 
 
Deel IV gaat dieper in op een ander veel voorkomend syndroom bij ouderen, namelijk frailty. 
In hoofdstuk 12, schatten we dat de prevalentie van fysiek fraile ouderen in een 
Nederlandse populatie 5,8% is. Verder vonden we dat frailty onder andere gekenmerkt 
wordt door een hogere leeftijd, vrouwelijk geslacht, een verminderde kwaliteit van leven en 
een verhoogde aanwezigheid van vallen en hospitalisaties. Fraile ouderen hadden bovendien 
een significant verhoogd risico op overlijden binnen de drie jaar in vergelijking met niet-fraile 
ouderen, zelfs na correctie voor leeftijd, geslacht en comorbiditeiten. Hoofdstuk 13 gaat 
dieper in op de onderlinge relatie tussen COPD en frailty. In deze studie identificeerden we 
fraile personen binnen COPD. Hierbij vroegen we ons af of sommige kwetsbare personen 
met COPD eerder baat zouden hebben bij een holistische benadering of dat hun 
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kwetsbaarheid vooral gedreven lijkt te zijn door de individuele comorbiditeiten. In 
hoofdstuk 14 hebben we verder de invaliditeit van personen met COPD onderzocht door de 
effecten van COPD op hun looppatroon te onderzoeken. In deze studie hebben we specifiek 
aangetoond dat personen met COPD langzamer stappen nemen dan personen zonder COPD. 
Verder konden we ook opmerken dat deze gang voornamelijk was aangetast in COPD 
personen met kortademigheid, met een ernstige beperking van de luchtstroom, met 
frequente exacerbaties en bovendien, met vallen. 
 
Deel V tenslotte, geeft een algemene interpretatie van de belangrijkste resultaten en plaatst 
de bevindingen in een breder perspectief. Daarnaast wou ik hierin een aantal 
methodologische kwesties met betrekking tot onze studies aanstippen en een aantal 
implicaties en suggesties voor de toekomst bespreken. 
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PART VII: DANKWOORD 
Dit proefschrift is een joint PhD, niet alleen internationaal, maar ook interdisciplinair werden 
de krachten gebundeld. Heel wat personen verdienen dan ook een bijzonder woord van 
dank gezien dit doctoraat zonder hen niet mogelijk was geweest.  
 
Vooreerst Prof. Guy Brusselle en Prof. Bruno Stricker, als coöperatieve realiseerder en 
kritische innovator respectievelijk, vormen jullie het dream team der promotoren. Bij jullie 
doctoreren is niet alleen een grote eer maar ook een garantie voor succes. Jullie delen een 
enorme wetenschappelijke kennis en passie die afvloeien in boeiende brainstormsessies en 
een gekend Iepers overaanbod aan katten om te geselen. Professor Brusselle, ik bewonder 
je efficiënte aanpak en onuitputtelijke literatuurkennis. Naast internationaal gerenommeerd 
longarts en uitstekend docent, zal ik je ook herinneren als een echte pater familias met het 
hart op de juiste plaats. Niet alleen omdat je steeds zo liefdevol over Kaatje en je prachtige 
dochters praat, maar ook omdat je hoogzwangere vrouwen tot bij de gynaecoloog brengt of 
voetbalminnende echtgenoten in nood onderdak biedt. Bruno, ik waardeer jouw impulsieve 
en creatieve aanpak en jouw bijzonder analytisch en tactisch vermogen. Dankzij jou komen 
wilde ideeën steeds in een praktische stroomversnelling.  
 
Ten tweede wil ik de leden van de leescommissie danken voor het beoordelen van dit 
proefschrift. Prof. Henk Hoogsteden, eveneens bedankt om als secretaris te willen optreden. 
Prof. Leonardo Fabbri, thank you for travelling all the way, it is an honor having you in my 
PhD committee. Prof. Dirkje Postma, ontmoetingen met onze Groningse collega’s zijn altijd 
bijzonder aangenaam en ik was dan ook verheugd dat u als wereldautoriteit bereid was om 
in mijn promotiecommissie te zetelen. Verder wil ik ook Prof. Joachim Aerts, Prof. Albert 
Hofman en Prof. Guy Joos bedanken om te opponeren bij de verdediging van mijn 
proefschrift. Als respectievelijk diensthoofd epidemiologie in Rotterdam en diensthoofd 
longziekten in Gent, wil ik Prof. Hofman en Prof. Joos eveneens danken dat ik onderzoek kon 
uitvoeren op hun afdeling. Zonder Prof. Hofman bestond er bovendien geen Rotterdam 
Studie. 
 
Daarnaast zou de Rotterdam Studie ook niet mogelijk zijn zonder de onvoorwaardelijke 
bereidheid van alle deelnemers, de betrokkenheid van Dr. Jan Heeringa en de verbonden 
huisartsen en apothekers, en de gigantische inzet van de onderzoeksmedewerkers en 
datamanagers. Hierbij verdienen Bernardina, Edith en Henriette een bijzonder woord van 
dank voor hun uitstekende begeleiding bij de longfuncties, Anneke voor de algemene 
coördinatie binnen het ERGO centrum, Anne-Monique, Lida, Marja en Marlies voor het 
nauwgezet fuppen, Trudi en Jolande voor de verdere dataverwerking en Eric, Frank, Hannie, 
Nano en de René’s voor het databeheer en de computerondersteuning. Jolande, jij bent van 
onschatbare waarde geweest tijdens mijn PhD! Het is onwaarschijnlijk hoeveel je van de 
Rotterdam Studie afweet en hoe divers jouw takenpakket is. Ik waardeer jouw nauwgezette 
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en snelle manier van werken. Steeds kon ik bij je terecht, voor praktische vragen of lange 
lijstjes, maar ook voor een leuke babbel of muzikale uitwisselingen.  
 
Mijn reizen naar Rotterdam werden vaak onderbroken door ellenlange files, afgeschafte 
treinen, aanvarende boten of aangereden dieren, waardoor ik vaak ronddwaalde ergens 
tussenin, in het West-Vlaams ook wel tjoolen genoemd. Mocht Nederland iets makkelijker te 
bereiken zijn, zou ik nog meer van dit mooie, vlakke land houden. Gelukkig kon ik naast de 
jarenlange financiële steun van het Fonds voor Wetenschappelijk Onderzoek (FWO), ook 
lange tijd rekenen op de Belgische Vereniging voor Pneumologie (BVP) voor mijn transport 
en verblijven, en kon ik vaak genieten van het aangename gezelschap van Kaatje wie ik ook 
veel dank verschuldigd ben om de longfuncties in nood te willen meebrengen. 
 
Dit doctoraat is niet alleen een samenwerking tussen Gent en Rotterdam. Het is ook een 
samenwerking geweest tussen de longziekten en de (pharmaco)epidemiologie, neurologie, 
radiologie, cardiologie, genetica,… waarbij ik in het bijzonder professoren en dokters 
Deckers, De Sutter, Devos, Franco, Ikram, Rivadeneira, Tiemeier, Uitterlinden, van der Lugt, 
Vernooij, Ziere en Zillikens wil danken, alsook mijn fantastisch talentvolle collega-coauteurs 
Daan, Henriette, Jos, Marieke, Marileen, Mark, Marten, Natalia, Peter, Quirijn, Saloua, 
Sirwan en Vincent. Daan, ondertussen heb jij jouw schitterende loopbaan verder gezet als 
dokter in de pneumologie, maar spring gerust nog eens binnen in je queeste naar West-
Vleteren. Naty, I wish you all the best in Costa Rica and thanks for the delicious fresh coffee 
and personalized birth gifts! Werken in Rotterdam zou niet hetzelfde geweest zijn zonder 
mijn immer opgewekte kamergenootjes Marieke, Nikkie, Toke, Loes en Rikje, alsook onze 
buren Kiki, Raymond, Robert-Jan & Brenda die we toch de loef afsteken met onze mooie 
mannen en mascottes. Maar ook met collega PhD studenten als Anne, Annemarie, Ben, de 
Cambridge girls, Eline, Lisette, Liz, Maarten, Mariana, Paul, Symen, Vincent en Virginie was 
het vaak lachen geblazen. Mijn paranimfen Marieke & Nikkie, ik vind het een eer dat jullie 
aan mijn zijde willen staan tijdens de verdediging van mijn proefschrift! Nikkie, het was leuk 
dat je me ook eens in Gent bent komen bezoeken. Marieke, naast Paul ben ik ook jou enorm 
veel dank verschuldigd bij het oplossen van mijn veelvuldige genetische mysteries of om 
gewoon even mijn praatpaal te zijn. Voor de genetische analyses was het verder fijn 
samenwerken met onze internationale collega’s binnen het CHARGE en Spiro-Meta 
consortium. Stephanie, thank you for your excellent guidance in the pulmonary group, 
Annah, Jeanne and Sina, thank you for all your hard work and efforts in our close 
collaboration. 
 
Graag wil ik ook iedereen bedanken die op een of andere manier heeft bijgedragen tot mijn 
fijne doctoraatsjaren! Om de stille kamer wat minder stil te maken kon ik steevast rekenen 
op mijn modieuze roommate Bibi, om een second opinion, wijze raad of gewoon een kopje 
koffie, op mijn vaste lunchpartner Kevin, en voor boeiende research meetings, uitstapjes of 
congressen op de lieve muizekes van Blok B aka Ken en z’n angels Tania, Sharen, Ellen, Fien, 
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Lisa, Griet, Leen, Smitha, Katrien, Elise en alle laboranten. Ik heb de voorbije jaren ook heel 
wat fijne dokters(assistenten), verpleging en medewerkers mogen ontmoeten in de gangen 
van K12 en de talloze verdiepingen van het ErasmusMC. Bedankt dat ik voor 
longfunctievragen steeds terecht kon bij Sven, Leen, Lucie, An of Philippe en voor de 
boekhouding of algemene ondersteuning bij Bart, Chantal of Annie. Verder was het een 
plezier om met ‘de vorige Kevin’ lange uren te kloppen en om de geniale internisten Tom, 
Kenny en Bastiaan te mogen begeleiden in hun masterproef. 
 
Een doctoraat laat je eigenlijk nooit los. Ontspannende boeken kunnen maar beter geruild 
worden voor die berg PhD lectuur, vrije momenten kunnen maar beter ingevuld worden met 
die oneindige to do list. Gelukkig heb ik talloze vrienden en familie die mijn vrije tijd 
maximaal inplannen met leuke feestjes, lekkere etentjes, dolle weekends, onvergetelijke 
trouws en gezellige babyborrels! Anne-Sophie, Bert, Bram, Brecht, Charlotte, Delphine, 
Diederick, Elien, Evelien, Frederik, Griet, Hanne, Hannelore, Hermien, Ilse, Ine, Jelle, Joachim, 
Jochen, Joke, Jorik, Julie, Karen, Kathy, Kjeld, Koen, Lana, Lien, Lieselotte, Marieke, Mariola, 
Matthias, Maxime, Mieke, Naomi, Nele, Paul, Pieter, Sanne, Sarah, Sofie, Stefanie, 
Stéphanie, Stijn, Thijs, Tine, Timon, Tom, Valentine, Wannes, Wouter…, duizendmaal dank, 
‘wuk zok ik doen zonder gidder’! Veel succes ook aan de promovendi in spe onder jullie. 
Bonte & Charlie, gezien jullie in New York verblijven moeten we jullie vaak missen maar dat 
tijdsverschil is toch al handig gebleken bij het nalezen van mijn introductie, waarvoor dank! 
Ook aan alle andere vrienden, familie en (schoon)ouders, een welgemeende dankjewel voor 
jullie interesse, steun en aanwezigheid op de promotie! 
 
En dan is er gelukkig nog een kleine filou die op tijd en stond laat weten dat het leven niet 
draait om een PhD maar om hemzelf, onze grootste schat Leander! Niets werkt meer 
relativerend dan jouw lieve lach. Afsluiten doe ik met de persoon waarvoor woorden te kort 
schieten. Kenny, gedurende deze PhD periode zijn we getrouwd, hebben we een (t)huis 
gebouwd, zijn we papa en mama geworden, jij dokter en ik hopelijk doctor. We hebben het 
graag druk maar boeiend geloof ik. De wereld is allezinds mooier met jou aan mijn zijde… 
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- Pharmaco-epidemiology  (August 29 – September 2, 2011)   
   Organized by NIHES, accepted by UGent 
-    Registration of Medicines (October-December 2013)- Organized by UGent 
 Research and validation: 
- Endnote (November 18, 2010) - Organized by UGent/UZGent 
- Advanced SPSS (January, 2011) - Organized by UGent/UZGent 
- Study Design (September, 2011) - Organized by NIHES, accepted by UGent 
- Good Clinical Practice (October 17, 2012) - Organized by UGent/UZGent 
 Career management: 
- Welcome Day. Everything you need to know about PhD studies in the Doctoral 
School of Life Sciences and Medicine (November 22, 2010) - Organized by UGent 
- Knowledge for Growth (May 5th, 2011) - Organized by FlandersBio-UGent 
- PhD-day (Juyl 4, 2014), including workshops on “Hora est and PhD training” and 
“How to print your thesis” – Organized by ErasmusMC 
- From PhD to Job Market: From PhD to Life (September 20, 2013) - Organized by 
UGent 
- PhD-day (Juyl 3, 2014), including workshops on “Popularizing your research” and 
“Defend your thesis” – Organized by ErasmusMC 
 Leadership and efficiency: 
- Leadership Foundation Course (November 12,20&27, 2012) - Organized by UGent 
 
3 Presentations  
 Interleukin 6 plasma levels, common variation in the IL6 gene and the risk of chronic 
obstructive pulmonary disease: a prospective population-based cohort study. 
- Poster presentation at the 2011 ATS International Conference in Denver, Colorado 
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- Oral presentation at the 2011 5th IUAP Meeting Ghent, October 28th 2011 
- Poster presentation at the 2012 Science Day Ghent, March 14th 2012 
 Statins, systemic inflammation and the risk of death in patients with COPD: the Rotterdam 
Study 
- Oral presentation at the 2012 BVP Meeting Brussel, April 25th 2012 
- Poster discussion at the 2012 ATS International Conference in San Francisco 
 Frailty affects quality of spirometry: the Rotterdam Study 
- Poster presentation at the 2013 ATS International Conference in Philadelphia 
 COPD exacerbations and carotid artery plaques: the Rotterdam Study 
- Oral presentation at the 2013 BVP Meeting Brussel, March 27th 2013 
- Poster discussion at the 2013 ERS International Conference in Barcelona 
 COPD and Sudden Cardiac Death: the Rotterdam Study 
- Oral presentation at the 2014 BVP Meeting Brussel, June 11th 2014 
 Cause-specific mortality in mild COPD: the Rotterdam Study 
- Poster presentation at the 2014 ERS International Conference in Munich 
 
4 International conferences 
2014 European Respiratory Society International Conference in Munich 
2013 European Respiratory Society International Conference in Barcelona 
2013 CHARGE International meeting in Rotterdam 
2013 American Thoracic Society International Conference in Philadelphia 
2012 European Respiratory Society International Conference in Amsterdam 
2012 American Thoracic Society International Conference in San Francisco 
2011 American Thoracic Society International Conference in Denver 
 
5 Supervising Master students 
2013  Bastiaan Maes, “Frailty and COPD: the Rotterdam Study” 
2012 Kenny Vlaemynck, “COPD and the risk of Open-Angle Glaucoma: the  
   Rotterdam Study” 
2011 Tom Holvoet, “Genetische determinanten en klinische risico’s van  
   Staphylococcus Aureus neusdragerschap” 
 
6 Awards & Fellowships 
International Trainee Travel Award 2011 from the National Emphysema Foundation   
honouring Claude Lenfant, ATS International Conference, Denver, 2011 
European Respiratory Society Short-term research fellowship, 2011 
Belgian Society for Pneumology (BVP) Short-term Research fellowship, 2012 
Travel Award 2012 to the ATS International Conference in San Francisco, 2012 
Belgian Society for Pneumology (BVP) Short-term Research fellowship, 2013 
ERS Young Scientist Sponsorship, ERS International Conference, Barcelona, 2013 
 
7 Other 
 Reviewing articles 
 Numerous intern presentations at the Department of Respiratory Medicine, Ghent 
University Hospital and at the Department of Epidemiology, Erasmus MC, Rotterdam 
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